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ABSTRACT 
 
HLA class II/peptide complexes (pHLA-II), organized into microdomains on 
the surface of antigen presenting cells (APCs) or on APC-secreted exosomes, engage 
CD4+ T cells for immune recognition. The association of the HLA-II alleles 
DRB1*0401/0404 with rheumatoid arthritis may be due to their propensity to present 
self-peptides for immune recognition. pHLA-II presentation on APCs is largely 
determined by HLA-DM, an intracellular chaperone, and its negative regulator, HLA-DO. 
Previously described DRB1*04-restricted epitopes (D11-0401, D13-0401, and D13-0404) 
were found dependent, sensitive, and resistant, respectively, to HLA-DM activity. The 
aims of this study were to determine whether (a) HLA-DO affects epitope expression; (b) 
cell surface microdomains concentrate these epitopes; and (c) exosomes express these 
epitopes. Key findings include: HLA-DO appears not essential, but its role in optimal 
epitope expression may be cell-context dependent; lipid raft disruption abrogated only the 
DM-dependent D11-0401epitope; exosomal expression of these epitopes was cell specific 
and independent of their cell surface expression. Altogether, this study has enhanced our 
knowledge of DM-dependent, -sensitive, and -resistant epitopes on rheumatoid arthritis-
associated pHLA-DRB1*04 molecules. 
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Chapter 1 
 
Introduction 
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1.1 The major histocompatibility complex 
1.1.1 Genetic organization 
The major histocompatibility complex (MHC) is a large genomic region in the 
mammalian genome that contains a tightly linked cluster of genes which encode several 
proteins that are involved in both innate and adaptive immunity. The human MHC, also 
referred to as the human leukocyte antigen (HLA) system, is located on the short arm of 
chromosome 6 and in mice on chromosome 17. More recently, the extended MHC 
(xMHC) has been described as shown in Figure 1.1, which includes gene clusters 
adjacent to the classical MHC (1). The xMHC contains upwards of 420 loci including 
both expressed genes and pseudogenes, making it one of the most gene-dense regions of 
the genome (1). Furthermore, several genes within the MHC are highly polymorphic in 
that multiple variants of each gene exist within the population. The human MHC contains 
several loci which encode structurally and functionally homologous proteins that are 
classified as HLA class I (HLA-I or class I), including HLA-A, -B, and -C, and HLA 
class II (HLA-II or class II), including HLA-DR, -DP and -DQ molecules. Both HLA-I 
and HLA-II molecules were first identified because of their role in mediating tissue 
rejection and acceptance in transplantation, but upon further analysis it was revealed that 
their main function involved antigen presentation to T lymphocytes (2).  
In humans, the MHC is organized into three distinct gene-rich regions that are 
designated from telomere to centromere as class I, III, and II regions (1, 3, 4). Each 
region contains several genes encoding immunologically relevant proteins detailed below, 
but also includes additional genes whose function is unrelated to the immune response 
3 
Figure 1.1. Gene map of the extended human MHC. 
A selected fragment of the extended major histocompatibility complex (xMHC) on the 
short arm of human chromosome 6 containing immunologically relevant genes is shown. 
The class I, II, and III subregions are described in the text. Some immunologically 
irrelevant genes have been excluded for ease of demonstration. Furthermore, pseudogenes 
have been omitted for presentation purposes. In total, the xMHC is comprised of 421 loci, 
of which 252 are classified as expressed genes, and 169 as pseudogenes and transcripts 
(1). The extended class I and II subregions are not described in detail, but include genes 
such as death domain associated protein (DAXX), TAP binding protein (TAPBP), retinoid 
x receptor beta (RXRB), myelin oligodendrocyte glycoprotein (MOG), ubiquitin D 
(UBD), protease, serine 16 (PRSS16), members of the butyrophilin subfamily of genes 
(BTN1A1, BTN2A1, BTN3A3, BTN3A1, BTN2A2, BTN3A2), and hemochromatosis 
(HFE). Adapted from (1). 
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ranging from cell growth, development, DNA repair and transcriptional regulation. The 
class I subregion contains genes encoding the alpha (α) chain of HLA-I molecules HLA-
A, -B, and -C, as well as the HLA-I-like genes encoding class Ib molecules HLA-E, -F, -
G, MICA, and MICB. The α chain of HLA-A, -B, and -C combine with a molecule 
termed beta-2-microglobulin (B2M), encoded outside the MHC on chromosome 15, 
forming a heterodimer whose function is to bind short peptides typically derived from 
endogenous antigens and present them to CD8+ T lymphocytes (5). By contrast, the 
functions of class Ib molecules is less well understood, but several studies demonstrate 
that they act as ligands for the activation and inhibition of natural killer cells, as well as 
perform important immunoregulatory functions (6-8). Several genes encoding members 
of the tripartite motif family (TRIM) are also located within the class I subregion, which 
are involved in a wide variety of cellular processes. Accumulating evidence suggests that 
several TRIM family members are important in the regulation innate immunity, as well as 
having a direct role in the restriction of viral infection in a variety of cell types (9, 10).  
The class III region does not contain genes for any classical class I or II antigens; 
however, approximately 62, many whose physiological function is unknown, are found in 
this subregion (11). The genes for complement proteins C2, factor B, C4A and C4B are 
located at the centromeric end of the class III region. Other immunologically relevant 
genes in this region encode for members of the tumor necrosis factor family of cytokines 
including tumor necrosis factor-α, lymphotoxin A, and lymphotoxin B (12). 
The class II region is located nearest to the centromere and contains genes 
encoding the classical HLA-II antigens HLA-DR, -DP, and -DQ as well as two non-
classical class II antigens HLA-DM and -DO. Both classical and non-classical class II 
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antigens consist of an α and beta (β) chain which associate in the endoplasmic reticulum 
to form a functional dimer. DR, DP, and DQ bind short peptides and present them to 
CD4+ T lymphocytes (13). DM and DO function within the class II processing and 
presentation pathway and shape the repertoire of peptides presented by class II molecules 
(14). Also included in this region are genes encoding the proteins tapasin, TAP1, TAP2, 
LMP2, and LMP7. Similar to DM and DO in the class II pathway, tapasin, TAP1, and 
TAP2 contribute to the formation of mature peptide-MHC complexes (pMHC) in the 
class I pathway as discussed below (15). Both LMP2 and LMP7 are subunits of the 
immunoproteasome which is responsible for generating optimal peptides for binding to 
HLA class I molecules (16).  
 
1.1.2 Polymorphism and nomenclature 
Several MHC genes exhibit a high degree of polymorphism, particularly the class 
I and class II antigens, in that several allelic variants exist within the global population. 
There are currently 3,399 HLA-A, 4,242 HLA-B, and 2,950 HLA-C different alleles 
described (17). The class II genes exhibit a similar degree of polymorphism. Currently 
911 and 644 variants have been identified for HLA-DQB1 and -DPB1 respectively and 69 
and 43 alleles for HLA-DQA1 and -DPA1 respectively (17). HLA-DR exhibits 
considerably more polymorphism than DP and DQ with 1883 and 7 known alleles for 
HLA-DRB1 and -DRA respectively (17). Since only 7 alleles are known for DRA (2 of 
which encode functional proteins), much of the DR polymorphism is a result of the DRB1 
gene. The DR region is further complicated due to the fact that a second DRB gene may 
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be expressed depending on the allele expressed at the DRB1 locus. With the exception of 
the DRB1*01, *08 and *10 alleles, all haplotypes contain a second DRB allele in addition 
to DRB1 (18). For example, the DRB3 gene is expressed when one or two of the 
DRB1*11, *12, *13, *14, *17 or *18 alleles are expressed at the DRB1 locus. The DRB4 
gene is expressed when one or two of the DRB1*04, *07 or *09 alleles are expressed at 
the DRB1 locus. Finally, the DRB5 gene is expressed when the allele DRB1*15 or *16 is 
expressed at the DRB1 locus. Several different alleles for DRB3, DRB4, and DRB5 exist 
within the population, albeit not nearly as polymorphic compared to DRB1. Currently, 77, 
24, and 26 alleles have been described for DRB3, DRB4, and DRB5 respectively (17). The 
extensive polymorphism of the MHC decreases the likelihood that two unrelated 
individuals express the same class I or II antigens. This genetic diversity confers 
protection against pathogens by a population as a whole by increasing the chances that an 
immune response against a given pathogen is generated in a proportion of the population 
and therefore eliminated. 
Due to the complexity of the class II antigens, particularly the DR loci, the system 
of HLA nomenclature has evolved over the years. Initial nomenclature of HLA was based 
on the identification of different HLA alleles using serological techniques (19). However, 
with the advent of molecular biology, several more allelic subtypes were discovered 
which could be distinguished using the serologically defined specificities. For example, 
under the old classification system, two individuals may be identified as carrying the DR4 
haplotype, however, they may carry very different alleles at the DRB1*04 locus. The new 
nomenclature system is based on DNA sequences of alleles and is able to accommodate 
the inadequacies of the old system (20). Using HLA-DRB1*04:01 as an example, ‘HLA’ 
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indicates the HLA region; ‘DRB1’ indicates the particular HLA locus; ‘04’ indicates the 
group of alleles which encode the DR4 antigen; ‘01’ indicates the specific allele. 
Additional notation is included to identify mutations and differences in level of 
expression.  
 
1.1.3 General function of HLA class I and II molecules 
As stated above, both HLA class I and II molecules bind and present antigen-
derived peptides to CD8+ and CD4+ T lymphocytes respectively. During the early stages 
of infection, an innate immune response is mounted against the pathogen. An important 
feature of this early response is that proteins derived from the pathogen are taken up and 
degraded by professional antigen presenting cells (pAPC) such as dendritic cells, and 
subsequently presented on their surface in complex with class I or class II molecules (21). 
Within the lymph nodes, dendritic cells expressing these MHC molecules in complex 
with antigenic peptides on their surface are able to interact with naive CD4+ (in the case 
of class II) or CD8+ (in the case of class I) T lymphocytes which bear the appropriate T 
cell receptor (TCR) leading to activation, proliferation, and differentiation of these cells, 
eventually mounting an adaptive immune response against the pathogen (21). In order for 
differentiated T lymphocytes to exert their effector functions as the adaptive immune 
response progresses, it is necessary that they recognize their corresponding pMHC on 
infected or accessory immune cells. Furthermore, both class I and class II molecules are 
crucial for the development of immune cells in the thymus acting as ligands for positive 
and negative selection of lymphocytes (22). Therefore, class I and II molecules are 
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responsible for generating the repertoire of circulating T lymphocytes, provide a vital link 
between innate and adaptive immunity, and at the same time are required for initiating the 
effector mechanisms of the adaptive immune response.  
 
1.1.4 HLA class I structure and antigen processing pathway 
HLA-A, -B, and -C are glycoproteins expressed by all nucleated cells within the 
body and are heterodimers consisting of a polymorphic 45 kDa α chain, encoded by the 
HLA-A, -B, and -C genes, and a nonpolymorphic 12 kDa protein B2M encoded outside 
the MHC on chromosome 15 (Figure 1.2). The α chain contains three domains α1, α2, 
and α3, with α1 and α2 forming a peptide binding groove that is distally oriented from the 
plasma membrane (23). Peptides 8 to 11 amino acids in length are able to interact with 
the peptide binding groove resulting in the formation of a stable pMHC that survives 
trafficking through the secretory pathway and prolonged display at the cell surface (25). 
The amino acid variability that exists as a result of the allelic polymorphisms is 
concentrated in the domains forming the peptide binding groove, more specifically, at 
residues which line the groove. Therefore, the repertoire of peptides able to bind this 
groove are entirely dependent on the sequence motif of the class I molecule.  
HLA class I molecules are synthesized de novo in the endoplasmic reticulum 
(ER) where several co-chaperone molecule assist in assembly and peptide loading (26). 
After translocation to the ER, the class I α chain associates with the chaperones calnexin 
and ERp57 which facilitate binding of B2M. Binding of calnexin and ERp57 promote the 
correct folding of the free α chain and retains it in the ER. The α chain eventually  
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Figure 1.2. Schematic representation of the structure of HLA class I and HLA class II 
molecules. 
HLA class I molecules are heterodimers consisting of a 45 kDa α chain and a 12 kDa 
protein B2M. The α chain contains three domains a1, α2, and α3, with α1 and α2 forming 
a peptide binding groove that is distally oriented from the plasma membrane. HLA class 
II molecules consist of a 35 kDA α and 29 kDa β chain forming a heterodimeric 
glycoprotein. Both the α and β chain contain a membrane-proximal domain termed a2 and 
b2 respectively. The membrane-distal domains of the α and β chains, termed α1 and β1 
respectively, form a peptide binding groove. The amino acid residues that contribute to 
formation of the peptide binding groove of both class I and class II molecules are highly 
polymorphic in that the main differences in amino acid sequence of different class I and 
class II alleles are within this region. Adapted from (24). 
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associates with B2M followed by formation of a peptide loading complex where 
calnexin-ERp57 is replaced by calreticulin-ERp57 and the entire complex associates with 
the transmembrane protein tapasin which in turn is associated with the peptide transporter 
TAP. This complex stabilizes the peptide receptive class I molecule so that peptides are 
able to bind (27). Tapasin also acts to optimize the repertoire of peptides bound to the 
class I by exchanging low affinity peptides in favor of peptides that bind with a higher 
affinity and thus are more stable upon egress of the pMHC-I from the ER (28, 29). TAP, 
functioning as an ATP-binding cassette transporter, allows transport of peptides 
approximately 8 to 16 residues in length into the ER from the cytosol for potential 
binding to MHC-I. Upon successful peptide binding, the co-chaperones and peptide 
loading machinery dissociate from the pMHC-I and the stable molecule is transported to 
the plasma membrane via the secretory pathway. 
The majority of peptides available for binding to MHC-I are generated in the 
cytosol by the proteasome and then transported into the ER by the TAP complex as 
described above. Therefore, the source proteins of the peptides presented by MHC-I are 
primarily of intracellular origin and include endogenous and viral antigens. MHC-I 
peptides can also be generated in a proteasome-independent manner in the cytoplasm by 
proteases such as calpains, tripeptidyl peptidase II, leucine aminopeptidase, bleomycin 
hydrolase and puromycin-sensitive aminopeptidase and in the ER by ER-associated 
aminopeptidase or ER aminopeptidase 1 and 2 (30, 31). 
Dendritic cells and macrophages are able to present antigens from their 
extracellular environment on MHC-I molecules in a process known as cross-presentation. 
Exogenous antigens taken up by endocytosis or phagocytosis can be transferred into the 
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cytosol for degradation followed by transport into the ER for MHC-I presentation. 
Alternatively, these antigens may be degraded by endosomal proteases and bind to MHC-
I in recycling endosomes or the ER following back-fusion of endocytic vesicles. In either 
case, cross-presentation is an important mechanism in the immune surveillance of tissues 
where cancers and viruses can be detected even if they do not directly infect dendritic 
cells. Furthermore, this mechanism enables the immune system to monitor bacterially 
infected pAPC by allowing cytotoxic T cells to eliminate cells harboring intracellular 
bacteria within their phagosomes (31).  
 
1.1.5 HLA class II structure and antigen processing pathway 
HLA class II antigens HLA-DR, -DP, and -DQ consist of a non-polymorphic 35 
kDA α and polymorphic 29 kDa β chain forming a heterodimeric glycoprotein (Figure 
1.2). Similar to the HLA-I α3 domain, HLA-II α and β chains contain a membrane-
proximal domain designated α2 and β2 respectively. The membrane-distal domains of the 
α and β chains, termed α1 and β1 respectively, form a peptide binding groove similar to 
that of HLA-I molecules. Similar to MHC-I molecules, the amino acid variability that 
exists as a result of MHC-II allelic polymorphism is concentrated at residues which form 
the peptide binding groove. However, the MHC-II binding groove differs from the MHC-
I groove in that a) it is formed by a combination of two chains instead of one and b) the 
terminal ends of the groove are open allowing longer peptides to bind, typically 13 to 25 
amino acids in length. 
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Compared to HLA-I, the expression of the HLA-II antigens HLA-DR, -DP, and -
DQ is more restricted, with constitutive expression largely confined to pAPC and thymic 
epithelial cells. This is due to the transcriptional control of class II genes by the class II 
MHC transactivator (CIITA) which also exhibits similar tissue restricted expression. 
CIITA is referred to as a transcriptional coactivator because it does not directly bind to 
DNA but instead initiates transcription of class II molecules by binding several 
transcription factors including RFX, CREB, and NF-Y which are bound to regulatory 
elements in the promoters of MHC-II genes. The expression of CIITA can be upregulated 
by IFN-γ, resulting in increased expression of MHC-II in immune cells and induction in 
endothelial and fibroblast cells. More recently, chromatin-modifying events such as 
histone acetylation, methylation, deacetylation, and ubiquitination have been suggested as 
additional regulators of class II and CIITA expression, suggesting that epigenetic events 
are additional influences in the MHC-II presentation pathway (32). 
A general schematic of the HLA class II antigen processing pathway is shown in 
Figure 1.3. MHC-II α and β chains are synthesized in the endoplasmic reticulum, where 
three αβ dimers associate with three invariant chain (Ii) proteins forming nonameric 
(β)3Ii3 complexes (33). The function of Ii is twofold, (a) to stabilize MHC-II dimer 
formation and prevent premature binding of peptides to the peptide binding groove in the 
ER and during transport through the endocytic pathway and (b) to target MHC-II to 
lysosome-like late endosomal compartments (34). The Ii chain contains a di-leucine motif 
in the N-terminal cytoplasmic domain which is required for targeting Ii and associated 
MHC-II to late endosomal compartments (35, 36). This can occur by direct targeting after 
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Figure 1.3. Schematic representation of the HLA class II antigen processing and 
presentation pathway.  
Newly synthesized MHC-II αβ heterodimers associate with the invariant chain (Ii) in the 
endoplasmic reticulum. After travelling through the Golgi apparatus, Ii-MHC-II 
complexes are either directly transported to late endosomal compartments or first to the 
plasma membrane where they are internalized by clathrin-mediated endocytosis. These 
late endosomal vesicles have a low pH and are enriched in several proteolytic enzymes 
and antigen presentation accessory molecules, and are commonly referred to as 
multivesicular endosomes, multivesicular bodies (MVB), or MHC-II loading 
compartments (MIIC) in pAPCs. Ii is sequentially degraded by proteolytic enzymes 
within MIIC leading to the generation of a fragment of Ii, termed class II-associated 
invariant chain peptide (CLIP), which remains in the peptide binding groove of MHC-II 
molecules. CLIP is released from the peptide binding groove by HLA-DM, which 
subsequently facilitates peptide binding resulting in the formation of a stable peptide-
MHC-II complex. The activity of DM is regulated by HLA-DO. After stable peptide 
binding, mature MHC-II molecules are transported to the plasma membrane for 
presentation to T lymphocytes. Adapted from (44).  
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exiting the trans-Golgi network, or by clathrin-mediated endocytosis from the plasma 
membrane (37-39). Following endocytosis, Ii-MHC-II complexes traffic through the 
endocytic pathway with the final destination being late endosomal-lysosomal antigen 
processing compartments which contain antigenic proteins and peptides (40). 
Although peptide-MHC-II complexes (pMHC-II) can be produced at several 
locations throughout the endocytic pathway (41), the typical antigen-loading 
compartments are specialized late endosomal organelle-like vesicles which have a low pH 
and are enriched in several proteolytic enzymes (40, 42, 43). Electron microscopy 
initially revealed an abundance of MHC-II concentrated in these late endocytic vesicles, 
and so they were termed MHC- II peptide loading compartments, or MIICs (45-47). In 
pAPCs, MIICs are heterogeneous in their morphology, contain several internal 
complexes, and are all forms of multivesicular bodies, or MVBs (13, 43). MVBs are so 
named due to the presence of intraluminal vesicles (ILVs) which are formed by the 
inward budding of the vesicle’s limiting membrane and contain several of the necessary 
co-molecules required for optimal antigen processing and presentation (48, 49). Proteins 
destined for degradation in lysosomes are also transported to these MHC-II-enriched late 
endosomes where they are cleaved into shorter peptides by the acidic proteolytic 
environment. 
At the same time, some of these endolysosomal proteases degrade the Ii chain of 
Ii-MHC-II complexes, leaving a short peptide fragment termed the class II associated 
invariant chain peptide (CLIP) in the MHC-II peptide-binding groove (50). Ii is 
sequentially degraded from its full length, which differs in size due to several isotypes, to 
the intermediates LIP (22 kDa), SLIP (10 kDA), and eventually CLIP (51, 52). 
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Depending on the cell type, several proteases have been implicated in these cleavage 
steps. In pAPC, cathepsin S has been shown to be responsible for late stage Ii degradation 
of the SLIP intermediate to CLIP (53, 54), whereas in thymic epithelial cells cathepsin L 
is mainly responsible for this cleavage step (55-59). Furthermore, cathepsin S, not 
cathepsin L, can degrade Ii in non-professional APC such as epithelial cells (60). Less is 
known concerning the proteases responsible for full length and intermediate (LIP – SLIP) 
cleavages; however, evidence suggests that multiple proteases can contribute (61). An 
unidentified aspartic protease and asparaginyl endopeptidase (AEP) in mice can initiate Ii 
processing (62, 63). However, others have demonstrated that AEP is dispensable and that 
initial Ii processing is redundant and may depend on the MHC-II allele expressed by the 
cell (64). The redundancy in Ii processing is likely a reflection of the differential 
expression of proteases across APC types. However, in all cases the end result is the 
creation of a MHC-II-CLIP complex, which serves as the template for MHC-II peptide 
loading. 
CLIP must be removed from the peptide-binding groove of MHC-II to allow the 
binding of antigenic peptides. This process is facilitated by the MHC-II-like molecule 
HLA-DM (DM), which is present in the MVB internal and limiting membranes, and 
interacts with MHC-II-CLIP complexes that have been sorted onto ILVs within these 
vesicles (13). DM acts as an enzyme to catalyze the exchange of CLIP for peptides within 
MIIC by facilitating CLIP release, stabilizing the peptide-receptive MHC-II, and enabling 
the stable binding of peptide species resulting in the formation of stable pMHC-II (65-
67). HLA-DO, a second MHC-II-like molecule expressed in B lymphocytes, thymic 
medullary epithelial cells, and primary dendritic cells inhibits DM activity by directly 
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binding it and preventing it from interacting with MHC-II (65, 68, 69). Following 
formation of stable peptide-loaded MHC-II, they are transported from MVB in 
tubulovesicular endosomes to the plasma membrane where they interact with T cell 
receptors (TCR) on CD4+ T lymphocytes. 
Once expressed on the cell surface, pMHC-II can be internalized through a 
clathrin-independent endocytosis pathway, resulting in either transportation to lysosomes 
for eventually degradation, or to early endosomes where they are recycled back to the 
plasma membrane (13). Although some pMHC-II are exclusively generated with MIIC as 
described above, other pMHC-II may be generated in these early endosomes in a process 
that is independent of nascent MHC-II synthesis, Ii-mediated transport, and DM peptide 
editing, and involves limited proteolytic processing (70-73). Furthermore, recycling 
pMHC-II may also return to conventional MIIC, resulting in the formation of new 
epitopes (74).  
 
1.2 HLA class II antigen presentation 
1.2.1 Role of HLA-DM and HLA-DO  
As mentioned above, both DM and DO act together in pAPC to regulate the 
loading of peptides derived from foreign and self antigens onto MHC-II. DM acts as a 
catalytic enzyme that binds transiently to MHC-II complexes resulting in the 
destabilization hydrogen bonding networks causing the release of CLIP, then stabilizing 
MHC-II dimers in an open conformation allowing repeated binding and dissociation of 
peptides, ultimately resulting in accumulation of stable pMHC-II with high affinity 
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peptides (14, 75-77). Spontaneous dissociation of CLIP from MHC-II can also occur and 
is dependent on the binding affinity of CLIP for the particular MHC-II allele (78, 79). 
CLIP has been shown to dissociate more rapidly from DRB1*04:01 and DRB1*04:04 
compared to DRB1*04:02 (78). Until recently, the precise mechanism by which DM 
binds MHC-II to facilitate peptide exchange was not clearly known; however, two recent 
studies which have identified the crystal structure of DM-MHC-II complexes provide 
some important clues (80, 81). Upon binding DR, DM does not appear to undergo any 
significant conformational changes when compared to crystal structures of DM alone (82-
84). However, DM induces a dramatic conformational alteration in DR at residues 35 to 
57 of the MHC-II α subunit, which is important in forming part of the floor of the peptide 
binding groove, as well as the P1 pocket (80). The P1 pocket and hydrogen bonds in this 
region are important for providing a stable interaction between peptide and the MHC-II 
molecule. These findings provide a direct molecular mechanism for the action of DM, 
where DM binding destabilizes pMHC-II by interfering with crucial peptide – MHC-II 
binding interactions (65). 
The importance of DM in autoimmunity is demonstrated by several studies that 
have reported a significant role for DM activity in the development of type 1 diabetes (85, 
86). Eliminating DM-function in the NOD mouse model for type 1 diabetes blocked the 
development of diabetes (86), suggesting that DM is responsible for the presentation of 
disease-initiating peptides. In contrast, other studies support a view where DM is 
responsible for editing out disease-causing peptides, and disease development is due to 
the generation of an epitope in recycling endosomes where DM activity is limited (87, 
88).  
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As stated above, DM function is regulated by the class II-like molecule DO, 
which is expressed in B lymphocytes, thymic medullary epithelial cells, and primary 
dendritic cells (68, 69). DO acts as a competitive inhibitor of DM by directly binding it 
and preventing interaction of DM with MHC-II-CLIP and pMHC-II complexes (89-91). 
Interestingly, DO is unstable in the absence of DM and may require association with DM 
in order for egress from the ER (92).  Expression of DO is modulated during B cell 
differentiation, where a reduction in DO expression is observed in germinal center B cells 
compared to naïve and memory B cells (93). Several studies have identified roles for DO 
in regulating antigen presentation and influencing the repertoire of MHC-II-bound 
peptides (94-98). DO-deficient cells present endocytosed antigens internalized by fluid-
phase endocytosis more efficiently than in the presence of DO. Furthermore, presentation 
of antigens internalized by surface immunoglobulin was improved in the presence of DO. 
These results suggest that the function of DO is to focus presentation on antigens that 
have been internalized by surface immunoglobulin (94). More recently, over expression 
of DO in DCs in the NOD mouse model for type 1 diabetes blocked development of 
diabetes suggesting that by inhibiting DM function, DO prevents the presentation of self 
antigens by possibly maintaining a broad peptide repertoire (99). The importance of DO 
in regulating autoimmunity is perhaps most apparent in a recent study utilizing H2-O (DO 
in mouse) knockout mice (100). Whereas only a few limited changes were observed in 
H2-O
-/- 
mice in previous studies (94, 95), Gu et al. demonstrated that DO knockout mice 
exhibit an autoimmune phenotype characterized by spontaneously development of higher 
titers of anti-nuclear antibodies and delayed antibody responses to model antigens, 
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suggesting that DO decreases immunity to self antigens while increasing immunity to 
foreign antigens (100).  
Since both DM and DO have a profound effect on the repertoire of peptides 
presented by MHC-II molecules, much attention has concentrated on determining the 
effect of these molecules on the presentation of specific peptide sequences (65, 90, 101). 
Based on the effect of DM on presentation, peptide antigens or epitopes can be divided 
into 3 groups (102-104). For one group of peptides, termed DM-resistant, presentation 
can occur in both the presence and absence of DM. Since DM does not affect presentation 
of these antigens, DM-resistant epitopes are expressed on all MHC-II+ cells (102). In 
contrast, DM-sensitive epitopes are suppressed by DM, and are thus only expressed in the 
absence of DM. Under circumstances of DO co-expression with DM as in pAPC, the 
presentation of DM-sensitive antigens can be restored (102). Finally, there is a category 
of peptides that are presented only in cells expressing DM, termed DM-dependent 
epitopes (103).  A main factor determining whether a particular epitope is DM-resistant, -
sensitive, or -dependent might be the affinity of the peptide for the specific MHC-II 
molecule (103). In summary, both DM and DO contribute to the peptide repertoire 
presented by MHC-II and further research will clarify the physiological roles of these 
molecules in maintaining tolerance and development of autoimmunity.  
 
1.2.2 Proteolytic processing of peptide antigens in the endocytic pathway 
APCs use several cellular processes to capture external antigens and deliver them 
to antigen loading compartments for processing and presentation by MHC-II, including 
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macropinocytosis, receptor-mediated endocytosis, and phagocytosis (40). Internalized 
antigens eventually enter acidic late endocytic vesicles containing proteases and 
reductases responsible for antigen denaturation and proteolysis. Proteins contain multiple 
sequences that are able to bind MHC-II, but only a few are finally presented to T cells. In 
the hierarchy of epitope presentation, immunodominant epitopes are important for 
immunity to pathogens, whereas subdominant and cryptic epitopes are associated with 
autoimmunity (105). The expression of a specific pMHC-II epitope is dependent on 
various cellular factors including the route of antigen entry, mechanism of peptide 
loading, the intracellular location of degradation, and perhaps most importantly, 
proteolytic processing (61, 106-108). Multiple endocytic proteases have been shown to 
contribute to processing antigens for specific pMHC-II presentation, including cathepsins 
B, D, L, S, and AEP (109). These proteases are typically classified according to their 
proteolytic activity, the major species active within pAPC being cysteinyl and aspartyl 
and either endo-, carboxy, - or aminopeptidases (110). Evidence to date suggests that 
generation of some CD4+ T cell epitopes may require the action of specific proteases 
while other epitopes may exhibit less strict processing requirements (61, 106, 109, 111). 
This was initially suggested following studies where treatment of pAPCs with inhibitors 
of endolysosomal proteases could either enhance or inhibit the presentation of epitopes 
(112). Redundancy in antigen processing is supported by the observations that knock-out 
mice for specific members of the cathepsin family of proteases have normal immune cell 
numbers and similar peptide repertoires in terms of complexity compared to wild type 
mice (113-115). Furthermore, several studies have highlighted instances where one 
protease may compensate for lack of another (61, 106, 109, 116). For example, analysis 
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of peptides eluted from MHC-II I-Ab-expressing embryonic fibroblast cells expressing 
either cathepsin S or L revealed that the majority of peptides are presented irrespective of 
the cathepsin expressed (117). However, this study also identified a subset of peptides 
that  were positively or negatively regulated depending on the cathepsin expressed, 
suggesting that individual proteases may contribute to the generation of specific peptides 
for MHC-II presentation (117).  
Several studies have investigated the effect of cathepsins on the generation of 
specific epitopes (57, 61, 106, 110, 116, 118). For example, cathepsin B and S were 
shown to mediate the degradation of 
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I-labeled F(ab)2 fragments, whereas cathepsin D 
and L were dispensable (119). Additional studies have investigated the role of cathepsins 
in the presentation of the immunodominant epitope from tetanus toxoid, with cathepsin D, 
E, and B implicated in generating the appropriate antigenic peptides (120-122). 
Furthermore, analysis of the protease processing requirements of hen egg lysozyme 
(HEL) demonstrated a reduction in expression of two H-2
b
-restricted T cell epitopes in 
the absence of cathepsin S in murine B cells (123). Endolysosomal proteases other than 
members of the cathepsin family, such as AEP and the IFN-γ inducible thiol reductase 
(GILT), can also contribute to the generation of class-II epitopes (124-128). Other studies 
propose that cytoplasmic processing events may also be required for the formation of 
some MHC-II epitopes (30, 129). 
Endolysosomal proteases can also contribute to the destructive processing of 
peptide epitopes, where lysosomal proteolysis of a protein can perturb the generation of 
some peptides epitopes (130, 131). For example, presentation of an I-A
b
-restricted 
immunoglobulin M epitope was inhibited by cathepsin S and L expression (117). 
25 
Expression of a DRB1*15:01-retricted myelin basic protein epitope (MBP85-99) was 
reduced in the presence of cathepsin G in human B lymphocytes, suggesting that this 
protease contributes to the destructive processing of the immunodominant epitope (132). 
Whereas the previous study demonstrated that AEP was dispensable in the processing of 
MBP, a second study demonstrated that this epitope is more efficiently presented in the 
absence of AEP due to a destructive cleavage by AEP within MBP85-99(60). AEP is highly 
expressed in thymic APC (133) and cathepsin G in peripheral DC (134), suggesting 
tissue-specific processing of the same antigen can occur and thus may contribute to the 
development of tolerance or autoimmunity (109, 135). 
Whereas the majority of peptides destined for MHC-II presentation are localized 
and processed in endocytic vesicles as described above, approximately 10-30% of the 
peptides bound to MHC-II are derived from nuclear or cytoplasmic proteins (136, 137). 
Within APC, the delivery of proteins and peptides from the cytoplasm and nucleus to the 
endosomal network is mediated by autophagy (137). Macroautophagy is a process where 
cytoplasmic material, including organelles, is engulfed by membranes resulting in the 
formation of autophagosomes which can fuse with lysosomal antigen-processing 
endosomes to form autophagolysosomes (138, 139). Chaperone-mediated autophagy, 
where cytoplasmic chaperones including Hsc70 and Hsp90 in conjunction with MIIC 
transmembrane protein marker LAMP-2A selectively deliver peptides to late endosomes, 
also contributes to the MHC-II peptide repertoire (140). Furthermore, cytoplasmic 
antigens can be captured by microautophagy for transport into endosomes, although the 
contribution of this process to the antigen presentation is less clear compared to the other 
forms of autophagy (141). The importance of autophagy in the generation of specific 
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MHC-II epitopes is highlighted by the finding that autophagy can cause the generation of 
citrullinated proteins and peptides by peptidylarginine deiminase (142). The presentation 
of citrullinated peptides by MHC-II has been linked to the pathophysiology of 
autoimmune rheumatoid arthritis (RA) (143). Macroautophagy-deficient dendritic cells 
are also unable to activate herpes simplex virus-specific CD4+ T cells, suggesting that 
autophagy may be required for generation of antigen-specific MHC-II epitopes in the 
periphery (144).  
 
1.2.3 MHC-II trafficking and presentation at the plasma membrane 
The precise mechanisms that regulate transport of peptide-loaded MHC-II from 
antigen-loading compartments to the plasma membrane are poorly understood and most 
likely differ between different types of APC (13). Kleijmeer et al. found that maturation 
of DCs resulted in a loss of ILVs from MVBs, suggesting that pMHC-II containing 
intraluminal vesicles back-fuse with the limiting membrane of MVB (145). However, this 
study did not rule out the degradation of ILVs or their release as exosomes. Once 
redistributed to the limiting membrane of MVBs, pMHC-II traffic into tubularvesicular 
endosomal structures which fuse with the plasma membrane (146-148). Movement of 
these tubular endosomes from MIIC to the plasma membrane involves several molecules 
including Rab GTPases, actin-dependent motor proteins, and cytoskeletal proteins (149).  
At the cell surface, a substantial proportion of pMHC-II cluster within distinct 
membrane microdomains including lipid rafts and tetraspanin-enriched microdomains 
(150, 151). Lipid rafts are cholesterol-rich stable lipid domains found in all cell types 
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which provide membrane organization in a less structured plasma membrane. 
Constitutive association of pMHC-II with lipid rafts has been detected in B cells, DCs, 
monocytes, macrophages, and thymic epithelial cells (152). Tetraspanin-enriched 
microdomains (TEMs), or tetraspanin webs, have also been shown to be responsible for 
the clustering of pMHC-II (153).Incorporation of pMHC-II into membrane microdomains 
is hypothesized to be functionally important for T cell activation in cases where there are 
low levels of a specific pMHC-II on the surface of APC (154-156). Activation of antigen-
specific CD4+ T cells requires T cell receptor-mediated recognition of cognate MHC-II 
loaded with a specific peptide. The repertoire of peptides eluted from MHC-II on APC is 
complex (157, 158), but T cells are somehow able to find their rare cognate pMHC-II. 
Studies estimate that CD4+ T cells require as little as 200 specific pMHC-II complexes 
per APC to be activated (159-161), and a more recent study demonstrates that as few as 
10 pMHC-II are able to stimulate a T cell response (162). Given that APCs contain 
upward of 10
5
 pMHC-II molecules on the plasma membrane at a given time, the ability of 
a T cell to recognize enough individual cognate pMHC-II to induce activation is difficult 
to imagine. It has thus been proposed that identical pMHC-II complexes are clustered into 
lipid rafts during transport to the cell surface of APC thus making TCR recognition of 
relevant pMHC-II more efficient (152, 163).  
 
28 
1.2.4 Role of membrane microdomains 
1.2.4.1 Lipid rafts 
Initial descriptions of the biological membranes described a membrane where all 
lipid and protein molecules were free to diffuse throughout the structure independent of 
other molecules in what was regarded as the fluid mosaic model (164). This model has 
since evolved and it is now generally accepted that membranes are not homogenous, but 
instead contain distinct and specialized membrane microdomains that are essential in a 
variety of cellular processes (165). Perhaps the most well studied membrane 
microdomains are lipid rafts, also known as detergent-insoluble glycolipid-enriched 
complexes (DIGs) or detergent-resistant membranes (DRMs) (166, Figure 1.4A). The 
alternative name DRMs is based on their insolubility in mild nonionic detergents such as 
Triton X-100 at low temperatures, which is likely a product of their highly organized 
structure and increased concentration of cholesterol (166). Lipid rafts are enriched in 
cholesterol, sphingomyelin, and glycosphingolipids (167, 168), resulting in a highly 
ordered structure compared to the adjacent cell membrane. They are also enriched in 
glycosyl-phosphotidylinositol (GPI)-anchored proteins and certain transmembrane 
proteins depending on cell type (169, 170). Lipid rafts are involved in a variety of cellular 
processes including signal transduction, endocytosis, vesicular trafficking, and cell 
adhesion (171, 172). A well described function of lipid rafts in the immune response is 
their role in the recruitment and concentration of intracellular signaling molecules in the 
case of T cell activation (173). Several proteins responsible for regulating T cell 
activation including the Src family kinase Lck and the adapter protein LAT are  
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Figure 1.4. Schematic diagram of (A) a lipid raft and (B) a tetraspanin-enriched 
microdomain in the cell plasma membrane.  
(A) Lipid rafts are enriched in cholesterol, sphingomyelin, glycosphingolipids, glycosyl-
phosphotidylinositol (GPI)-anchored proteins, and certain transmembrane proteins 
depending on the cell type (167-170). (B) Tetraspanin-enriched microdomains (TEMs) 
are characterized by their enrichment in tetraspanin proteins (179). Several members of 
the integrin family of membrane proteins are known to associate with tetraspanin proteins 
and are concentrated in TEMs (180). Depending on the cell type, certain cell-specific 
membrane proteins have been found to cluster in TEMs, including MHC-II molecules in 
APCs (179, 181, 182). Most relevant to this study, TEMs were also shown to cluster on 
the cell surface of APC with a select set of peptide-MHC-II containing the CDw78 
epitope (153). 
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concentrated in lipid rafts along the intracellular face of the plasma membrane and several 
studies have demonstrated the importance of these lipid rafts in T cell activation (174, 
175). Early studies utilizing electron microscopy and confocal microscopy revealed that 
pMHC-II were not uniformly distributed on the cell surface, but instead are found in 
small clusters (176, 177). The first indication which implicated the involvement of lipid 
rafts in this clustering was the observation that antibody cross-linking of pMHC-II 
induced association of MHC-II with Triton X-100 insoluble lipid rafts (178). An 
additional study by Hiltbold et al. confirmed pMHC-II association with rafts since 
pMHC-II clusters co-localized with cholera toxin B subunit, a typical lipid raft marker 
that binds GM1 glycosphingolipids (150). Further evidence which suggests clustered 
pMHC-II represent lipid raft-associated pMHC-II is that treatment with methyl-beta-
cyclodextrin (MBCD), a chemical that disrupts protein association within lipid rafts by 
sequestering cholesterol from the plasma membrane (183), caused a redistribution of 
pMHC-II from their clustered formation (156).  
Additional studies by Roche and colleagues and other laboratories have resulted in 
several important findings regarding the importance of lipid rafts in antigen presentation 
(150, 152, 154, 184). A substantial fraction of MHC-II is constitutively associated with 
lipid rafts in APC, including Epstein-Barr virus (EBV)+ and EBV- B cell lines (154, 185, 
186), primary B cells (187), monocytes (188), and DCs (155, 156, 189, 190), indicating 
that MHC-II association with lipid rafts is not restricted to particular cell lines or types. 
For example, approximately 50% of surface MHC-II was found to reside in membrane 
rafts in both human and murine B cells (154). MHC-II molecules also colocalize with 
conventional raft markers, including GM1-ganglioside, in Triton X-100-resistant 
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membranes on the surface of intact B cells (150). Disruption of rafts with MBCD results 
in an approximate 60% reduction in the total amount of MHC-II associated with rafts 
(154). In the same study, treatment with MBCD inhibited the ability of B cells to 
stimulate antigen-specific T cells in conditions of low antigen dose. Since MBCD did not 
disrupt the formation of SDS-stable MHC-II dimers or total MHC-II surface expression, 
this suggests that lipid rafts concentrate pMHC-II at the plasma membrane of APC prior 
to T cell contact thereby allowing efficient antigen specific T cell activation at low 
antigen availability (154). APC lipid rafts containing pMHC-II traffic to the 
immunological synapse during the initial stages of T cell interaction with an APC and 
relevant pMHC-II are eventually recruited to the central region of the synapse while 
irrelevant pMHC-II are excluded (150, 191). In summary, these results support the 
hypothesis the lipid rafts function to concentrate specific pMHC-II at the plasma 
membrane to facilitate T cell activation.  
Despite these studies evaluating the functional role of raft-associated pMHC-II, 
less is known about what controls the incorporation of pMHC-II into these microdomains. 
Both palmitoylation and ubiquitylation are two important post-translational modifications 
that modulate protein targeting to membrane microdomains (192). However, deletion of 
the cytoplasmic domain of both the α and β chains does not affect recruitment of MHC-II 
into lipid rafts, suggesting raft recruitment is mediated through interaction with additional 
molecules or proteins (187). Pulse-chase biosynthetic radiolabeling and protein transport 
inhibiting experiments have demonstrated that MHC-II become associated with lipid rafts 
prior to peptide binding, possibly as early as the Golgi apparatus, and up to 60% of these 
MHC-II remain raft-associated during Ii degradation, peptide loading, and transport to the 
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plasma membrane (184, 193). Interestingly, one of these studies suggested that MHC-II-
bound peptides may modulate the affinity of MHC-II to membrane rafts by inducing 
conformational changes (193). Some pMHC-II epitopes may exhibit an inherent affinity 
for membrane lipid rafts, as evidenced by the observation that some anti-pMHC-II mAbs 
recognize a subset of lipid-raft resident pMHC-II (186). However, the molecular 
mechanisms governing this possible association are currently not fully understood. 
Additional findings suggest that MHC-II may associate with lipid rafts during 
transport onto ILVs within MVB (152, 194). ILVs contain several of the molecules 
associated with lipid rafts including cholesterol, sphingomyelin, and gangliosides (195-
197). Furthermore, the pMHC-II present on exosomes is detergent insoluble suggesting 
that exosome-, and thus ILV-associated MHC-II is largely present in lipid rafts (195). 
Peptide loading is likely to occur on ILV-associated MHC-II, and it has been suggested 
that fusion of ILV with the MVB limiting membrane occurs prior to transport of mature 
pMHC-II to the plasma membrane (145). A hypothetical model has been proposed where 
ILVs containing raft-associated MHC-II containing similar antigenic peptides fuse with 
the limiting membrane of MVB, followed by outward budding of the MVB and formation 
of a transport vesicle which eventually docks and fuses with the plasma membrane, 
thereby delivering raft-associated pMHC-II into the plasma membrane (152). This model 
is supported by the observation that pMHC-II generated in antigen-loading compartments 
arrive at the plasma membrane of DCs in small microclusters which resemble lipid rafts 
(156). While there is much left to be known about the role of lipid rafts in antigen 
presentation, if the above model holds true, it will represent a mechanism for APCs to 
temporally and spatially coordinate the presentation of relevant antigens.  
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1.2.4.2 Tetraspanin-enriched microdomains 
In addition to associating with lipid raft microdomains, pMHC-II also bind a class 
of membrane proteins termed tetraspanins (151, 181, 182), which form larger membrane 
complexes called tetraspanin-enriched microdomains (TEMs) or the tetraspanin web 
(198, 199). As their name suggests, TEMs are enriched in tetraspanins, a family of 
proteins containing four transmembrane domains (Figure 1.4B). A conserved feature of 
tetraspanin proteins is the presence of a small extracellular loop and large extracellular 
loop that connects four transmembrane domains (200). These extracellular domains 
mediate specific protein-protein interactions with laterally associated proteins within the 
plasma membrane, ultimately resulting in the formation of a larger scaffolding complex. 
The cytoplasmic regions of tetraspanins contain palmitoylation sites which contribute to 
the clustering of tetraspanin molecules and mediate associations with cytoskeletal and 
signaling molecules (201, 202). Tetraspan microdomains are important in several diverse 
cellular processes including signal transduction, cell proliferation, cell adhesion, cell 
fusion, cell migration, and host-pathogen interactions (203, 204). 
Membrane clustering of TEMs involves several protein-protein interactions that 
can be classified as primary, secondary or tertiary (199, 205). All three types of 
tetraspanin interactions contribute to the formation and preservation of TEM structure and 
function (206). Primary interactions involve the association of tetraspanins with other 
non-tetraspanin molecules. Tetraspanin molecules can form different primary interactions 
in different cell types. For example, the tetraspanin CD81 associates with CD19 in B 
cells, forming part of the coreceptor for antigen recognition by surface immunoglobulin 
(207). However, CD81 associates with CD4 and CD8 in T cells (208). Tetraspanins 
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expressed in immune cells are also well known to directly bind a variety of integrins 
(180). Secondary interactions include associations of tetraspanins with other members of 
the tetraspanin family and require the palmitoylation of tetraspan cytoplasmic residues to 
maintain such interactions (209). Whereas primary and secondary interactions involve 
direct binding of tetraspanins, tertiary interactions involve the indirect association of 
tetraspanins with additional proteins in TEMs as a result of the clustering of several 
proteins (205). Similar to lipid rafts, TEMs are enriched in membrane cholesterol and are 
relatively detergent insoluble (210). Furthermore, the different types of tetraspanin 
interactions described above can be alternatively classified based on their susceptibility to 
disruption by different detergents (211). 
Tetraspanins are expressed in a variety of cell types and modulate several distinct 
cellular processes including but not limited to endocytosis, exocytosis, adhesion, 
migration, signaling, and intracellular protein transport (207). Nearly all cells of the 
immune system express tetraspanins including CD9, CD37, CD53, CD63, CD81, CD82, 
and CD151 (179, 207). There are several reports which demonstrate the ability of MHC-
II to associate with different tetraspanin family members (153, 179, 182, 212). The 
endolysosomal tetraspanins CD81 and CD82 co-immunoprecipitate with MHC-II in 
human B cell lines (182, 198, 212). CD63 associates with peptide-loaded MHC- II within 
intracellular vesicles of immature DCs, whereas other tetraspanins including CD9, CD53, 
and CD81 associate with MHC-II at the plasma membrane (181). Furthermore, MHC-II 
associates with CD9 and CD38 in human monocytes (188), and with CD9, CD53, CD81, 
and CD82 in human DCs (212).  
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Tetraspanins were also reported to cluster on the cell surface of APC with a select 
set of MHC-II containing the CDw78 epitope identified by the mAb FN1 which interacts 
only with clustered MHC-II epitopes. Immunoprecipitation with this antibody in mild 
detergents resulted in the enrichment of tetraspanins and DM, compared with an antibody 
recognizing the entire pool of DM molecules (153). Moreover, these tetraspanin-
associated CDw78+ clusters of MHC-II were shown contain a select set of peptides that 
were functionally enhanced in their ability to activate T cell responses (151, 153, 213). 
These findings supported the idea that TEMs facilitate pMHC-II clustering into distinct 
membrane microdomains separate from lipid rafts (153, 214). However, an additional 
study found no correlation between expression of CDw78 and expression of tetraspanins 
and instead concluded that rather than defining a unique tetraspanin-associated subset of 
MHC-II, CDw78 is instead a conformational epitope generated during intracellular 
trafficking of MHC-II (212). It has been suggested by some that the distinction between 
lipid raft microdomains and TEMs is artificial and non-existent in vivo (152), supported 
by several studies which have indicated that tetraspanins can be isolated in detergent-
insoluble fractions in a cholesterol-dependent manner along with lipid rafts (215, 216).  
More recently, Unternaehrer et al. have suggested that the ability of distinct forms 
of mouse MHC-II to cluster is largely dependent on the direct association of MHC-II with 
the tetraspanin CD9 (217). Conversely, a follow-up study demonstrated that deletion of 
CD9 and CD81 had no effect on this clustering of MHC-II, and that association with lipid 
rafts was responsible for this clustering (190). Moreover, an additional study 
demonstrated that silencing of CD9, CD63, and CD81 actually enhanced MHC-II 
expression (218). Given the inconsistency in studies which have evaluated tetraspanin 
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association with MHC-II, the concept that TEMs function to cluster unique functionally-
relevant subsets of pMHC-II at the surface of APC is controversial, and the functional 
role of TEMs in antigen presentation remains uncertain. 
 
1.3 Exosomes 
Antigenic presentation of peptides by MHC-II to CD4+ T cells can also occur in 
the absence of cell-cell contact between an APC and T cell via a mechanism involving 
membrane vesicles termed exosomes (219-221). As previously mentioned, the typical 
mode of MHC-II presentation involves the creation of mature pMHC-II on the ILVs 
within MIICs followed by back-fusion of ILVs with the MIIC limiting membrane and 
subsequent transport to the cell surface. In some instances, an entire MVB fuses directly 
with the plasma membrane, releasing its entire contents including ILVs into the 
extracellular milieu and the secreted ILVs are referred to as exosomes (222). The term 
exosome was first used to describe microvesicles that were secreted by neoplastic cell 
lines (223). However, exosomes were not widely studied until EBV-transformed B cells 
were shown to secrete exosomes that could induce antigen-specific MHC-II-restricted T 
cell responses (219). These results were further extended to dendritic cells (220, 221). In 
addition to professional APCs, exosomes are secreted by a wide variety of cell types such 
as T cells, mast cells, intestinal epithelial cells, and tumor cells (224). The possibility that 
exosomes are involved in several pathological conditions including the spread of 
pathogens (225, 226) and modulation of immune responses (227, 228) has stimulated 
further research on these vesicles. 
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Exosomes can be distinguished from other membrane vesicles based on their size, 
density in sucrose, sedimentation value, intracellular origin, and protein and lipid 
composition (229). Exosomes have been purified from a variety of biological sources 
including plasma (230), serum (231), urine (232), milk (233), and several body tissue 
fluids (234-236) suggesting that these vesicles are actively secreted from cells in vivo. 
The protein composition of exosomes is dependent on the cell type which it has been 
secreted from, but all exosomes share some ubiquitous protein markers. Proteomic 
analysis of exosomes purified from cultured cells and biological fluids have identified a 
broad range of exosomal markers including adhesion molecules (integrins, intercellular 
adhesion molecule 1, lymphocyte function-associated antigen 3, CD11 a, b, and c) 
signaling molecules (kinases, Src homology 2 domain-containing proteins, phosphatases, 
catenins), membrane trafficking and MVB formation proteins (lysosomal-associated 
membrane proteins 1 and 2, Rab GTPases, annexins), cytoskeletal proteins (tubulin, 
coifilin, actin, moesin), lipid raft-associated molecules (lysobisphosphatidic acid, flotilin-
1, cholesterol), tetraspanins (CD9, CD37, CD53, CD63, CD81, CD82), and antigen 
presentation molecules (CD86, MHC-I, MHC-II) as shown in Figure 1.5 (229, 237). 
Given the variety of molecules which are carried by exosomes, these vesicles have been 
implicated in a variety of cellular processes (229). 
Since the initial discovery that EBV-transformed B cells secrete significant 
amounts of specific pMHC-II on exosomes after incubation with intact protein which can 
in turn stimulate antigen specific T cell responses (219), much work has concentrated on 
understanding the role of exosomes in antigen presentation and their ability to trigger 
immune responses. Exosomes themselves can function as a source of antigen for dendritic 
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Figure 1.5. Diagram of the protein composition of exosomes compiled from various cell 
types. 
Adapted from (237). 
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cells to present to T cells. For example, exosomes purified from tumor cell lines contain 
tumor antigens that can induce activation of antigen-specific T cells in the presence of 
DCs (238). As previously stated, exosomes can also function as APCs and present antigen 
on their own when they express pMHC-II on their surface. APC-derived exosomes can 
directly activate CD4+ T cell lines (219, 239) and primary CD4+ T cells in vitro and in 
vivo, respectively (220, 240, 241). Furthermore, exosome-derived pMHC-II can be 
transferred to recipient DCs to generate peptides to load onto their own MHC molecules 
(242) or may remain intact and be expressed on the cell surface of recipient DCs for the 
activation of allogeneic T cells (243). Exosomes purified from mature rather than 
immature DCs are more efficient at inducing T cells activation suggesting that mature DC 
co-stimulatory molecules on exosomes may assist in T cell activation (239, 242). 
Plasmacytoid DCs are relatively poor activators of naïve CD4+ T cells due to their 
limited phagocytic activity, but after capturing and internalizing exosomes from the 
environment, they become effective T cell stimulators (244).  
Interestingly, exosomes purified from human monocyte-derived DCs, various cell 
lines, and human plasma were found to contain novel MHC-I structures as detected by 
conformational-dependent antibodies, suggesting that exosomes may contain unique 
MHC complexes or epitopes for recognition by T cells that are not present on the surface 
of APCs (245). Given their ability to function as APCs and activate specific T cell 
responses, preliminary studies investigating the therapeutic potential for exosomes to be 
used as a possible alternative to DC-based immunotherapy have been performed, 
especially in the case of anti-tumor immunotherapy (246-250). Further studies are 
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required in order to understand the role of exosomes in vivo and their importance in the 
immune response to pathogens and immune tolerance.   
 
1.4 Peptide-dependent anti-MHC-II antibodies 
The generation of antibodies against MHC-II molecules has proven to be useful 
tools in the study of fundamental processes in antigen presentation. One of the first 
identified peptide-MHC-II specific antibodies, termed Y-Ae, recognizes self Eα peptide 
bound to mouse I-A
b
 molecules (251). Initial studies using this antibody provided the first 
evidence for differential expression of pMHC-II between the thymic medulla and cortex, 
supporting the hypothesis that different ligands are involved in the positive and negative 
selection of T lymphocytes (252). Since its description, several additional anti-pMHC-II 
antibodies have been described (253-256). For example, antibodies recognizing specific 
pMHC-II complexes have been useful in quantifying the abundance of these complexes in 
a variety of cell types. Using the Y-Ae antibody, the Eα peptide was found to be bound to 
12% of all I-A
b
 molecules on APCs (256). Another mAb termed 30-2, which binds a 
partially degraded intermediate of Ii in the context of I-A
b
, was also used to show similar 
levels of surface expression of this self pMHC-II complex when compared to Y-Ae (254). 
The mAb Aw3.18 which recognizes murine I-A
k
 molecules bound to the peptide residues 
48-62 of the exogenous antigen hen egg lysozyme, was used to determine the fraction of 
I-A
k
 molecules loaded with this peptide after culture of APC with exogenous antigen 
(253). The mAb UL-5 A1 recognizes a conformational epitope formed by 
DRB1*01:01molecules containing HLA-A2 derived peptides, and binds to pMHC-II in a 
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similar fashion as T cells (257). The use of these pMHC-II specific mAbs in these early 
studies resulted in key findings that contributed to our early understanding of the peptide 
repertoire expressed by antigen presenting cells. It has been well documented that pMHC 
complexes can exist in multiple conformations as a result of their traffic through the 
endocytic pathway and eventual binding of peptide (14, 258). The initial detection and 
description of these conformational changes was aided by the use of anti-MHC mAbs that 
were sensitive to these shifts in conformational states (259-264). One such example is the 
mAb 25-9-17 (265) which was shown to bind I-A
b
 molecules on the surface of B cells. 
25-9-17 recognized I-A
b
 molecules containing CLIP but failed to recognize I-A
b
 loaded 
with a peptide derived from the Eα chain of I-E suggesting bound peptides induce subtle 
changes in MHC-II conformation (266).  
Additional studies using the anti-HLA-DR3 mAb 16.23 and mutant B cell lines 
revealed that HLA-DR3 molecules can exist in different conformational states (267, 268). 
Mutagenized B lymphoblastoid cells selected for loss of the 16.23 epitope were unable to 
process and present protein antigen, contained SDS-instable MHC-II dimers, and lost the 
expression of two DR3 determinants (267, 269). The role of HLA-DM in the MHC-II 
pathway had not yet been uncovered; however, it was not long until the absence of HLA-
DM was attributed to the defective antigen presenting phenotype in these mutant B 
lymphoblastoid cell lines (270, 271). Formation of the 16.23 epitope was later shown to 
be influenced by interaction with HLA-DM and the Ii (272, 273). These conformational 
differences are important because they can affect T cell reactivity. For example, it was 
shown that T cells could differentiate between the 16.23+ or – conformations of DR3 
(273). Others have also found that T cells can selectively recognize distinct pMHC-II 
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conformations which result from different antigen processing and peptide loading 
pathways (274, 275). Given that these findings were partly based on the detection of 
conformers using anti-MHC-II mAbs, one cannot discredit the value of these mAbs as a 
valuable research tool in uncovering particulars of antigen presentation.   
 
1.5 Antibody-defined epitopes on HLA-DRB1*04 molecules 
1.5.1 NFLD.D1, NFLD.D2, NFLD.D10 
Several mouse monoclonal antibodies that recognize different epitopes on HLA-
DRB1*04 molecules have been previously produced and characterized in our laboratory 
(276-281). These antibodies were generated using class-II-negative murine L-cell 
fibroblasts transfected with human HLA-DR molecules as immunogens. The NFLD.D1 
mAb recognizes an epitope in the β2 domain of all DRβ1*04 molecules (278). Both a 
leucine at position 180 and a threonine at position 181 are critical for this epitope (282). 
The NFLD.D2 mAb binds DRB1 molecules near the peptide binding groove which have 
the amino acid sequence QKRAA or QRRAA from position 70 to 74. The epitope for 
NFLD.D2 is influenced by peptide in the peptide-binding groove and other amino acids at 
positions 28, 67, and 86 (278, 279). An additional mAb, NFLD.D10, recognizes an 
epitope on DRB1 molecules near the peptide binding groove, with amino acids at 
positions 70 and 73 playing a critical role in mAb binding (279). These mAbs have been 
useful in studying the expression of HLA-DRB1*04 in professional and non-professional 
antigen presenting cells (278-282).  
45 
1.5.2 NFLD.D11 and NFLD.D13 
Two other mAbs, which are the main focus of this thesis, are NFLD.D11 and 
NFLD.D13. Compared with the mAbs described above, their epitopes are more restricted 
in their cellular expression. NFLD.D11 was previously shown to bind an epitope on 
DRB1*04:01 and 04:13, but not 04:02, 04:04, 04:05, 04:06, 04:07, 04:08, 04:10, or 04:11 
molecules, in EBV-transformed B cell lines (78, 280).  These results demonstrated that 
both a lysine at position 71 in pocket 4 and a glycine or valine at position 86 in pocket 1of 
the DRB1*04 molecule are important for NFLD.D11 binding. Further investigation 
demonstrated that expression of this epitope requires co-expression of HLA-DM in the 
context of DRB1*04:01, as this epitope is not expressed in B cells lacking DM but is 
restored after reconstitution of DM expression (280). In addition, the epitope was not 
expressed by the DM- B cell line 9.5.3 0401, but abundantly expressed by its DM+ parent 
cell line 8.1.6 0401 (78). Further investigation showed that binding of NFLD.D11 to its 
epitope can be prevented by blocking with antibodies which bind near the peptide binding 
groove including NFLD.D2 and NFLD.D10 (283). Given the DM-requirement for 
presentation of this epitope, it is similar to and can be classified as a DM-dependent 
epitope as previously described (102). 
The epitope recognized by NFLD.D11, hereafter referred to as D11-0401, requires 
DM for expression, but DM alone is not sufficient for expression, suggesting that 
formation of this epitope is contingent on other cellular factors (280). Furthermore, 
several cells which express both DM and DRB1*04:01 lack expression of D11-0401 
including IFN-γ stimulated synovial, epithelial, and breast cancer cells (281), as well as 
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the Burkitt’s B cell lymphoma line Daudi and T cell line Jurkat transfected with 
DRB1*04:01, suggesting that normal and EBV-transformed B cells contained the correct 
combination of cellular factors responsible for D11-0401 expression (280).  
Similar to NFLD.D11, the NFLD.D13 mAb binds an epitope on DRB1*04:01 
molecules in B cell lines (283). However, whereas NFLD.D11 binding to DRB1*04:01 
requires co-expression of DM, NFLD.D13 binds to DRB1*04:01 only in the absence of 
DM (78). For example, the NFLD.D13 epitope on DRB1*04:01, hereafter referred to as 
D13-0401, is abundantly expressed by the DM- B cell line 9.5.3 0401, whereas the DM+ 
parent cell line 8.1.6 0401 lacks expression of this epitope (78). D13-0401 is also 
expressed on other DM- B cell lines including 5.2.4 0401, SJO Dw4, BLS Dw4, and T2 
Dw4 (283). Similar to D11-0401, the D13-0401 epitope is near the peptide binding 
groove of DRB1*04:01 because binding can be prevented by blocking with antibodies 
that bind near this region including NFLD.D2 and NFLD.D10 (283). Since the presence 
of DM prevents the presentation of the D13-0401 epitope, it can be classified as DM-
sensitive, as described for other peptide epitopes (102-104). 
Since the 8.1.6 and 9.5.3 cell lines were important in characterizing the D11-0401 
and D13-0401 epitopes in previous studies, both cell lines were routinely used in the 
current study. For this reason, a brief summary of the derivation of these cell lines, as 
well as an additional DM- cell line, 5.2.4, is shown in Figure 1.6. As previously reported, 
9.5.3 0401 lacks expression of DM compared to its parent 8.1.6 0401, while both retain 
expression of intact HLA-DR molecules (Figure 1.7). 
NFLD.D13 also recognizes an additional epitope on DRB1*04:04, but not 
04:05, 04:08, 04:10, 04:13, 01:01, 01:02, or 14:02 molecules, in EBV-transformed B cell  
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Figure 1.6. Derivation of the cell lines 8.1.6, 5.2.4, and 9.5.3 from the B lymphoblastoid 
cell line T5-1 and mapping of gene deletions.  
Cell lines were derived from their parent by ethyl methane sulfonate mutagenesis 
followed by immunoselection with the indicated antibody and complement lysis (267). 
The vertical bars indicate approximate locations of HLA-I and HLA-II genetic loci. 
Additional genes located in this region of the MHC, as shown in Figure 1.1, have been 
omitted for ease of demonstration. Adapted from (271). 
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Figure 1.7. The cell line 9.5.3 lacks expression of DM compared to its parent cell line 
8.1.6. 
The cells lines 8.1.6 and 9.5.3 (both transfected with DRB1*04:01) were stained for 
HLA-DM and HLA-DR using immunocytochemistry. Cells were removed from cell 
culture and washed in PBS. Cell preparations were made using a cytocentrifuge by 
centrifuging 50 000 cells/prep at 1600 rpm for 5 minutes. Slides were allowed to dry at 
room temperature for a couple of hours and were then fixed in ice cold acetone at -20
o
C 
for 10 minutes followed by a 1 hour drying period at room temperature. Following 
fixation, cells were rehydrated with PBS, rinsed with wash buffer (0.5% BSA, 0.05% 
Tween-20 in PBS), and incubated in H2O2 for 10 minutes. Cells were then washed 3 x 5 
minutes with wash buffer and blocked for 1 hour with 15% goat serum in PBS. Cells 
were incubated for 1 hour at room temperature with primary antibodies anti-DR (L243), 
anti-DM (MaP.DM1), and an isotype control diluted in wash buffer, followed by 3 x 5 
minute washes as above and 30 minute incubation with a peroxidase-conjugated 
secondary antibody. Cells were washed again as above and stained with ImmPACT 3, 3`-
diaminobenzidine peroxidase substrate (Vector) for 4 minutes and counterstained with 
Mayers’ hematoxylin for 1 minute. Slides were viewed using a Leica stereomicroscope 
and images were captured using a SPOT RT CCD Cool Camera. Images shown are 100x. 
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lines. Comparing the amino acid sequence of these DRB1 molecules, four residues that 
contribute to formation of the NFLD.D13 epitope, hereafter referred to as D13-0404, 
were deduced: tyrosine at position 37, aspartic acid at position 57, arginine position 71, 
and valine at position 86 (283). Interestingly, all four of these positions are contact points 
for either T cell or peptide recognition, which suggest that this epitope is also near the 
peptide-binding groove of DRB1*04:04, similar to D11-0401 and D13-0401 on 
DRB1*04:01. 
Unlike D11-0401 and D13-0401, it is not clear whether DM alters expression of 
this epitope. As with NFLD.D11, mAbs known to bind near the peptide binding groove 
such as NFLD.D2 and NFLD.D10 were able to block binding of NFLD.D13 to its epitope 
on DRB1*04:04 molecules (283). 
Given the allele-dependent and cell-restricted expression of the D11-0401, D13-
0401, and D13-0404 epitopes, additional work by Spurrell D.R. examined other factors 
contributing to formation of these epitopes (283). It was observed that D11-0401, D13-
0401, and D13-0404 formation required newly synthesized DRB1*04 molecules. In 
addition to being expressed at the cell surface, both D11-0401 and D13-0404 were 
observed in the endosomal pathway and co-localized with markers for peptide loading 
compartments. Given that these epitopes are modulated by DM, are located near the 
peptide binding groove, and reside intracellularly within MIICs, he further hypothesized 
that cellular-restricted peptides or specific peptide processing events contribute to the 
formation of these epitopes. Both D11-0401 and D13-0401 were found to require a subset 
of cysteine proteases for epitope formation, indeed suggesting that specific peptides 
contribute to formation of these epitopes (283). 
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1.6 Rationale and objectives 
As previously described, the formation of the DRB1*04:01-restricted D11-0401 
epitope requires expression of the peptide-editor HLA-DM, and is thus DM-dependent 
(78, 280, 283). Conversely, the D13-0401 epitope is DM-sensitive as it is only expressed 
on DRB1*04:01 molecules in the absence of DM (78, 283). Interestingly, this epitope is 
similar to the D13-0404 epitope present only on DRB1*04:04 molecules. Prior to my 
thesis work, Spurrell, D.R. and Drover, S. demonstrated that these epitopes mapped to the 
peptide-binding groove, suggesting that peptides directly contribute to epitope formation. 
Additional findings supporting this hypothesis were (a) the cell-specific expression 
profile of these epitopes (278-280); (b) D11-0401 and D13-0404 co-localized with 
markers of MIICs (283); and (c) inhibition of a particular subset of cellular cysteine 
proteases abrogated D11-0401 and D13-0401 expression (283). The hypothesis that 
bound peptide contributes to the formation of these epitopes is further investigated in this 
thesis. Since these DM-modulated epitopes are expressed on DRB1 alleles carrying the 
shared epitope (SE) that is strongly associated with the development of RA (284, 285), 
and DM has been suggested to play a role in RA (286-288), further investigation into the 
formation of these epitopes may provide insight into the mechanism of SE-associated 
autoimmunity. 
Although the DM requirements of these epitopes were partially understood when 
this thesis work began, the role of HLA-DO to the formation of these epitopes was 
unknown. HLA-DO can affect DM-mediated peptide loading and has also been shown to 
alter the presentation of antigen-specific epitopes (68, 97, 289, 290). Since D11-0401 
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requires DM for formation and is likely influenced by the bound peptide, we questioned 
whether HLA-DO also influences this epitope. Similarly, we examined the role of DO in 
the presentation of the DM-sensitive D13-0401 epitope. Understanding the antigen 
processing events that govern the formation of these epitopes may give insight into the 
formation of DM-resistant, DM-sensitive, and DM-dependent antigenic epitopes and their 
role in DRB1*04-associated autoimmune disease. 
Although the previous study identified D11-0401 complexes on exosome-like 
vesicles using electron microscopy, analysis of these epitopes on purified exosome 
populations was not done (283). Other evidence to suggest this included colocalization of 
these epitopes with exosomal tetraspanin markers CD63 and CD82 within MVBs, the sire 
of exosome biogenesis (283). EBV-transformed B lymphocytes are known to 
constitutively secrete exosomes that contain functionally competent pMHC-II complexes 
on their surface (219). Recently, novel MHC-I epitopes have been detected on exosomes 
derived from DCs, suggesting that unique MHC epitopes not expressed on the cell surface 
may be present on exosomes for recognition by the immune system (245). For these 
reasons, we investigated the expression of D11-0401, D13-0401, and D13-0404 on B-
LCL-derived exosomes. 
The tetraspanins CD63 and CD82 are also integral components of TEMs, which 
are able to concentrate particular epitope-defined pMHC-II complexes in the plasma 
membrane (153). These TEM-associated pMHC-II complexes were associated with DM 
and contained a select set of antigenic peptides (153). After preliminary experiments 
indicated that apparent disruption of TEMs caused a decrease in expression of D11-0401 
and D13-0404 (283), we hypothesized that these epitopes may represent a distinct subset 
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of DRB1*04 molecules that associate with TEMs similar to other previously described 
epitopes (153, 217). We also investigated the role of another type of membrane 
microdomain, lipid rafts, in the presentation of these epitopes, since distinct pMHC-II 
molecules have been shown to associate with these microdomains (156, 163). The 
possibility that the DRB1*04 epitopes described here may represent distinct pMHC-II 
complexes associated with particular membrane microdomains would further our 
understanding of expression of DM-sensitive, DM-dependent, and DM-resistant epitopes 
and implications for T cell recognition. 
 
Objectives: 
 
1.  To determine the role that HLA-DO has in regulating the expression of the 
D11-0401, D13-0401, and D13-0404 epitopes in B-LCL. 
2. To further investigate if endogenous cell-specific peptides are involved in 
forming D11-0401, D13-0401, and D13-0404.  
3. To characterize the expression of the D11-0401, D13-0401, and D13-0404 
epitopes on B-LCL-derived exosomes. 
4. To determine if lipid rafts and TEMs contain specific subsets of pMHC-II 
expressing the D11-0401, D13-0401, and D13-0404 epitopes. 
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Chapter 2 
 
Materials and Methods 
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2.1 Cell lines, reagents, and antibodies 
The human B cell lines SAVC (DRB1*04:01), MT14B (DRB1*04:04), Boleth 
(DRB1*04:01), PF97387 (DRB1*04:01), WT51 (DRB1*04:01), GM2219 
(DRB1*04:01), and BM92 (DRB1*04:04) were obtained through the 10
th
 International 
Histocompatibility Workshop (291). The DRB1-transfected human B cell lines 8.1.6 
0401, 9.5.3 0401, 5.2.4 0401, 5.2.4 0401 DM, 5.2.4 0404, and 5.2.4 0404 DM were 
kindly provided by Dr. E. D. Mellins (Stanford University) and are previously described 
in detail (78, 270). The B cell lines BJAB.DO2 (BJAB DO) and BJAB.V2 (BJAB V) 
were kindly provided by Dr. P. Roche (National Institutes of Health) and are described 
elsewhere (68). Both B cell lines BJAB and RAMOS were kind gifts from Dr. J. 
Thibodeau (University of Montreal). Ramos, BJAB, BJAB V, and BJAB DO were 
transfected with DRB1*04:01 using a previously described method (292) and successful 
transfection of DRB1*04:01 was confirmed by flow cytometric analysis of surface 
expression. DRA*01:01 and DRB1*04:01 transfected cells lacking DM expression 
(T2.Dw4, BLS-1.Dw4, SJO.Dw4) and DM-expressing cell lines (T2.Dw4DM, BLS-
1.Dw4 x .174, SJO.Dw4 x .174) are described elsewhere in detail (280). T2.Dw4 was 
provided by Dr. W.W. Kwok (Benaroya Research Institute at Virginia Mason) while 
T2.Dw4DM was a kind gift from Dr. P. Cresswell (Yale University School of Medicine). 
All cell lines were maintained in either RPMI-1640 or Iscove’s modified Dulbecco’s 
medium (IMDM) supplemented with 10% heat inactivated fetal calf serum (FCS), 100 
units/ml penicillin, 100 g/ml streptomycin, 0.25 g/ml amphotericin B, and 2 mM L-
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glutamine (Gibco), and incubated in a humidified air chamber containing 5% CO2 at 
37oC. 
HLA-DR expression was analyzed using the following monoclonal antibodies 
(mAbs): L243, which binds a conformational epitope on DR dimers near the peptide 
groove (293, 294); NFLD.D1 specific for an epitope in the beta-2 (β2) domain of 
DRB1*04 (278); NFLD.D11,  specific for an allele-specific DM-dependent epitope on 
DRB1*04:01 dimers; NFLD.D13, cross reactive for  a DM-sensitive epitope on 
DRB1*04:01 dimers and a DM-resistant epitope on DRB1*04:04 DR dimers (78, 103, 
280). Other mAbs used in this study included mAbs against HLA-DO (DOB.L1), HLA-
DM (MaP.DM1), CLIP (cerCLIP), Ii (LN2), CD71 (M-A712), CD45 (HI30), ICAM-1 
(HA58), CD55 (phycoerthryin (PE)-conjugated IA10), CD40 (5C3), CD86 (IT2.2), CD82 
(50F11), and LAMP-1 (H4A3) from BD Pharmingen; GAPDH (6C5), HLA-DM (Tal 
18.1), HLA-DRB (Tal 14.1), Ii (PIN.1), CD59 (MEM-43), and CD82 (TS82b) from 
Abcam; and CD63 (CLB-180) from Cedarlane. The mAb clone W6/32 was used to detect 
MHC-I. Isotype control mAbs were locally prepared or obtained from BD Pharmingen, 
eBioscience, or Abcam depending on the application. Secondary antibodies included 
peroxidase-conjugated goat anti-mouse F(ab)2 IgG and IgM for cell enzyme-linked 
immunosorbent assay, PE-conjugated goat anti-mouse IgG Fcγ and PE-conjugated goat 
anti-mouse IgM  chain for flow cytometry, horse radish peroxidase (HRP)-conjugated 
goat anti-mouse F(ab`)2 IgG Fcγ and HRP-conjugated goat anti-mouse IgM µ chain for 
immunoblotting (Jackson Immunoresearch Laboratories, Inc.), and Alexa Fluor 488-
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conjugated goat anti-mouse IgG1 Fc fragment for confocal microscopy (Life 
Technologies). 
 
2.2 Flow cytometry  
Freshly harvested cells were washed twice with wash buffer (phosphate buffered 
saline (PBS) containing 0.2% FCS and 0.02% sodium azide) and adjusted to 1 x 10
7
 
cells/ml for staining. 5 x 10
5
 cells per stain were incubated with the indicated primary 
antibody diluted in a total volume of 100 µl wash buffer for 30 minutes at 4
o
C. Incubation 
with an isotype control was performed in parallel. Cells were then washed twice with 
wash buffer and incubated with 100 µl of the appropriate fluorochrome-conjugated 
secondary antibody diluted in wash buffer for 30 minutes at 4
o
C in the dark. After 2 
washes as described above, cells were fixed with 1% paraformaldehyde (PFA) diluted in 
PBS and analyzed using a BD FACSCalibur flow cytometer (Becton Dickinson). 
Analysis of flow cytometric data was performed using FlowJo 7.6 software (FlowJo, 
LLC). 
For assessment of intracellular antigens by flow cytometry, cells were fixed with 
2% PFA in PBS for 15 minutes at room temperature, washed with media followed by a 
wash with PBS, then permeabilized with 0.2% Tween-20 diluted in PBS for 10 minutes at 
room temperature. After permeabilization, cells were stained as described above for 
surface staining, except that both primary and secondary antibodies were diluted in 
permeabilization buffer. 
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For flow cytometric analysis of exosome-coated beads, 10 µl of exosome-labeled 
beads was incubated with the indicated primary antibody diluted in wash buffer (PBS 
containing 0.5% bovine serum albumin (BSA)) in a total volume of 50 µl for 30 minutes 
at 4
o
C. Incubation with an isotype control antibody was performed in parallel. Beads were 
then washed twice in wash buffer and incubated with the appropriate fluorochrome-
conjugated secondary antibody diluted in wash buffer in a total volume of 50 µl for 30 
minutes at 4
o
C. Beads were washed two more times and resuspended in wash buffer for 
analysis. Fluorescence was analyzed on the single beads only by gating on the single bead 
population. 
 
2.3 Cell enzyme-linked immunosorbent assay 
Cell surface expression of DR molecules and epitopes was measured in some 
experiments using a modified enzyme-linked immunosorbent assay, termed cell enzyme-
linked immunosorbent assay (CELISA), as previously described in detail (295, 296). 
Cells were fixed in 2% PFA diluted in PBS, washed with media followed by a wash with 
PBS, and seeded in a 96 well round-bottom plate at 2.5 x 10
4 
cells per well. Cells were 
incubated for 1 hour at room temperature with the indicated primary antibody or isotype 
controls. Cells were washed 3 times with CELISA wash buffer (PBS containing 0.5% 
BSA and 0.05% Tween-20) and incubated for 1 hour at room temperature with the 
appropriate peroxidase-conjugated secondary antibody. After 3 washes as described 
above, cells were incubated for 30 minutes in the dark with o-phenylenediamine 
dihydrochloride substrate (Sigma) for colorimetric detection. The reaction was stopped by 
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the addition of sulfuric acid and results were analyzed using a Multiscan 
spectrophotometer (Biorad) using a 490nm filter. Background optical density (OD) values 
obtained from isotype controls were subtracted from each test OD and values from 
triplicate samples were averaged. Where indicated, CELISA results are presented as the 
fold change in expression of the particular molecule or epitope, calculated by dividing the 
mean OD of treated cells by the mean OD of control cells, where a value equal to 1 
indicates no change in expression. 
 
2.4 Western blot analysis 
Whole cell lysates were prepared in either Triton X-100 lysis buffer (PBS pH 8.0, 
1% Triton X-100, 0.5 M ethylenediaminetetraaccetic acid (EDTA))  or 3-[(3-
Cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate (CHAPS) lysis buffer 
(PBS pH 8.0, 1% CHAPS, 0.5 M EDTA) containing the inhibitors aprotinin (1 µg/ml), 
leupeptin (1 µg/ml), pepstatin A (1 µg/ml), and phenylmethylsulfonyl fluoride (10 µg/ml) 
(Sigma). The protein content of lysates was determined using the bicinchoninic acid assay 
(Thermo Fisher Scientific). Proteins were separated by sodium dodecyl sulfate – 
polyacrylamide gel electrophoresis on 8 – 12 % gels (SDS-PAGE) under non-reducing or 
reducing conditions where indicated, followed by western blotting. Nitrocellulose 
membranes were blocked with blocking buffer (tris buffered saline (TBS) containing 
0.05% Tween-20 and 5% milk powder) for 1 hour at room temperature and incubated 
overnight with primary antibodies diluted in blocking buffer at 4
o
C. Membranes were 
thoroughly washed with TBS containing 0.05% Tween-20. Blots were subsequently 
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probed with the appropriate HRP-conjugated secondary antibody diluted in blocking 
buffer for 1 hour at room temperature, followed by thorough washing as above, and 
detection with Immobilon Western Chemiluminescent HRP substrate (Millipore).  
 
2.5 Lipid raft labeling and confocal microscopy 
Cells from culture were washed in serum-free culture media and incubated with 
antibody against the molecule of interest for 30 minutes on ice. The cells were then 
washed three times in PBS containing 2% FCS, followed by a 30 minute incubation on 
ice with the appropriate fluorophore-conjugated secondary antibody. Plasma membrane 
lipid rafts were detected using the Vybrant Alexa Fluor 555 Lipid Raft Labeling Kit 
(Invitrogen) according to the manufacturer’s instructions. Cells were incubated with 
Alexa Fluor 555-conjugated cholera toxin subunit B (CT-B) for 10 minutes at 4
o
C, 
followed by three washes as above. Cells were then incubated with anti-CT-B antibody 
for 15 minutes at 4
o
C. All cells were washed twice with PBS containing 2% FCS, fixed 
with 4% PFA, and mounted on slides in Vectashield anti-fade mounting media (Vector 
Labs). Slides were viewed using an Olympus FluoView 1000 confocal laser scanning 
microscope (Olympus). 
 
2.6 Fluorescent aerolysin (FLAER) assay  
To measure the surface expression of GPI-anchored proteins on cells using flow 
cytometry, we performed the unique diagnostic FLAER assay which utilizes an Alexa 
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Fluor 488-conjugated version of a non-lysing, mutated form of proaerolysin (297). 
Proaerolyisn is a bacterial toxin secreted by Aeromonas hydrophila. After converting to 
its active form, aerolysin binds to the GPI moiety of GPI-linked molecules resulting in the 
formation of channels in the cell membrane causing cell lysis (298, 299). The FLAER 
assay was initially generated for clinical use to aid in the diagnosis of paraoxysmal 
nocturnal hemoglobinuria (PNH) (300, 301). PNH is an acquired hematopoietic stem cell 
disease characterized by a mutation in the phosphatidyl-inositol glycan gene resulting in a 
deficiency of GPI-linked proteins in a clone of hematopoietic cells (302). 
The FLAER assay was performed as previously described (297). Approximately 2 
x 10
5
 cells were washed with PBS and resuspended in 50 µl PBS containing 2% FCS. 
Either 25 µl of a FITC-conjugated isotype control antibody (BD Pharmingen) or 5 µl of 
FLAER (Protox Biotech working solution (diluted 1:10 in PBS from stock) was added to 
the cells and incubated for 15 minutes at room temperature. Finally, 50 µl of PBS 
containing 2% FCS was added to the cells and the samples were immediately analyzed 
using a BD FACSCalibur flow cytometer.  
 
2.7 Epitope blocking assay 
The location of D11-0401, D13-0404, and D13-0401 epitopes on DRB1*04:01 
and DRB1*04:04 molecules was ascertained using several mAbs with known epitopes to 
block NFLD.D11 and NFLD.D13 binding measured using CELISA and flow cytometry. 
For CELISA, cells were washed in PBS, plated in 96 well plates, and incubated for 1 hour 
at room temperature  with either anti-DRB1*04 (NFLD.D1), anti-CLIP/DR (cerCLIP), or 
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anti-DR (L243) at several concentrations (4 – 500 µg/ml). Cells were washed 3 times 
with PBS containing 0.5% BSA followed by a 1 hour incubation at room temperature 
with either NFLD.D11 for SAVC cells or NFLD.D13 for MT14B cells. The remainder of 
the assay was carried out as described above for CELISA. 
For flow cytometry, cells were first incubated with anti-DR (L243) or an isotype 
control antibody for 30 minutes on ice followed by 2 washes with flow cytometry wash 
buffer. Cells were incubated with NFLD.D11, NFLD.D13, or isotype control antibodies 
for 30 minutes on ice followed by 2 washes with flow cytometry wash buffer. Cells were 
then incubated with a goat anti-mouse IgM  chain-specific PE-conjugated secondary 
antibody for 30 minutes on ice in the dark. Finally, cells were fixed in 2% PFA dissolved 
in PBS. 
 
2.8 Protease inhibitor treatment 
B-LCL were treated for 18 hours in culture with 25 µM leupeptin (Sigma), 25 µM 
pepstatin A (Sigma), 100 µM cathepsin B inhibitor II (CBI II, Ac-Leu-Val-lysinal) 
(Calbiochem), or 50µM calpeptin (Calbiochem) as previously described (30, 280). 
Control cells were similarly treated with an equivalent volume of the protease inhibitor 
diluent (PBS or dimethyl sulfoxide). The protease inhibitors had minimal effect on cell 
viability evaluated by trypan blue exclusion. Following inhibitor treatment, cells were 
harvested from culture and flow cytometry was performed to determine surface 
expression of DR epitopes. Alternatively, cells were fixed with 2% PFA for 15 minutes at 
4
o
C, washed with culture media and PBS, and analyzed by CELISA.  
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2.9 Exosome purification 
Exosomes were purified from SAVC, MT14B, 8.1.6 0401, and 9.5.3 0401 cultures 
by differential ultracentrifugation as previously described in detail (303) and outlined in 
Figure 2.1. The procedure involves successive centrifugations at increasing speeds to 
eliminate dead cells and large cellular debris leading to the collection of a pellet 
containing small vesicles corresponding to exosomes. Prior to cell culture, RPMI-1640 
medium supplemented with 10% heat-inactivated FCS was depleted of contaminating 
FCS-derived exosomes by overnight centrifugation at 100, 000 x g at 4
o
C in a Sorvall 
Discovery 100SE ultracentrifuge (Thermo Fisher Scientific), after which the supernatant 
was filtered sterilized using a vacuum-connected 0.22 µm filter attached to a sterilized 
bottle. Exosome-depleted media (ED-media) was stored at 4
o
C up to 4 weeks until 
required for exosome purification. Prior to cell culture, media was supplemented with 2 
mM L-glutamine.  
Cells were cultured under standard conditions in 50 ml of complete media until 
they reached approximately 70% of their maximum concentration in suspension. Cells 
were then centrifuged for 10 minutes at 300 x g at 4
o
C, and resuspended in 50 ml of ED-
media and cultured for 48 hours. Cells were then centrifuged for 10 minutes at 300 x g at 
4
o
C to separate exosomes from the pelleted cells. Making sure not to disturb the cell 
pellet, the supernatant containing exosomes was collected and transferred to a 50 ml 
conical tube and centrifuged for 20 minutes at 2000 x g at 4
o
C. The resulting supernatant 
was transferred to ultracentrifugation tubes and centrifuged for 30 minutes at 10, 000 x g 
at 4
o
C with a Sorvall TH-641 rotor (Thermo Fisher Scientific) in a Sorvall Discovery 
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Figure 2.1. Purification of exosomes from B-LCL.  
Exosomes were isolated from cell culture supernatants of the B-LCL SAVC, MT14B, 
8.1.6 0401, and 9.5.3 0401 by differential ultracentrifugation as described in detail in the 
Materials and Methods and as illustrated in the flow diagram. Adapted from (303). 
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100SE ultracentrifuge. The resulting supernatant was transferred to new 
ultracentrifugation tubes and subsequently centrifuged for 70 minutes at 100, 000 x g at 
4
o
C, after which the supernatant was carefully removed with a pipette as not to disturb the 
pelleted exosomes. Exosomes were resuspended in 1 ml PBS and pooled from several 
tubes into a single ultracentrifugation tube and centrifuged for 60 minutes at 100, 000 x g 
at 4
o
C to wash the purified vesicles. Finally, the supernatant was completely removed and 
exosomes were resuspended in 100 µl PBS and cryopreserved at -80
o
C. 
 
2.10 Electron microscopy analysis of exosomes 
Purified exosomes were visualized by whole mount electron microscopy as 
previously described (303). Exosomes were fixed in 2% PFA diluted in PBS and 
deposited on formvar-carbon coated electron microscopy grids and allowed to absorb for 
20 minutes. The grids were then washed with PBS and incubated with 1% glutaraldehyde 
(Sigma) for 5 minutes. Finally, grids were washed 8 times with distilled water and whole-
mounted exosomes were imaged using a 1200EX transmission electron microscope (Jeol 
Ltd). 
 
2.11 Attachment of exosomes to latex beads for flow cytometric analysis 
To determine the expression of DR epitopes and associated proteins on the surface 
of exosomes, the vesicles were attached to latex beads and analyzed by flow cytometry as 
previously described (303). Five micrograms of exosomes, determined using the 
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bicinchoninic acid assay, was incubated with 10 µl surfactant-free aldehyde/sulfate, 4% 
weight/volume 3.9 µm latex beads (Interfacial Dynamics) for 15 minutes at room 
temperature to allow nonspecific absorption of the vesicles to the latex beads. The total 
volume of the latex bead – exosome mixture was brought to 1ml with PBS and incubated 
on a rotator wheel for 2 hours at room temperature. Free binding sites on the latex beads 
not bound by exosomes were saturated by adding 110 µl of 1M glycine (Sigma) and 
incubating for 30 minutes at room temperature to prevent nonspecific absorption of 
reagents to the beads during downstream steps. The exosome-labeled beads were then 
centrifuged for 3 minutes at 4000 rpm at room temperature. The supernatant was 
discarded and the bead pellet was washed three times with 1 ml PBS containing 0.5% 
BSA.  After the final wash, exosome-labeled beads were resuspended in 0.5 ml PBS 
containing 0.5% BSA for analysis of protein expression by flow cytometry as described 
above. 
 
2.12 Disruption of plasma membrane microdomains 
To determine whether the DRB1*04 epitopes associate with membrane 
microdomains, lipid rafts and TEM were disrupted using MBCD and saponin 
respectively, as previously described (153). To disrupt lipid rafts, cells were washed with 
serum-free culture media and cultured for 10 minutes at 37
o
C initially with 2.5, 5, or 10 
mM MBCD (Sigma) dissolved in serum-free culture media. MBCD disrupts protein 
association with lipid rafts by depleting cholesterol from the plasma membrane of cells 
(304-306). After MBCD treatment, cells were washed in serum-free culture media at 
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room temperature and fixed in 2% PFA in PBS for 15 minutes at 4
o
C to prevent the 
reassembly of rafts. Fixation was stopped by washing with 100 mM glycine diluted in 
PBS followed by a second wash with PBS. FCS was omitted from all buffers to prevent 
incorporation of cholesterol into cholesterol-depleted cells (307). Cells were then 
analyzed by flow cytometry for surface expression of relevant molecules and compared to 
untreated control cells. All concentrations of MBCD selectively disrupted expression of 
raft-associated proteins without compromising cell health and viability measured by 
forward vs side scatter plot analysis in flow cytometry and examination of cellular 
morphology by microscopy. Subsequent experiments were performed using 5 mM 
MBCD treatment unless indicated otherwise. 
Saponin was previously shown to selectively disrupt tetraspanin-tetraspanin 
interactions (153, 210). Cells from culture were washed in PBS, fixed in 2% PFA in PBS 
for 15 minutes at room temperature, and further washed with culture media and PBS. 
Fixed cells were then incubated with 0.1% saponin (Sigma) diluted in PBS with 2% FCS 
for 20 minutes at 4
o
C. Cells were washed twice with flow cytometry wash buffer. Cells 
were then analyzed by flow cytometry for surface expression of relevant molecules and 
compared to untreated control cells. 
  
2.13 Isolation of detergent resistant membranes  
Detergent resistant membranes (DRMs) containing lipid rafts were isolated using 
sucrose density gradient ultracentrifugation as previously described (308). Freshly 
harvested cells (approximately 5.5 x 10
7
) were lysed in Triton X-100 lysis buffer (PBS 
70 
pH 8.0, 1% Triton X-100, 0.5 M EDTA) containing the inhibitors aprotinin (1 µg/ml), 
leupeptin (1 µg/ml), pepstatin A (1 µg/ml), and phenylmethanesulfonyl fluoride (10 
µg/ml) for 1 hour at 4
o
C on a rotator. The lysate was mixed with an equal volume of 80% 
sucrose dissolved in lysis buffer and overlaid with 35% sucrose and 5% sucrose dissolved 
in lysis buffer. The samples were then centrifuged at 280, 000 x g for 18 hours at 4
o
C 
with a Beckman SW 55 Ti rotor (Beckman Coulter) in a Sorvall Discovery 100SE 
ultracentrifuge. Fractions approximately 400 µl in volume were carefully collected by 
pipetting from the top of the gradient. The second, third and fourth fractions corresponded 
to the visible 5 / 35% sucrose interface where DRMs float after ultracentrifugation in a 
sucrose gradient (309). To solubilize the DRMs for SDS-PAGE and western blotting 
analysis, 1% n-octylglucoside was added to each gradient fraction and incubated for 1 
hour at 4
o
C on a rotator. For SDS-PAGE, 10 µl of each gradient fraction was loaded per 
lane run under non-reducing conditions. Fractions were stored at -80
o
C. 
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Chapter 3 
 
 
Endosomal chaperones and proteases contribute to the formation of 
allele specific epitopes on HLA-DRB1*04 molecules 
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3.1 Preamble and objectives 
As described in the rationale (Section 1.6), it was previously shown that D11-
0401, D13-040, and D13-0404 epitopes were differentially modulated by DM, mapped to 
the peptide binding groove, and were peptide-dependent (78, 278-280, 283). Since DO is 
a negative regulator of DM and has a profound effect on the peptide repertoire presented 
by MHC-II to T cells (14, 68, 75-77, 97, 289, 290), we hypothesized that presentation of 
the DM-dependent D11-0401 and DM-sensitive D13-0401 epitopes is modulated by DO. 
It should be noted that this was not addressed in any preceding published or unpublished 
work and thus represents new information about these epitopes.  
As described in the co-authorship statement, the role of cytoplasmic and 
endogenous proteases in generating these epitopes was previously explored using various 
inhibitors and the cell based assay, CELISA (283). Here we expanded the study to include 
western blotting analysis of the antigen processing pathway in each cell line, as well as 
new experiments using flow cytometry. For completeness and clarity and aspirations to 
prepare this chapter for a manuscript for publication, some of the previous work is 
included in the following results as previously detailed in the co-authorship statement. 
 
The specific objectives addressed in this chapter are: 
 
1. To compare the expression of DRB1*04 epitopes in B cell lines differing in 
their expression of HLA-DO. 
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2. To further investigate whether cell-restricted peptides contribute to formation of 
D11-0401, D13-0401, and D13-0404 by examining the effect of protease inhibitors on the 
formation of these epitopes in B cell lines. 
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3.2 Results 
 
3.2.1 DM-dependent DRB1*04:01 epitope is cell context but not DO-dependent 
The DM-dependency of the allele-specific D11-0401 epitope on DRB1*04:01+ 
peripheral blood B lymphocytes and Epstein-Barr virus (EBV)-transformed B 
lymphoblastoid cell lines (B-LCL) was demonstrated by its absence on DM- 
DRB1*04:01+ antigen presentation mutant B cell lines and restoration in DM-
reconstituted cells (78, 280, 310). Given the well documented modulatory effects of DO 
on DM-mediated peptide loading (65, 311) and the DM-requirements of the D11-0401 
epitope (78, 280), we queried whether the DO molecule modulated D11-0401 expression. 
Thus, we analyzed D11-0401 expression on DM- DO- 5.2.4 0401 cells, also derived from 
8.1.6 but lacking both copies of the DOB gene (271, 312).  As expected, no D11-0401 
was detected on 5.2.4 0401, but surprisingly it was poorly reconstituted in the DM 
transfected cells (Figure 3.1A). This was not due to reduced DRB1*04:01 since both DM- 
and DM+ cells expressed equivalent amounts, nor due to deficient DM since severely 
reduced surface MHC-II/CLIP on 5.2.4 0401 DM is indicative of functional DM in these 
cells (Figure 3.1A).  
D11-0401 expression was analyzed on Burkitt lymphoma (BL) cell lines, which 
are DM+ but DO-deficient (93, 313, 314), potentially explaining lack of D11-0401 
expression on the BL cell line, Daudi-Dw4 (280). Similarly, BL cell lines BJAB and 
Ramos transfected with DRB1*04:01 barely expressed D11-0401 despite DRB1*04:01 
levels comparable to the control cell SAVC (Figure 3.1B). Western blot and flow  
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Figure 3.1. Expression of the DM-dependent D11-0401 epitope is cell-context 
dependent.  
(A) Restoration of DM in the DO- 5.2.4 0401 cell line does not reconstitute the D11-0401 
epitope.  Surface expression of DRB1*04 (NFLD.D1), MHC-II/CLIP (cerCLIP), and 
D11-0401 was analyzed by flow cytometry on DM- and DM+ 5.2.4 0401 B cell lines. 
Isotype controls are shown in grey. (B) DRB1*04 surface expression on BJAB and 
Ramos transfected with DRB1*04:01 (BJAB 0401 and Ramos 0401) was compared to 
SAVC using flow cytometry. Isotype controls are shown in grey. D11-0401 expression 
was plotted against increasing dilutions of NFLD.D11 used to stain cells for flow 
cytometry (0.1 = 1:10 dilution). Results are representative of three independent 
experiments. (C) Western blot analysis of DMA (Tal 18.1) and DOB (DOB.L1) 
expression in whole cell lysates of BJAB 0401 and Ramos 0401 compared to SAVC. 
Results are representative of two experiments. (D) Intracellular expression of DM 
(MaP.DM1), Ii (LN2), and surface expression of MHC-II/CLIP (cerCLIP) was 
determined by flow cytometry. Isotype controls are shown in grey. (E) D11-0401 is not 
modulated by transfection of DO in BJAB 0401 cells. Surface expression of DRB1*04 
(NFLD.D1), MHC-II/CLIP (cerCLIP), and D11-0401 was analyzed by flow cytometry on 
BJAB 0401, BJAB 0401 transfected with DO (BJAB DO 0401), and BJAB transfected 
with a vector control (BJAB V 0401). Isotype controls are shown in grey. Results are 
representative of two experiments.  
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cytometric analysis demonstrated that DM expression was higher in BJAB 0401 than in 
Ramos 0401, but reduced compared to SAVC (Figures 3.1C, 3.1D). Consistent with 
previous reports (93, 313, 314), DOB was not detected in BJAB and was deficient in 
Ramos (Figure 3.1C). Although all cells expressed similar amounts of Ii, MHC-II/CLIP 
complexes were drastically reduced on BL lines compared to SAVC, indicating deficient 
DO and functional DM in these cells (Figure 3.1D). 
To determine whether the D11-0401 epitope could be reconstituted in BL cells, 
we analyzed its expression on BJAB cells transfected with both DO and DRB1*04:01. As 
shown in Figure 3.1E, D11-0401 expression remained deficient on both BJAB DO 0401 
and BJAB V 0401 despite equivalent DRB1*04:01 expression. Increased MHC-II/CLIP 
levels on BJAB DO 0401 compared to BJAB V 0401 and BJAB 0401 indicated 
functional DO in this cell line (Figure 3.1E). Taken together, these results suggest that 
DO does not contribute to formation of the D11-0401 epitope, but as will be discussed 
later, it is possible that these cells are missing other factors that generate the appropriate 
peptides bound to the DBR1*04:01 molecules which affects D11-0401 expression. 
 
3.2.2 Endolysosomal and cytoplasmic cysteine proteases contribute to formation of 
the D11-0401 epitope  
The aforementioned and published data suggest the D11-0401 epitope is created 
by peptides stably bound to the groove of DRB1*04:01 molecules (280). This idea was 
further supported using antibody blocking assays, where NFLD.D11 binding to SAVC is 
inhibited by mAb L243, which blocks peptide-specific T-cell responses (34-35). 
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However, it was not inhibited by the pan-DRB1*04 β2 domain specific mAb NFLD.D1 
(Figures 3.2A, 3.2B), or by cerCLIP, an anti-MHC-II/CLIP mAb (Figure 3.2A). While 
these results suggest peptides other than CLIP are involved in the D11-0401 epitope, we 
cannot prove a restricted set of peptides contributes to its topology due the unsuitability of 
NFLD.D11 for pMHC-II immunoprecipitation and analysis of eluted peptides. 
To investigate the peptide source and intracellular antigen processing mechanisms 
contributing to D11-0401, SAVC cells were treated or not with pepstatin A, an inhibitor 
of aspartyl proteases; leupeptin, a broad inhibitor of cysteine proteases; CBI II, a 
cathepsin B inhibitor; or calpeptin, an inhibitor of cytoplasmic calpain proteases for 18 
hours, followed by analysis using CELISA. No inhibitor significantly altered total DR or 
DRB1*04:01; however, D11-0401expression was reduced by at least half in cells treated 
with leupeptin, CBI II, or calpain, but not reduced in cells treated with pepstatin A 
(Figure 3.3A). This suggests that antigen processing by endosomal and cytoplasmic 
cysteine proteases but not aspartyl proteases, contribute to generating peptides requisite 
for the D11-0401 epitope. Western blot analysis of non-reduced samples from whole cell 
lysates treated with cysteine protease inhibitors as described above confirmed large 
amounts of SDS-stable DR and DRB1*04 dimers in treated and untreated cell, as well as 
increased DR monomers in cells treated with leupeptin and calpeptin (Figure 3.3B). 
Furthermore, SAVC cells treated with both leupeptin and CBI II or calpeptin, or CBI II 
and calpeptin resulted in greater than 95% decrease in D11-0401 (Figure 3.3C).  By 
contrast, SAVC treated with combinations of pepstatin A with each cysteine inhibitor 
showed no further D11-0401 decrease compared to single inhibitor treatments, indicating 
that aspartyl protease-derived peptides do not contribute to the D11-0401 epitope (Figure  
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Figure 3.2. D11-0401 is located on the peptide binding groove of DRB1*04:01 
molecules. 
(A) D11-0401 expression measured by CELISA on SAVC cells, after prior incubation 
with the indicated concentrations of blocking mAbs: NFLD.D1, specific for an epitope on 
the β2 domain of all DRB1*04 molecules;  cerCLIP, MHC-II/CLIP complexes; L243, 
specific for a conformational epitope near the peptide binding groove on all DR 
molecules. D11-0401 expression is given as OD values. (B) D11-0401 expression 
measured by flow cytometry on SAVC cells, previously incubated with the blocking mAb 
L243 (anti-DR) or with an isotype control mAb. Filled histograms represent isotype 
control staining. Unfilled histograms represent D11-0401 expression. 
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Figure 3.3. Generation of the D11-0401 epitope is partially abrogated by cysteine 
protease inhibitors. 
(A)  SAVC cells treated with 25µM pepstatin A, 50µM calpeptin, 25µM leupeptin, 
100µM CBI II, or with a diluent control and were analyzed for pan-DR (L243), 
DRB1*04:01 (NFLD.D1), and D11-0401 expression by CELISA. Results are presented 
as the fold change in expression (treated/control), calculated by dividing the mean OD of 
inhibitor-treated cells by the mean OD of control cells. A value equal to 1 (solid line) 
indicates no change in expression. Values are means of at the least three experiments with 
bars representing standard error (n ≥ 3). Significant changes in expression due to protease 
inhibition were determined by comparing with total DR using a paired t-test, where an 
asterisk denotes p < 0.05. (B) The effect of cysteine protease inhibitors on formation of 
SDS-stable DR dimers in SAVC cells. Whole cell lysates prepared from SAVC cells 
treated with indicated cysteine protease inhibitors or diluent control were analyzed by 
SDS-PAGE (20 µg/lane) under non-reducing conditions and western blotting to detect 
SDS-stable DR dimers (L243), DRB1*04 dimers (NFLD.D1) or DRB monomers (Tal 
14.1). GAPDH served as a loading control. Results are representative of two experiments. 
(C) SAVC cells treated with combinations of indicated protease inhibitors were analyzed 
by CELISA for DR, DRB1*04, and D11-0401 expression as described in A. 
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3.3C). Since cellular expression of mature pMHC-II complexes and DRB1*04:01 were 
minimally affected by protease inhibitor combinations, it is likely that D11-0401 loss was 
specific and not due to a general effect on DR molecules. Similar experiments using 
lactacytsin, a proteasome inhibitor; wortmannin, an autophagy inhibitor; bafilomycin, an 
endosomal acidification and late autophagy inhibitor; and chloroquine, an endosomal 
acidification inhibitor, did not significantly alter presentation of D11-0401 epitope 
(Appendix A). Altogether, these results support the idea that endogenous proteins cleaved 
by cysteine proteases within both endolysosomal and cytoplasmic compartments are the 
source of peptides forming the D11-0401 epitope. Alternatively and later examined in 
more detail, inhibition of cellular proteases may adversely affect the entire DM-mediated 
pathway of peptide loading, thus preventing formation of the DM-dependent D11-0401 
epitope. 
 
3.2.3 Expression analysis of the DM-sensitive D13-0401 epitope 
We previously showed that a cross reactive epitope on DRB1*04:01 (D13-0401) 
and DRB1*04:04 (D13-0404) molecules, was strongly expressed on DM- DO+ 9.5.3 
0401 cells but lost on the DM+ DO+ parental cell line 8.1.6 0401 (78). Consistent with 
these results, D13-0401 was expressed on the mutant cell lines T2.Dw4, BLS-1.Dw4, and 
SJO.Dw4 (all DM- DO-), and abrogated by DM restoration in these cells either by 
transfection or by gene complementation (Figure 3.4A).  In addition, weak D13-0401 
expression observed on DM- DO- 5.2.4 0401 cells was lost after DM restoration (Figure 
3.4B). Not surprisingly, DM+ BL cell lines BJAB 0401, BJAB 0401 DO, and Ramos 
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Figure 3.4. Cell surface expression of the D13-0401 epitope on DRB1*04:01 molecules 
occurs in the absence of DM. 
(A) DM- and DM-restored mutant B cell lines transfected with DRB1*04:01 were 
analyzed for D13-0401 by flow cytometry. DM was restored by either transfection or cell 
fusion with the DM-expressing cell line .174 as previously described (280). D13-0401 
binding is expressed as a percentage of total DRB1*04 surface expression (NFLD.D1). 
(B) Weak D13-0401 expression on DO- 5.2.4 0401 is further diminished by DM 
restoration. Surface expression of D13-0401 was analyzed by flow cytometry on DM- 
and DM-restored 5.2.4 0401 cells. Isotype controls are shown in grey. (C) BJAB 0401 
and Ramos 0401 do not express D13-0401. D13-0401 surface expression on BJAB 0401 
and Ramos 0401 was compared to its expression on 9.5.3 0401 cells using flow 
cytometry. D13-0401 expression was plotted against increasing dilutions of NFLD.D13 
used to stain cells for flow cytometry (0.1 = 1:10 dilution). Results are representative of 
three experiments. (D) D13-0401 is located on the peptide binding groove of 
DRB1*04:01 molecules. CELISA was used to determine NFLD.D13 binding to the D13-
0401 epitope on 9.5.3 0401 cells after prior incubation with the blocking mAbs: anti-
DRB1*04 (NFLD.D1), anti-MHC-II/CLIP (cerCLIP), anti-DR (L243), or an isotype 
control. D13-0401 expression is shown as OD values. Bars indicate standard deviation 
from triplicate measurements (n=1).  
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0401 also did not express D13-0401 (Figure 3.4C). Taken together, these results suggest 
that the D13-0401 epitope is negatively modulated by DM regardless of the presence of 
DO, but may well depend on whether the appropriate peptides are generated in these cell 
lines.  
Since DM- cells express abundant MHC-II/CLIP complexes, we initially 
suspected the D13-0401 epitope was formed by CLIP bound to DRB1*04:01.  However, 
its weak expression on 5.2.4 0401 cells which contains abundant MHC-II/CLIP 
complexes shown in Figure 3.1A suggests otherwise. Furthermore, the epitope was not 
blocked by cerCLIP or NFLD.D1, while it was fully blocked by L243 (Figure 3.4D), 
suggesting that peptides other than CLIP, but similar in terms of their DM-sensitivity are 
responsible for its formation and cell surface expression. 
 
3.2.4 Endolysosomal and cytoplasmic cysteine proteases are necessary for D13-0401 
expression in DM- cells, but contribute to its loss in DM+ cells 
Although the D13-0401 epitope is clearly sensitive to expression of DM 
transgenes in antigen presentation mutants, it was variably expressed on SAVC cells. In 
particular, we noted substantially increased D13-expression in leupeptin-treated cells 
analyzed using CELISA (Figure 3.5A). However, this assay uses PFA-fixed cells and 
wash buffer containing Tween-20 detergent which may result in membrane 
permeabilization, thus allowing detection of intracellular epitopes. To clarify this, we 
analyzed D13-0401 and D11-0401 expression on leupeptin-treated SAVC cells using 
surface and intracellular flow cytometry. Leupeptin treatment minimally affected surface  
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Figure 3.5. Leupeptin treatment differentially modulates cell surface and intracellular 
DRB1*04 epitopes in SAVC cells.   
(A) SAVC cells were analyzed for D13-0401 expression by CELISA after treatment with 
protease inhibitors or diluent control. Results are presented as the fold change in 
expression (treated/control), calculated by dividing the mean OD of inhibitor-treated cells 
by the mean OD or MFI of control-treated cells, where a value equal to 1 (solid line) 
indicates no change in expression. Presneted values are the mean of at the least three 
independent experiments with bars representing standard error (n ≥ 3). Significant 
changes in expression due to protease inhibition were determined by comparing with total 
DR using a paired t-test, where an asterisk denotes p < 0.05. (B) SAVC, treated with 
25μM leupeptin (filled histograms) or with diluent (unfilled histograms), were analyzed 
by flow cytometry for surface and intracellular expression of DR (L243), DRB1*04 
(NFLD.D1), D11-0401, D13-0401, and DM (Map.DM1). Broken line histograms 
represent isotype controls. Leupeptin-treated / diluent control-treated values (T/UT) were 
calculated as: (MFI of leupeptin-treated cells – MFI of isotype control) / (MFI diluent-
control cells – MFI isotype control). Results are representative of two independent 
experiments.  
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peptide-DR conformers, DRB1*04:01 and DM, but resulted in severe loss of surface 
D11-0401, and slightly diminished D13-0401 (Figure 3.5B). In contrast, intracellular flow 
cytometric analysis revealed a 2.5-fold increase in intracellular D13-0401 expression in 
leupeptin-treated cells, no appreciable change in D11-0401, and increased expression of 
pDR conformers and DM (Figure 3.5B). These results indicate that 1) the DM-sensitive 
D13-0401 epitope is present intracellularly in DM+ SAVC cells, but its formation is 
inhibited by cysteine proteases; 2) leupeptin-mediated increase in intracellular D13-0401 
is not observed on the cell surface likely due to increased amounts of DM which prevent 
surface expression of DRB1*04:01 molecules bearing the D13-0401 epitope; and 3) 
leupeptin treatment diminishes surface expression of DM-dependent D11-0401 despite 
increased intracellular DM levels. 
To validate the effect of cellular proteases in generating the DM-sensitive and 
DM-dependent DRB1*04:01 epitopes, SAVC, 8.1.6 0401, and 9.5.3 0401 cells were 
treated with protease inhibitors and analyzed for D11-0401 and D13-0401 using surface 
flow cytometry. Consistent with CELISA results, no inhibitor treatment significantly 
affected expression of total DR or DRB1*04 in all 3 cell lines (Figures 3.6A, 3.6B, 3.6C), 
while leupeptin, CBI II, and calpeptin, but not pepstatin A, significantly reduced D11-
0401 surface expression on SAVC (Figure 3.6A). D13-0401 expression was variable on 
SAVC, but not significantly altered by any treatment (Figure 3.6A). 8.1.6 0401cells 
treated with leupeptin or calpeptin similarly showed a noticeable decrease in D11-0401, 
while CBI II had little effect (Figure 3.6B). D13-0401, not normally expressed on the 
surface 8.1.6 0401 cells, was somewhat elevated on the cysteine protease inhibitor-treated 
cells (Figure 3.6B).  In contrast, treatment of 9.5.3 0401 cells with the same cysteine  
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Figure 3.6. Expression of DM-dependent D11-0401 and DM-sensitive D13-0401 
epitopes requires similar proteases. 
SAVC (A), 8.1.6 0401 (B), and 9.5.3 0401 (C) cells were treated with 25µM pepstatin A, 
50µM calpeptin, 25µM leupeptin, 100µM CBI II (filled histograms), or with the 
appropriate diluent control (unfilled histograms) and surface expression of DR (L243), 
DRB1*04 (NFLD.D1), D11-0401, and D13-0401 was analyzed by flow cytometry. 
Broken line histograms represent isotype controls. Results from one to four independent 
experiments are shown in the bar plots (n = 1-4), where values represent the mean fold 
change in expression due to protease inhibitor treatment (treated/control) calculated as: 
(MFI of inhibitor-treated cells – MFI of isotype control) / (MFI diluent-control cells – 
MFI isotype control), where a value equal to 1 (solid line) indicates no change in 
expression. Error bars indicate standard error. Significant changes in expression due to 
protease inhibition were determined by comparing with total DR using a paired t-test, 
where an asterisk denotes p < 0.05. (D) The effect of cysteine protease inhibitors on 
formation of SDS-stable DR dimers in 8.1.6 0401 and 9.5.3 0401 cells. Whole cell lysates 
prepared from 8.1.6 0401 and 9.5.3 0401 cells treated with cysteine protease inhibitors or 
a diluent control were analyzed by SDS-PAGE (20 µg/lane) under non-reducing 
conditions and western blotting to detect SDS-stable DR dimers (L243), DRB1*04 
dimers (NFLD.D1), and DRB monomers (Tal 14.1). Detection of GAPDH served as a 
loading control. 
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protease inhibitors resulted in severe loss of D13-0401 despite no significant reduction in 
cell surface DRB1*04 surface expression (Figure 3.6C). Thus, endosomal and 
cytoplasmic cysteine proteases contribute to expression of D11-0401 and loss of D13-
0401 epitope in DM+ cells, while the same proteases are required for D13-0401 
expression in DM- cells.  
The sensitivity of D13-0401 to DM and cysteine proteases suggests this epitope is 
formed by less stable immature DRB1*04:01/peptide complexes. We therefore compared 
SDS-stable DR dimers in 8.1.6 0401 and 9.5.3 0401 cells, treated with or without the 
cysteine protease inhibitors. The amount of total SDS-stable DR and DRB1*04 dimers 
were noticeably decreased in lysates from leupeptin-treated 8.1.6 0401 cells along with a 
concomitant increase in DRB monomers (Figure 3.6D). The effects of CBI II and 
calpeptin on DR and DRB1*04 dimers in 8.1.6 0401cells were not perceptible, but DRB 
monomers were increased by CBI II treatment (Figure 3.6D). Consistent with previous 
reports (270), 9.5.3 0401 exhibited considerably reduced amounts of endogenous SDS-
stable DR dimers and increased DRB monomers compared to 8.1.6 0401, while protease 
inhibitor treatment had minimal effect (Figure 3.6D). No SDS-stable DRB1*04 dimers 
were observed in 9.5.3 0401 indicating that DRB1*04:01 molecules in these DM- cells 
primarily exist in a SDS-unstable conformation. The amounts of DM were not 
appreciably reduced in lysates from inhibitor-treated 8.1.6 0401 cells indicating that the 
loss of D11-0401 and gain of D13-0401 is not a result of alterations in DM expression 
(Figure 3.9A). In summary, the above results suggest that endosomal and cytoplasmic 
cysteine proteases differentially effect formation and surface expression of D13-0401 in 
presence or absence of DM.  
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3.2.5 Expression analysis of the DM-resistant D13-0404 epitope 
The cognate epitope D13-0404 recognized by the mAb NFLD.D13 was initially 
identified on DRB1*04:04 molecules and is restricted to pAPCs as well as DM- antigen 
presentation mutants transfected with DRB1*04:04 (283, unpublished). Flow cytometric 
analysis of D13-0404 expression demonstrated that this epitope is expressed by 5.2.4 
0404 irrespective of DM expression, although at noticeably reduced levels in the DM+ 
cells (Figure 3.7A). Similar to the other DRB1*04 epitopes, D13-0404 is unlikely formed 
by DRB1*04:04/CLIP complexes as epitope blocking assays showed no inhibition of 
NFLD.D13 binding by the mAb cerCLIP (Figure 3.7B). However, successfully blocking 
by L243 and not with NFLD.D1 further suggests that the D13-0404 epitope is formed on 
mature pMHC-II complexes (Figure 3.7C). 
 
3.2.6 Aspartyl and cysteinyl proteases are dispensable in formation of D13-0404 
The contribution of peptides generated by endosomal and cytoplasmic antigen 
processing to the D13-0404 epitope was analyzed by CELISA on MT14B cells treated 
with pepstatin A, leupeptin, CBI II, or calpeptin. Expression of both total DR and 
DRB1*04:04, and the amounts of SDS-stable DR dimers were not appreciably affected 
by any of the inhibitors, although an accumulation of DRB monomers in leupeptin-treated 
cells was observed (Figures 3.8A, 3.8B). Whereas treatment with leupeptin, CBI II, or 
calpeptin noticeably altered the presentation of D11-0401 and D13-0401, expression of 
D13-0404 was unaffected (Figure 3.8A). Furthermore, additional experiments using 
lactacystin, wortmannin, bafilomycin, chloroquine, or the endosomal cysteine protease 
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Figure 3.7. The D13-0404 epitope is a DM-resistant epitope expressed on DRB1*04:04 
cells. 
(A) Surface expression of DRB1*04:01 (NFLD.D1), class-II-CLIP (cerCLIP),  and D13-
0404 was measured by flow cytometry in DO- 5.2.4 0404 cells with or without 
transfection with DM. Isotype controls are shown in grey. (B) The D13-0404 epitope is 
located near the peptide binding groove of DRB1*04 molecules. CELISA was used to 
determine binding of NFLD.D13 to the D13-0404 epitope on MT14B cells after 
incubation with the indicated concentrations of the blocking mAbs: anti-DRB1*04 
(NFLD.D1), anti-MHC-II/CLIP (cerCLIP), anti-DR (L243), or an isotype control. D13-
0404 expression is shown as OD values. (C) D13-0404 expression was measured by flow 
cytometry on MT14B cells previously incubated with the blocking mAb L243 (anti-DR) 
or with an isotype control mAb. Filled histograms represent isotype control staining. 
Unfilled histograms represent D13-0404 expression. 
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inhibitor E64d, did not significantly modify presentation of D13-0404 (Appendix A). 
These results demonstrate that endosomal and cytoplasmic cysteine proteases are 
dispensable in generating the peptides required for D13-0404 and that there is significant 
redundancy in the proteolytic processing of peptides necessary for formation this epitope. 
 
3.2.7 Inhibition of Ii processing by protease inhibitors may modulate DRB1*04 
peptide-dependent epitopes 
For DM to facilitate efficient loading of endosomal peptides onto DR molecules, 
Ii must be cleaved by proteases into CLIP. Incomplete degradation of Ii with an 
accumulation of Ii degradation intermediates may occur in leupeptin-treated cells, 
resulting in unstable pMHC-II molecules and a decrease of CLIP depending on which 
MHC-II alleles are present (53, 78, 79, 117, 315, 316). Our studies on the DRB1*04 
epitopes in DM+ cells using cysteine protease inhibitors similarly showed increased DRB 
monomers, although the amount of surface DR and SDS-stable dimers were still abundant 
(Figures 3.3, 3.6, 3.8). As an indicator of DM function, we determined the expression of 
DM and Ii intermediates in all four cell lines, as well as the surface expression of MHC-
II/CLIP complexes. The amounts of DM were similar in inhibitor-treated and control 
cells, while an accumulation of the Ii degradation intermediate Ii-p10 was observed in 
cells treated with leupeptin, CBI II, or calpeptin, indicating some inhibition of Ii 
degradation to CLIP (Figure 3.9A). This is further supported by diminished cell surface 
expression of MHC-II/CLIP complexes in cells treated with cysteine protease inhibitors 
(Figure 3.9B). Notably, the largest decreases in MHC-II/CLIP complexes occurred on 
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Figure 3.8. Inhibition of aspartyl and cysteinyl proteases does not alter D13-0404 
expression in MT14B cells. 
(A) MT14B cells treated with 25µM pepstatin A, 50µM calpeptin, 25µM leupeptin, 
100µM CBI II, or with the appropriate diluent control were analyzed for total DR (L243), 
DRB1*04:01 (NFLD.D1), and D13-0404 by CELISA. The results are presented as the 
fold change in expression (treated/control), calculated by dividing the mean OD of 
inhibitor-treated cells by the mean OD of control cells, where a value equal to 1 (solid 
line) indicates no change in expression. Values are the mean of at the least three 
independent experiments with bars representing standard error (n ≥ 3). Significant 
changes in expression due to protease inhibition were determined by comparing with total 
DR using a paired t-test, where an asterisk denotes p < 0.05. (B) The effect of cysteine 
protease inhibitors on the formation of SDS-stable DR dimers in MT14B cells. Whole 
cell lysates prepared from of MT14B cells treated with cysteine protease inhibitors or 
diluent as above were analyzed by SDS PAGE (20 µg/lane) under non-reducing 
conditions and western blotting to detect SDS-stable DR dimers (L243), DRB1*04 
dimers (NFLD.D1), and DRB monomers (Tal 14.1).  Detection of GAPDH served as a 
loading control. Results are representative of two experiments. 
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leupeptin treated SAVC and MT14B cells (Figure 3.9B). Taken together, these results 
suggest that impaired peptide loading of DRB1*04 molecules due to insufficient Ii 
cleavage may contribute to a portion of the observed protease inhibitor-induced reduction 
in expression of D11-0401 and D13-0401. 
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Figure 3.9. The effect of protease inhibitors on DM, Ii, and MHC-II/CLIP in DRB1*04 B 
cell lines. 
(A) Whole cell lysates of SAVC , MT14B, 8.1.6 0401, and 9.5.3 0401 cells treated with 
the indicated cysteine protease inhibitors or diluent control were analyzed by SDS-PAGE 
(20 µg/lane) under non-reducing conditions and western blotting for expression of  DMA 
(Tal 18.1) and Ii cleavage intermediates (PIN.1). (B) Inhibition of cysteine proteases 
reduces MHC-II/CLIP expression. The surface expression of MHC-II/CLIP (cerCLIP) 
was analyzed by flow cytometry on SAVC, MT14B, 8.1.6 0401, and 9.5.3 0401 cells 
treated with protease inhibitors or a diluent control. Results are displayed as the fold 
change in expression due to protease inhibitor treatment (treated/control), calculated as: 
(MFI of inhibitor-treated cells – MFI of isotype control) / (MFI diluent-control cells – 
MFI isotype control), where a value equal to 1 (solid line) indicates no change in 
expression. Displayed values are the mean of one to four independent experiments, with 
error bars indicating standard error (n = 1-4). Significant changes in expression due to 
protease inhibition were determined by comparing with total DR using a paired t-test, 
where an asterisk denotes p < 0.05. 
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3.3 Discussion 
The results herein show that the cellular mechanisms underlying cell surface 
expression of antibody-defined allele-specific DRB1*04 epitopes are multifaceted. The 
epitopes, located on the peptide binding sites of DRB1*04 molecules, are formed by 
allele-specific residues with bound peptides contributing to their topology. While DM 
was previously known to be requisite for the D1l-0401 epitope and deleterious for the 
D13-0401 epitope, we show here that co-expression of its co-chaperone, DO, only 
marginally affected the epitopes in B-LCL and not in BL.  Our results further suggest that 
both endosomal and cytoplasmic cysteine proteases are necessary for their expression; 
however, whether their role is to directly provide processed peptides or indirectly via 
inhibition of Ii degradation is currently unclear. By contrast, the D13-0404 epitope 
displayed much less dependence on DM or antigen processing pathways.  
Preferential expression of these epitopes on EBV-transformed B-LCL suggests 
either cellular specific proteins, different antigen processing mechanisms, or both acting 
in concert to contribute to their presentation. The paucity of D11-0401 on BL 0401 
transfectants cannot be fully explained by DM levels since DM expression in these cells, 
although reduced compared to SAVC, was at least equivalent to DM in the D11-0401+ 
8.1.6 0401 cell line (Figure 3.1). We reasoned that since DM-mediated peptide loading is 
modulated by DO, expressed MHC-II alleles, and the peptide source, the absence of D11-
0401 on BL cells may be due to their deficiency in DO expression (Figure 3.1C, 93, 314). 
However, no further enhancement of D11-0401 expression in BJAB DO 0401 (Figure 
3.1E) nor in T2.Dw4DMDO cells (E. Mellins, unpublished) suggests otherwise. An 
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alternative explanation is that DO may indeed influence D11-0401 expression, but the 
peptide source for this epitope is not present in some cell types.  For example, the 
peptidome in BL cell lines likely differs substantively from B-LCL as they are derived 
from germinal center B cells (317, 318), differentially express EBV genes and CD 
antigens (319), and are defective in some antigen processing mechanisms (320). 
Similarly, the T2 cell line, a T cell - B cell hybrid, is likely to have a different peptidome 
from EBV-transformed and normal B cells.  
The potential role of DO in the DM-sensitive D13-0401 epitope was also 
explored. This epitope, like MHC-II/CLIP, is abundant on the DM- DO+ 9.5.3 0401 cell 
line, but is also amply expressed by DM- DO- mutant cell lines and abrogated by DM 
restoration (Figure 3.4C). However, low levels of D13-0401 on the T2.Dw4DMDO cells 
(E. Mellins, unpublished) as well as variable membrane and intracellular expression in 
SAVC cells, suggest that DO may sufficiently inhibit DM to allow low levels of D13-
0401 expression. Such HLA-II-restricted epitopes including several endogenous minor 
histocompatibility antigens and CLIP have been previously described as DM-sensitive 
(102, 104). While MHC-II/CLIP was clearly upregulated in our DO+ transfected cells 
regardless of DM expression, there was no strict correlation between CLIP and D13-0401 
expression. The absence of D13-0401 on the CLIP+ transfectants BJAB DO 0401 and 
5.2.4 0401 combined with no inhibition by the MHC-II/CLIP-specific mAb cerCLIP 
(Figure 3.4), argues against CLIP contributing to the epitope.  
Although we have not identified peptides contributing to the DRB1*04 epitopes, 
our data suggest that both D11-0401 and D13-0401 require endogenous and not 
exogenous proteins. We base this on our finding that calpeptin, an inhibitor of cytosolic 
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calpain, when combined with the endosomal cysteine inhibitors leupeptin or cathepsin B, 
severely reduced epitope expression in comparison to treatment with either single 
inhibitor. One interpretation is that cytoplasmic proteins first processed by calpain are 
translocated to MIIC to undergo further processing by cathepsin B and other leupeptin-
sensitive proteases before binding to DRB1*04:01. Supporting this notion are several 
reports of MHC-II presentation of cytoplasmic antigens (30, 71, 139, 321-323) including 
a seminal study by Lich et al. (323) where they demonstrated that a DRB1*04:01-
restricted endogenous glutamic decarboxylase immunodominant epitope required 
cytoplasmic processing with subsequent processing in endosomes or lysosomes.  In 
addition to calpain, both the proteasome and autophagy have been described as 
mechanisms by which cytoplasmic antigens are degraded for presentation by the MHC-II 
pathway (71, 139, 322, 324-326). However, the proteasome inhibitor lactacystin and 
autophagy inhibitor wortmannin had little effect on their presentation, (Appendix A), 
suggesting a different mechanism is responsible for calpain-processed peptides gaining 
access to the MHC-II pathway. 
In contrast to the D13-0401 loss in DM- 9.5.3 0401 cells, inhibition of calpain and 
cysteine proteases in DM+ SAVC and 8.1.6 0401cells resulted in an increase in the 
epitope (Figures 3.5, 3.6), suggesting that different peptides contribute to D13-0401 in 
DM- and DM+ cells. Among the repertoire of endogenously-derived presented peptides 
in DM+ cells are likely sets of peptides that form D13-0401 and D11-0401. However, 
DM-editing licenses transport and expression of D11-0401 molecules, but not D13-0401, 
for cell surface expression. In the absence of DM, DRB1*04:01/peptide complexes 
forming D13-0401 (or MHC-II/CLIP) are well-expressed on the cell surface. It is 
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tempting to speculate that similar peptides form DM-dependent D11-0401 and DM-
sensitive D13-0401 since they are inhibited by the same protease inhibitors.  However, 
the D13-0401 epitope formed in DM+ cells likely results from different peptides, which 
become more available by inhibition of cytoplasmic and endosomal proteases. These 
results suggest that it may be possible to induce the presentation of a MHC-II epitope 
normally destroyed by DM by inhibiting cellular proteases, similar to a study which 
demonstrated presentation of a MHC-I epitope after proteasome inhibition (327). 
Current models of DM function propose that DM dissociates low-stability pMHC-
II and stabilizes the unbound or open conformation of MHC-II thereby allowing binding 
of high affinity peptides, thus shaping the repertoire of epitopes expressed by pAPC (14). 
The differing DM requirements between D11-0401 and D13-0401 may provide insight 
into concepts of immunodominance and crypticity. Initial explanations for crypticity 
argued that differences in proteolytic processing of immunodominant and cryptic peptides 
could account for crypticity because these epitopes would be degraded during antigen 
processing. However, others have demonstrated that presentation of immunodominant 
epitopes are enhanced by DM while cryptic epitopes are antagonized by DM, suggesting 
that DM determines the immunodominant or cryptic fate of a given MHC-II epitope (328, 
329). Our results support this view because even though both D11-0401 and D13-0401 
epitopes exhibit similar protease requirements, they are differentially expressed 
depending on the presence or absence of DM. Furthermore, the intracellular levels of 
D13-0401 epitope in DM+ DO+ B-LCL suggest that this epitope forms within the 
endosomal pathway, but is antagonized by DM before it can reach the surface. 
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A major limitation of this study is peptide elution and mass spectrometry studies 
were not possible due to unsuitability of the NFLD.D11 and NFLD.D13 mAbs for 
immunoprecipitation. Although our results suggest cytoplasmic proteins are the likely 
source of peptides contributing to D11-0401 and D13-0401, we can only speculate on the 
actual protein source. Given the epitopes are largely restricted to EBV-transformed B cell 
lines, possible candidate antigens include B cell specific proteins such as 
immunoglobulin, or EBV viral proteins including nuclear antigen, or latent membrane 
proteins. Many of the latter are not expressed in BJAB and Ramos cells (330, 331), which 
were notably negative for D11-0401 or D13-0401 (Figures 3.1, 3.4). Peptides derived 
from HLA-I molecules are also strong candidates as they were previously shown to 
constitute an antibody-defined epitope in the context of DRB1*01 (255), and were 
abundant among peptides eluted from DRB1*04:01 molecules analyzed by mass 
spectroscopy (158). Incomplete reconstitution of D11-0401 on T2.Dw4DM, a line which 
poorly expresses HLA-I, combined with a lack of D11-0401 expression on HLA class-I-
negative Daudi-Dw4 cells (280), initially suggested HLA-I molecules were the peptide 
source.  However, failure to induce D11-0401 in Daudi-Dw4 by transfecting with B2M to 
reconstitute MHC-I expression, does not support this view (S. Drover, unpublished). A 
further argument against HLA-I as the peptide source is that BJAB and Ramos both 
express HLA-I, with the caveat that other defects in the HLA-I antigen processing 
pathway have been reported in BL cells (320).  
Given the strong genetic relationship between both DRB1*04:01 and 
DRB1*04:04 and severe RA (284, 285, 332, 333), we previously tested and showed 
expression of D11-0401 and D13-0404 epitopes on DRB1*04+ B cells from RA patients 
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and healthy patients (310).  In that study, DRB1*04 was identified using the DR4-specific 
mAb, NFLD.D1 and the designation of DRB1*04:01 and DRB1*04:04 was based on 
NFLD.D11 and/or NFLD.D13 binding, not allele-specific DRB1*04 typing.  Since DM is 
critical to modulation of both D11-0401 and D13-0401 (potentially same topology as 
D13-0404) and given reports of decreased DM levels in B cells from RA patients (286), a 
further analysis of these epitopes combined with DM expression in RA is warranted.  
Such a study may provide further understanding of cross reactive HLA-DRB1*04 
epitopes formed from self-peptides in the context of DM expression and DRB1*04-
associated autoimmune disease. 
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Chapter 4 
 
A study on the role of exosomes, lipid rafts, and tetraspanin 
microdomains in the formation of DRB1*04 epitopes 
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4.1 Preamble and objectives 
In addition to presenting pMHC-II on their cell surface, pAPC constitutively 
secrete a significant amount of pMHC-II on exosomes that are able to directly and 
indirectly activate antigen-specific T cells both in vitro and in vivo (219, 220, 240, 241), 
as well as mediate the transfer of antigen between cells (244, 334). Exosomes have also 
been found to contain unique MHC molecules that are not expressed in the plasma 
membrane (245), suggesting that antigen presentation via exosomes may result in the 
presentation of unique epitopes that are not generated in the classical pathway of antigen 
presentation. Previous work by Spurrell D. R. identified expression of D11-0401 on 
exosome-like vesicles near the cell surface of B-LCL, as well as localization of D11-0401 
and D13-0404 to sites of intracellular exosome biogenesis (283). Based on this, we 
hypothesized that the DRB1*04 epitopes are expressed on B-LCL-derived exosomes. 
Investigating the repertoire of pMHC-II expressed on exosomes has the potential to 
impact our understanding of how exosomes contribute to cellular communication between 
distant immune cells. 
Recent studies suggest that pMHC-II are not uniformly distributed throughout the 
plasma membrane in pAPCs, but instead are concentrated and organized into 
supramolecular complexes such as lipid rafts or TEMs in a way which facilitates antigen 
presentation (145, 151-156, 163, 193). Preliminary work performed by Spurrell D.R. 
suggested that DR molecules bearing the D11-0401 and D13-0404 epitopes were 
associated with tetraspanins CD63 and CD82 and that disruption of TEMs caused a 
notable decrease in surface expression of these epitopes (283), suggesting that these 
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epitopes may be expressed on a distinct subset of DRB1 molecules that are associated 
with TEMs. However, these previous experiments did not include the analysis of 
appropriate control molecules. In addition, these experiments suggested no association of 
these epitopes with lipid rafts, but MBCD treatment to disrupt rafts was performed on 
cells fixed with paraformaldehyde, making it difficult to understand how this treatment 
could disrupt chemically cross-linked proteins. Using an updated methodology where 
MBCD treatment was performed prior to cell fixation and included analysis of additional 
control molecules, as well as preparation of DRMs containing rafts, we further 
investigated the hypothesis that the D11-0401, D13-0401, and D13-0404 epitopes are 
concentrated in TEMs and lipid rafts. The results from these experiments will hopefully 
help clarify the role of membrane microdomains in concentrating speicifc pMHC-II 
complexes on the cell surface. Since an effective immune response relies heavily upon the 
activation of T cells by APCs, this reaearch may further reveal the ways in wcih 
membrane organization of MHC-II enhances this process. 
 
The specific objectives addressed in this chapter are: 
 
1. To characterize the expression of the D11-0401, D13-0401, and D13-0404 
epitopes on exosomes secreted from B-LCL to gain a further understanding of the 
formation of these epitopes within the antigen processing pathway. 
2. To determine if lipid rafts and TEMs contain pMHC-II containing as specific 
repertoire of peptides by examining whether the D11-0401, D13-0401, and D13-0404 
epitopes segregate into these membrane microdomains. 
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4.2 Results 
 
4.2.1 DRB1*04-restricted epitopes are differentially expressed on B-LCL-derived 
exosomes. 
MIICs, the late endocytic vesicles where most DM-mediated peptide loading of 
MHC-II occurs, are also important for exosome biogenesis (237). Co-localization of D11-
0401 and D13-0404 with MIIC markers suggested these and possibly the D13-0401 
epitope might be expressed on exosomes (283). Exosomes isolated from SAVC, MT14B, 
8.1.6 0401 and 9.5.3 0401 cell cultures (Figure 4.1) were analyzed for DRB1*04 epitopes 
along with known exosomal markers using a modified flow cytometric assay in which 
exosomes were coupled to latex beads. The latex beads were easily detected by flow 
cytometry using forward and side scatter analysis, where single, double, and multiple 
clumps of beads were distinguishable (Figure 4.2A). Single beads typically represented 
70% to 85% of the total bead population, denoted by the region R1 in Figure 4.2A, and 
were used for all subsequent analysis.  
Adsorption of exosomes to the beads was confirmed by flow cytometric analysis 
using various markers (Figure 4.2B). CD82, CD86, and CD40 were present on exosomes 
from all cells while ICAM-1 was detected on all except MT14B. CD59, a GPI-anchored 
raft protein, was present on all except 9.5.3 0401 exosomes (Figure 4.2B), an unexpected 
finding since exosomes from the parental cell line 8.1.6 0401 contained CD59. Non-
exosomal proteins CD71and LAMP-1 were not detected on exosomes (Figure 4.2B), even 
though they were abundant on all cell lines (Appendix B). Since the marker profile of  
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Figure 4.1. Whole-mount electron microscopy of purified exosomes from B-LCL.  
Whole-mount electron microscopy of the 100 000 x g pellet from MT14B culture 
supernatants. The pellet consists of vesicles similar in size (< 200 nm) to that reported for 
exosomes. Arrows indicate exosomes. Similar results were observed for SAVC, 8.1.6 
0401, and 9.5.3 0401. No vesicles were observed in the PBS control. Images are 40 000x. 
Bar = 200 nm. The image shown is representative of several fields of view for one 
experiment. 
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Figure 4.2. Characterization of exosomes isolated from B-LCL. 
(A) Exosomes isolated from B cell culture supernatants as outlined in Figure 2.1 were 
coated onto 3.9 μm latex beads and analyzed by flow cytometry using forward versus side 
scatter analysis to distinguish single beads from clumps of multiple beads. Single beads, 
typically representing 70-85% of the total bead population and denoted by region R1, 
were selected for gating in all subsequent analysis. (B) Beads coated with exosomes from 
SAVC, MT14B, 8.1.6 0401, and 9.5.3 0401were analyzed by flow cytometry to 
determine expression of relevant markers. Open histograms represent exosome-coated 
beads. Filled histograms represent unlabeled beads, which consistently had an MFI < 10. 
Beads incubated with exosome-depleted media and exosome-coated beads labelled with 
isotype control antibodies had comparable MFIs to unlabeled beads (data not shown). 
Results are representative of two independent experiments.  
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these vesicles was comparable to that of previously described exosomes (335, 336), we 
next analyzed them for antigen presentation molecules DM and Ii, and DR complexes 
including total DR, MHC-II/CLIP, and DRB1*04 epitopes. DM and Ii were not detected 
on exosomes from any of the cells (Figure 4.3). In addition, MHC-II/CLIP complexes 
were absent from exosomes isolated from DM+ cells (SAVC, MT14B, and 8.1.6 0401), 
but were abundant on DM- 9.5.3 0401 exosomes (Figure 4.3), likely due to the inability 
of CLIP to dissociate from MHC-II in the absence of DM. DR dimers and DRB1*04 
molecules were present on exosomes from all four cell lines (Figure 4.3), consistent with 
previous reports of abundant MHC-II on APC-derived exosomes (335, 336). D11-0401 
and D13-0404 were well expressed and restricted to SAVC and MT14B exosomes, 
respectively (Figure 4.3); however, D11-0401 expression was reduced on 8.1.6 0401 
exosomes compared to SAVC exosomes, possibly due to reduced levels of exosomal 
DRB1*04:01 (Figure 4.3). As expected, D11-0401 and D13-0401 were not detected on 
9.5.3 0401 and 8.1.6 0401 exosomes, respectively, since these epitopes are not naturally 
expressed on these cells. Thus, the exosomal profile of D11-0401 and D13-0404 is 
consistent with their cell surface expression. Surprisingly, D13-0401 was not detected on 
exosomes from 9.5.3 0401 despite abundant DRB1*04 molecules and total DR (Figure 
4.3), suggesting that its expression may be dependent on different antigen processing or 
trafficking mechanisms. The intriguing finding that 9.5.3 0401 exosomes lacked the GPI-
anchored protein CD59 led us to question whether GPI-anchored proteins influenced the 
expression of these DRB1*04 epitopes. 
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Figure 4.3. Epitopes D11-0401 and D13-0404, but not D13-0401, are present on 
exosomes from B-LCL. 
Exosome-coated latex beads, as described for Figure 4.2A, were analyzed for expression 
of antigen presentation molecules and DRB1*04 epitopes by flow cytometry. Open 
histograms represent exosome-coated beads. Filled histograms represent unlabeled beads 
and consistently had an MFI < 10. Beads incubated with exosome-depleted media and 
exosome-coated beads labelled with isotype control antibodies had comparable MFIs to 
unlabeled beads (not shown). Results are representative of two independent experiments. 
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4.2.2 Analysis of the contribution of GPI-anchored proteins to expression of 
DRB1*04 epitopes  
Consistent with the exosomal profiles, subsequent analysis using cell surface flow 
cytometry revealed abundant CD59 expression on 8.1.6 0401 but only a trivial amount on 
9.5.3 0401 (Figure 4.4A). Similarly, CD55, another GPI-anchored protein was 
substantially reduced on 9.5.3 0401 compared to 8.1.6 0401 suggesting 9.5.3 is deficient 
in GPI-anchored proteins. Further testing using FLAER, a flow cytometric assay utilizing 
a fluorescently-labelled inactive variant of aerolysin which binds to GPI-linked proteins 
(299), revealed significantly reduced expression on 9.5.3 0401 compared to 8.1.6 0401 
(Figure 4.4A). Since 9.5.3 0401 also does not express DM and D11-0401, but is strongly 
positive for D13-0401, and the converse is true for 8.1.6 0401, we hypothesized that lipid 
rafts or lipid raft-associated GPI-anchored proteins may influence expression of these 
epitopes.  
To address this, CD59 was analyzed by flow cytometry on a panel of DM+ and 
DM- DRB1*04:01 cell lines. All DM+ / D11-0401+ / D13-0401- cell lines including 
SAVC, Boleth, PF97387, WT51, and 8.1.6 0401 had comparable amounts of CD59 
(Figure 4.4B). Similarly, DM- / D11-0401- / D13-0401+  cells such as SJO Dw4, T2 
Dw4, BLS Dw4, and 5.2.4 0401 were also positive for CD59 (Figure 4.4B). These results 
suggest 1) expression of GPI-linked proteins are not required for D11-0401 expression, or 
if so, it is only in the presence of DM; and 2) GPI-linked proteins do not contribute to the 
D13-0401 epitope since CD59 is abundant on other D13-0401+ cell lines (Figure 4.4B). 
Thus, while GPI-anchored proteins or lipid rafts cannot be eliminated as contributing 
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Figure 4.4. GPI-anchored proteins are severely reduced in 9.5.3 0401 cells, but do not 
associate with expression of D11-0401 or D13-0401 epitopes. 
(A) Surface expression of GPI-anchored proteins CD59 (MEM-43) and CD55 (IA10), 
and total GPI-anchored proteins in 9.5.3 0401 and 8.1.6 0401 were compared using flow 
cytometry and the FLAER assay as described in Materials and Methods.  FLAER, a non-
lysing form of proaerolysin conjugated with Alexa Fluor 488, specifically binds to the 
GPI moiety of GPI-linked proteins. CD59, CD55, and FLAER expression are represented 
by the open histograms. Filled histograms indicate isotype controls. (B) Surface 
expression of CD59 was measured on D11-0401+/D13-0401– and D11-0401– /D13-
0401+ B-LCL by flow cytometry. Open histograms represent CD59 expression. Filled 
histograms indicate isotype controls. Results are representative of two independent 
experiments. 
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factors to presentation of the DM-dependent D11-0401 epitope, the results suggest they 
do not influence D13-0401 expression.  
 
4.2.3 Association of DRB1*04 epitopes with membrane microdomains 
MHC-II molecules are not uniformly distributed throughout the plasma 
membrane, but are organized into smaller patches or clusters on the surface of pAPC, 
which facilitate efficient antigen presentation to CD4+ T cells especially in circumstances 
of limited antigen (152, 177, 337). Two types of membrane microdomains, lipid rafts and 
tetraspanin enriched microdomains (TEMs), have been implicated in clustering MHC-II 
on the surface of APC prior to interaction with T cells (153, 163). Since lipid rafts are 
enriched in GPI-anchored proteins such as CD59 (338) and given the differential 
expression of GPI-anchored proteins between 8.1.6 0401 and 9.5.3 0401 as previously 
shown, we queried whether differences in lipid raft dynamics or other types of membrane 
microdomains might underlie the expression of the DRB1*04 epitopes. This idea was 
also supported by our finding that both D11-0401 and D13-0404 colocalize with 
tetraspanins CD63 and CD82 and preliminary experiments showing that chemical 
disruption of TEMs in B -LCL resulted in some loss of D11-0401 and D13-0404 (283). 
As described below, we investigated whether D11-0401, D13-0401, and D13-0404 
epitopes are modulated by clustering into membrane microdomains. 
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4.2.3.1 DRB1*04 epitopes are differentially susceptible to lipid raft disruption 
To evaluate whether the DRB1*04 epitopes associate with lipid raft membrane 
microdomains, raft integrity was disrupted using MBCD, which extracts cholesterol from 
the plasma membrane and disturbs protein association with cholesterol-enriched rafts 
(304-306). Preliminary experiments were performed with MT14B cells to determine the 
optimal concentration of MBCD that would selectively disrupt surface expression of lipid 
rafts in cells treated with 2.5 mM, 5 mM, and 10 mM MBCD. MBCD treatment resulted 
in a 30% or more decrease in CD59 and DRB1*04, while CD71 was not inhibited but 
actually increased, suggesting that a proportion of cell surface DRB1*04 molecules are 
associated with lipid rafts (Figures 4.5A, 4.5B). Additional analysis by confocal 
microscopy confirmed the MBCD-induced disruption of lipid raft protein expression, as 
evidenced by decreased CD59 and HLA-DR in MBCD-treated MT14B cells, whereas no 
obvious change in CD71 expression was observed (Figure 4.5C). Furthermore, MBCD 
treatment resulted in a reduction of GM1 ganglioside (Figure 4.5C), a well-known marker 
of membrane rafts (174, 339, 340). Subsequent experiments were performed with 5 mM 
MBCD to minimize any toxic effect of MBCD while still mainaining adequate lipid reaft 
disruption. 
MBCD- and control-treated SAVC, MT14B, 8.1.6 0401, and 9.5.3 0401 cells 
were analyzed for surface expression of membrane proteins and DRB1*04 epitopes by 
flow cytometry (Figure 4.6). Compared to control, MBCD-treatment significantly 
reduced CD59 on all B-LCL except the GPI-linked protein deficient 9.5.3 0401 (Figure 
4.6A), significantly reduced CD45 on MT14B, and markedly reduced CD82 and MHC-I 
on all B-LCL. In contrast, CD71 expression was increased on all MBCD-treated cells 
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Figure 4.5. Surface expression of lipid-raft associated molecules and HLA-DR is 
adversely affected by MBCD treatment. 
(A) Titration of MBCD was performed in a single experiment to determine the optimal 
concentration to disrupt lipid rafts. MT14B cells were treated with 2.5 (blue), 5 (green), 
and 10 mM (red) MBCD as described in the Materials and Methods. Surface expression 
of CD59 (MEM-43), CD71 (M-A712), and DRB1*04 (NFLD.D1) was analyzed by flow 
cytometry and compared to untreated control cells (grey histograms). Filled histograms 
represent isotype controls. (B) The bar chart shows the degree of MBCD disruption of 
lipid rafts. MFI values of CD59, CD71, and DRB1*04 for MBCD-treated cells were 
divided by the MFI expression values of untreated control cells. The broken line 
represents no change in expression mediated by MBCD. Results are representative of one 
experiment. (C) MT14B cells were treated with 5 mM MBCD and surface expression of 
CD59, CD71, total HLA-DR (L243), and GM1-ganglioside (Vybrant Lipid Raft Labeling 
Kit) was compared to untreated control cells by immunofluorescence and confocal 
microscopy. Each field of view contains approximately equal number of cells. Images 
were acquired at 20x objective magnification and are representative of several fields of 
view from at least two independent experiments.  
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Figure 4.6. The effect of lipid raft disruption on the surface expression of transmembrane 
proteins and DRB1*04 epitopes. 
Lipid rafts were disrupted using MBCD to treat SAVC, MT14B, 8.1.6 0401, or 9.5.3 
0401 cells. Surface expression of (A) CD59 (MEM-43), CD45 (HI30), CD71 (M-A712), 
CD82 (TS82b), MHC-I (W6/32), and (B) total DR (L243), DRB1*04 (NFLD.D1), MHC-
II/CLIP (cerCLIP), D11-0401, and D13-0401/D13-0404 was determined following 
MBCD treatment (thick lines) and compared to untreated control cells (thin lines). Filled 
histograms represent isotype controls. Representative data from one experiment are 
shown in the histogram plots. Cumulative data from one to five independent experiments 
are shown in the bar graphs (n = 1-5), where the mean MFI was compared between 
MBCD-treated (grey bars) and untreated control (black bars) cells. A paired t-test was 
performed to compare expression between MBCD-treated and untreated cells and 
significant differences are indicated by an asterisk (p < 0.05). Bars represent standard 
error. ND = not determined. Data from individual experiments for (A) and (B) are shown 
in Appendix D and E, respectively. 
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(Figure 4.6A). Total DR and DRB1*04 were also significantly reduced in all four cell 
lines (Figure 4.6B), suggesting that a large portion of DR molecules are located in lipid 
raft microdomains. MBCD treatment had no effect on MHC-II/CLIP expression on DM+ 
SAVC, MT14B, and 8.1.6 0401 cells, but significantly decreased its normally strong 
expression in DM- 9.5.3 0401 cells (Figure 4.6B). Similar to total DR and DRB1*04, 
D11-0401 was significantly reduced on MBCD-treated SAVC cells, but unchanged on 
8.1.6 0401 cells (Figure 4.6B). Both D13-0404 and D13-0401 epitopes in MT14B and 
9.5.3 0401, respectively, were unaffected by MBCD-treatment (Figure 4.6B). Taken 
together, the results suggest that only the D11-0401 epitope is associated with lipid rafts 
in the plasma membrane. 
Since D11-0401 expression was susceptible to lipid raft disruption in SAVC, but 
not in 8.1.6 0401 cells, we investigated this in additional D11-0401+ B-LCL, Boleth and 
PF97387. Similar to SAVC and 8.1.6 0401, MBCD treatment resulted in lipid raft 
disruption in both cell lines as demonstrated by substantially reduced CD59, total DR, 
and DRB1*04, with no change in CD71 (Appendix C). More importantly, D11-0401 
expression was diminished in both Boleth and PF97387 comparable to that observed in 
SAVC cells (Appendix C). Therefore, these results demonstrate that D11-0401 is partially 
associated with membrane rafts in cells that naturally express DRB1*04:01. 
To confirm that the D13-0404 epitope does not associate with lipid-rafts as was 
observed on MT14B (Figure 4.6B), we performed similar experiments using another 
D13-0404+ B-LCL, BM92. In contrast to MT14B, the D13-0404 was markedly decreased 
in MBCD-treated BM92 (Appendix C) while changes in CD59, total HLA-DR, and 
DRB1*04 and CD71 were consistent with those observed in MT14. Thus, the incongruent 
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results are not due to technical issues with MBCD, but suggest D13-0404 association with 
rafts could be cell type-dependent.  
 
4.2.3.2 The D13-0404 epitope is not associated with detergent resistant membranes 
extracted from MT14B 
Detergent resistant membranes (DRMs) extracted from cells are closely related to 
lipid rafts because both are enriched in similar lipids and proteins including cholesterol, 
GPI-anchored proteins, and specific transmembrane proteins (341). Similar to DRMs, 
lipid rafts are resistant to nonionic detergents, such as Triton X-100, due to extensive, 
strong interactions between their constituents (342). Therefore, the association of a 
protein with DRMs provides a good measure of its affinity to lipid rafts in vivo.  To 
determine the affinity of DRB1*04 epitopes for lipid rafts, DRMs were isolated from 
MT14B, 8.1.6 0401, and 9.5.3 0401 cells using sucrose density gradient 
ultracentrifugation followed by western blot analysis of gradient fractions. Although the 
D11-0401 and D13-0401 epitopes are either not or poorly detected by western blotting of 
total cell lysates, the possibility that DRM isolation would result in DRB1*04 molecules 
with these epitopes concentrating in DRMs or detergent-soluble fractions warranted these 
experiments. 
As controls, the DRM-association of the GPI-anchored protein CD59 and the non-
DRM protein CD71 were analyzed. CD59 was mostly located in fractions 2 to 4 in 
MT14B and 8.1.6 0401, corresponding to the expected location of isolated DRMs 
(Figures 4.7, 4.8A). Consistent with exosomal and surface expression, no CD59 was 
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Figure 4.7. The D13-0404 epitope is located on detergent soluble DRB1*04:04 
molecules. 
Detergent resistant membranes were isolated by sucrose density ultracentrifugation from 
MT14B total cell lysate as described in the Materials and Methods. Fractions were 
collected from the top of the sucrose gradient and subject to SDS-PAGE under reducing 
conditions followed by western blotting for molecules CD59 (MEM-43), CD71 (M-
A712), DR dimer (L243; Tal 14.1), DRB1*04 (NFLD.D1), DM (Tal 18.1), Ii (LN2), and 
D13-0404. DRMs migrated to the 5/35% sucrose interface of the sucrose gradient, which 
visually corresponded to fractions 2 to 4. The approximate size (kDA) of the identified 
protein bands is indicated. 
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Figure 4.8. 9.5.3 0401 exhibits reduced DRM-associated proteins compared to 8.1.6 
0401. 
Detergent resistant membranes were isolated by sucrose density ultracentrifugation from 
8.1.6 0401 (A) and 9.5.3 0401 (B) total cell lysates as described in the Materials and 
Methods. Fractions were collected from the top of the sucrose gradient and subject to 
SDS-PAGE under reducing conditions followed by western blotting for molecules CD59 
(MEM-43), CD71 (M-A712), DR dimer (L243; Tal 14.1), DRB monomer (Tal 14.1), 
DRB1*04 (NFLD.D1), DM (Tal 18.1), Ii (LN2), D11-0401, and  D13-0404. DRMs 
migrated to the 5/35% sucrose interface of the sucrose gradient, which visually 
corresponded to fractions 2 to 4. The approximate size (kDA) of the identified protein 
bands is indicated. 
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detected in the gradient fractions of 9.5.3 0401 cell lysates. CD71 was exclusively 
detected in fractions 11 to 14 from MT14B (Figure 4.7), 8.1.6 0401 (Figure 4.8A), and 
9.5.3 0401 (Figure 4.8B), corresponding to the detergent-soluble fractions. Taken 
together, these results confirm that DRM-associated proteins localize to fractions 2 to 4, 
while non-DRM proteins remain in the detergent-soluble lysate fractions 11 to 15. 
Analysis of DRM-association of DR in MT14B showed the majority DR dimers localized 
to the detergent-soluble fractions, as shown by three different anti-DR antibodies (Figure 
4.7). However, a subset of DR dimers was detected in the DRMs, indicating a minor pool 
of lipid-raft associated DR molecules. Both DM and Ii were predominantly found in 
detergent-soluble fractions (Figure 4.7), with only a tiny fraction of Ii-complexes (60-70 
kDa) and DM detected in DRMs. DRB1*04:04 molecules containing the D13-0404 
epitope were only detected in the detergent soluble fractions in MT14B, indicating that 
DR molecules with this epitope do not have an affinity for lipid rafts (Figure 4.7). These 
results are consistent with the previous findings where the disruption of lipid rafts with 
MBCD did not affect D13-0404 expression in MT14B cells (Figure 4.6B).  
Similar to MT14B, SDS-stable DR dimers in 8.1.6 0401 were primarily in 
detergent-soluble fractions, with only small amounts present in DRM fractions (Figure 
4.8A). DRB monomers were solely detected in the detergent-soluble fractions (Figure 
4.8A). Both DM and Ii molecules were confined to the detergent-soluble fractions in 
8.1.6 0401, except for a small proportion of Ii-complexes found in DRMs (Figure 4.8A). 
As shown, no D11-0401 epitope was detected in any fractions, even though a portion of 
DRB1*04 was detected in the DRM fractions. Most likely this is due to the instability of 
this epitope to detergents, as it is also poorly detected in lysates prepared from its cognate 
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cell line SAVC (data not shown). No SDS-stable DR dimers or DRB monomers were 
detected in the DRM fractions in 9.5.3 0401 (Figure 4.8B), which was not surprising 
given that it does not express DM (Figure 4.8B). Ii and Ii-complexes were exclusively 
detected in detergent-soluble fractions in 9.5.3 0401 (Figure 4.8B). Although the 
NFLD.D13 mAb detected its cognate D13-0404 epitope in the detergent soluble fractions 
of MT14B (Figure 4.8A), it does not detect the cross-reactive epitope D13-0401 in 9.5.3 
0401 fractions (Figure 4.8B).  
 
4.2.3.3 Saponin treatment of cells resulted in an overall decrease of membrane 
proteins  
Saponin treatment of B cells was previously shown to interfere with formation of 
TEMs containing MHC-II molecules carrying a select set of peptide antigens defined by a 
specific epitope, CDw78 (153). To determine whether D11-0401, D13-0401, or D13-
0404 associate with TEMs, their expression was measured on B-LCL after treatment with 
saponin and compared to untreated control cells. To ensure saponin treatment selectively 
disrupted TEMs, TEM-associated and non-TEM proteins were analyzed by flow 
cytometry. Although the tetraspanin marker CD82 was significantly decreased on 
saponin-treated cells, non-tetraspanin markers CD59, CD45, and CD71 were also 
significantly reduced (Figure 4.9A). In addition, MHC-I, total HLA-DR, and MHC-II/ 
CLIP complexes were dramatically reduced in all cell lines (Figures 4.9A, 4.9B). 
Interestingly, DRB1*04 expression was unaffected on saponin-treated SAVC and MT14B 
cells despite significantly reduced total DR (Figure 4.9B). As for the DRB1*04 epitopes, 
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Figure 4.9. Saponin treatment of B-LCL results in a non-specific decrease in cell surface 
protein expression. 
SAVC, MT14B, 8.1.6 0401, and 9.5.3 0401 cells were treated with saponin to 
preferentially disrupt tetraspanin microdomains and surface expression of (A) CD59 
(MEM-43), CD45 (HI30), CD71 (M-A712), MHC-I (W6/32), CD82 (TS82b) and (B) 
total DR (L243), DRB1*04 (NFLD.D1), MHC-II/CLIP (cerCLIP), D11-0401, and D13-
0401/D13-0404 was compared to control cells. Cumulative data from one to five 
independent experiments are displayed (n = 1-5). A paired t-test was performed to 
compare expression between saponin-treated and untreated cells and significant 
differences are indicated by an asterisk (p < 0.05). Bars represent standard error. ND, not 
determined.   
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D11-0401 was significantly reduced by saponin treatment in SAVC, but not on 8.1.6 
0401-treated cells (Figure 4.9B). Presentation of both D13-0404 and D13-0401 epitopes 
was decreased in saponin-treated MT14B and 9.5.3 0401 cells, respectively (Figure 
4.9B). Taken together, these results suggest that the effects of saponin are not restricted to 
TEMs or TEM-associated proteins, making this method impractical for evaluating 
association of pMHC-II with TEMs on intact cells. 
 
4.3 Discussion  
Our previous studies on the DM-dependent D11-0401 and the DM-resistant D13-
0404 epitopes indicated they require nascent DRB1*04 molecules and are formed in 
DM+ CD63+ CD82+ intracellular compartments resembling late endosomes and MVBs 
from which exosomes are secreted (283). In this study, we show strong expression of 
D11-0401 and D13-0404 epitopes on exosomes prepared from SAVC and MT14B cells, 
respectively, thus supporting their generation in late endocytic vesicles. However, the 
DM-sensitive D13-0401 epitope was not present on 9.5.3 exosomes while MHC-II/CLIP 
complexes, also DM-sensitive, were abundantly expressed.  Since MHC-II/CLIP is 
generated in late endocytic vesicles and amply expressed on DM- cells, the absence of 
D13-0401 on exosomes suggests it is not formed in late endosomal compartments.  
 Exosomes are only one of the many types of extracellular membrane vesicles, 
all of which differ in origin, function, size, sedimentation, and protein composition (229). 
Based on appearance and size by electron microscopy, < 200 nm in diameter, and protein 
marker profile (ICAM-1+, CD59+, CD82+, CD86+, HLA-DR+, DRB1*04+, and CD71- 
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or LAMP-1-),  the preparations used in this study are largely consistent with previously 
described exosomes (335, 343, 344). However, the presence of CD40 on exosomes from 
all four B-LCL somewhat contrasts with other reports that did not detect CD40 on B cell-
derived exosomes (335, 343, 345). Others have shown that signaling via CD40 on B cells 
can lead to B cell activation and increased exosome release from the activated cells (346-
348). Since the EBV-antigen, LMP-1, a known CD40 mimic and activator of B cells 
(349, 350) is expressed on most B-LCL, it is possible that this led to CD40 packaging in 
the exosomes described herein. 
Although expression of pMHC-II complexes on exosomes from various cell types 
is well documented, evaluation of DM-modulated allele-specific epitopes on exosomes is 
lacking (219, 335, 343). Here we showed DRB1*04 molecules bearing either the DM-
dependent D11-0401 or the DM-resistant D13-0404 epitope were expressed on the 
relevant exosomes, whereas the DM-sensitive D13-0401 epitope was completely 
excluded from 9.5.3 0401 exosomes despite strong expression of DRB1*04:01 (Figure 
4.3). To our knowledge, this is one of the first described instances of differential pMHC-
II presentation on exosomes compared to the cell membrane within a given cell type. A 
previous report found that exosomes derived from human monocyte-derived DCs, various 
cell lines, and human plasma contained novel MHC-I structures as detected by 
conformational-dependent antibodies, suggesting that exosomes may contain unique 
MHC-I complexes or epitopes for recognition by T cells that are not present on the 
surface of APCs (245). Our results suggest that D13-0401 is not present in MVBs, which 
is consistent with the hypothesis that this epitope may form in early or recycling 
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endosomes similar to previously described DM-sensitive epitopes (102) or ‘type B’ 
conformers (258, 274, 351). 
An alternative explanation is D13-0401+ molecules are actively removed from 
ILVs prior to secretion or excluded from packaging onto exosomes entirely. Mechanisms 
governing protein packaging onto ILVs for extracellular release are incompletely 
understood.  For example, some studies show entry into ILVs required ubiquitination and 
involves the ESCRT protein machinery (352, 353), while others show ubiquitination is 
not required for DR entry onto exosomes (354-357). Other proposed mechanisms include 
a ceramide-dependent mechanism (358) and a lipid raft domain-mediated mechanism 
(194, 359), but neither are well characterized. Although 9.5.3 0401 exosomes were 
negative for D13-0401, the presence of ample DR and specifically DRB1*04:01 show 
this cell line is capable of packaging DR complexes onto exosomes. While our results 
suggest D13-0401 is not generated in the late endosomal compartments, unfortunately, its 
susceptibility to fixation and permeabilization makes it difficult to evaluate by 
immunocytochemistry and confocal microscopy. Given the ability of exosomes to 
function as APCs with the capacity to activate antigen-specific or autoimmune T cell 
responses, the finding that exosomes and the plasma membrane may contain a different 
repertoire of peptide/DRB1*04:01 complexes emphasizes the importance of determining 
the mechanisms responsible for recruitment of pMHC-II onto exosomes. 
Our finding that DM and Ii were also excluded from B-LCL-derived exosomes is 
consistent with previous reports (343, 344). During transport to multivesicular antigen 
processing compartments, some MHC-II complexes are sorted into the ILVs of MVBs, 
where proteolysis within this acidic protease rich environment leads to the degradation of 
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Ii to CLIP. DM, which is present in the MVB internal and limiting membranes, facilitates 
CLIP removal and peptide binding (13, 42). Thus, both Ii degradation and CLIP 
dissociation are likely completed prior to exosome release. This is further supported by 
the absence of MHC-II/CLIP complexes on exosomes from the DM+ cells SAVC, 
MT14B, and 8.16 0401, and abundant expression on DM- 9.5.3 0401 exosomes.  
An unexpected finding regarding 9.5.3 0401 was the absence of exosomal CD59, 
which was subsequently shown to be due to a general deficiency of GPI-linked proteins 
on 9.5.3 despite normal levels on 8.1.6. Since 9.5.3 was derived from 8.1.6 by ethyl 
methane sulfonate (EMS) mutagenesis and immunoselection with the 16.23 mAb specific 
for a DM-dependent DRB1*03 epitope followed by complement lysis (271), it is possible 
that EMS introduced random mutations not only in the HLA-DMB, but also in PIGA gene 
which is required for biosynthesis of GPI-anchors (270, 360). Indeed, EMS has been 
previously shown to cause preferential mutations in the CD59 gene or generate GPI-
deficient cells (361, 362).  
Abundant expression of the D13-0401 epitope coinciding with absence of GPI-
anchored membrane proteins on exosomes and the cell membrane of 9.5.3 0401, raised 
the possibility that D13-0401 and other DRB1*04 epitopes were modulated by CD59 or 
by assembly into lipid rafts. GPI-anchored proteins are a defining component of lipid 
rafts, with which they associate through their distinctive lipid anchors (363). Furthermore, 
GPI-anchored proteins promote the incorporation of additional membrane proteins into 
larger functional clusters that may interact with rafts (364), suggesting a deficit of GPI-
anchored proteins in a cell may significantly affect the protein composition of rafts. 
Although further analysis of several normal and mutant DRB1*04:01 B-LCLs, either 
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D11-0401+ / D13-0401- or D11-0401- / D13-0401+, revealed no correlation between 
CD59 and their expression (Figure 4.4), it remains possible that DM-dependent epitopes 
such as D11-0401 requires the combination of DM and CD59. Interestingly, BL cells 
which poorly express the D11-0401 epitope (Figure 3.1), are reported to have reduced 
levels of GPI-linked proteins (365, 366), a finding that we subsequently confirmed (S. 
Drover, unpublished). A more direct test of this hypothesis would involve monitoring 
D11-0401 expression after knockdown or transfection of CD59 in DM+ / D11-0401+ or 
DM+ / D11-0401- cells, respectively. These findings would provide some insight into the 
possible importance and role of CD59, or other GPI-linked proteins, to the presentation of 
DM-modulated eptiopes. 
A considerable proportion of pMHC-II at the cell surface and in internal 
membranes is associated with lipid rafts. This association occurs early in MHC-II 
biosynthesis during transit through the Golgi apparatus, resulting in more than half of 
newly synthesized MHC-II complexes being lipid raft-associated after peptide loading for 
final transport to the plasma membrane (184, 193). The presence of pMHC-II in lipid 
rafts is particularly important for T cell activation by APCs as rafts concentrate the 
normally low levels of a specific pMHC-II on their surface (154-156).  For example, 
Bosch et al. demonstrated that newly formed pMHC-II generated in intracellular antigen 
processing compartments in DCs arrive at the plasma membrane in microclusters which 
could be dispersed by MBCD treatment (156). In this study, we found a substantial 
proportion of global surface DR species and DRB*04:01 molecules reside in lipid rafts in 
several B-LCL (Figure 4.6B, 4.7, 4.8). Significantly reduced amounts of D11-0401 on 
MBCD-treated SAVC and other DRB1*04:01 B-LCL (Figure 4.6B, Appendix C) 
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indicated that optimal expression of this DM-dependent epitope requires intact lipid rafts. 
The exception to this was the meagre reduction of D11-0401 on 8.1.6 0401 (Figure 4.6B), 
which may be related to reduced levels of DM and DO in 8.1.6 due to it being 
hemizygous for these loci (112). Both DM and DO have a role in the localization of 
proteins within MVB subdomains and are associated intracellularly with lipid rafts (367, 
368). 
Similar amounts of the DM-sensitive D13-0401 was found on untreated control 
and MBCD-treated 9.5.3-0401 cells, suggesting this epitope segregates with DRB1*04:01 
molecules that are not partitioned in lipid raft microdomains. It is possible the absence of 
GPI-anchored proteins in 9.5.3 0401 may have significantly altered raft protein 
composition based on the lack of DRMs in lysate fractions prepared from 9.5.3 0401 as 
compared to 8.1.6 0401 (Figure 4.8). However, its resistance to MBCD is not entirely 
surprising given its sensitivity to DM, its absence on exosomes, and considerable 
evidence that both exosomes and lipid raft-associated MHC-II molecules arise from DM+ 
late endosomes and IVLs (145, 195-197). Intriguingly, the DM-resistant D13-0404 
epitope was also unaffected by MBCD-treatment of MT14B cells, although its expression 
was reduced in another DRB1*04:04 cell line, BM92 (Appendix C). Aside from cell 
context differences, we have no explanation for this incongruity; however, the finding 
that the D13-0404 epitope segregated in the detergent-soluble and not in the DRM 
fractions of lysates prepared from MT14B (Figure 4.7) is consistent with its resistance to 
lipid raft disruption on MBCD-treated MT14B cells. Thus, although this epitope localizes 
to MIIC and is found on exosomes, it is primarily DM resistant and protease redundant, 
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suggesting this epitope may be formed in other intracellular vesicles that contain a 
smaller proportion of rafts.  
In comparison to lipid rafts, tetraspanin protein family members contribute to the 
formation of membrane microdomains termed TEMs, which are responsible for clustering 
of some pMHC-II (153). Tetraspanins form homodimers and heterodimers resulting in the 
formation of larger membrane microdomain complexes which promote the recruitment of 
several other membrane proteins, lipids, and signaling molecules (151). In B cells, CD63 
and CD82 form complexes with HLA-DR, DM, and DO within endosomal compartments 
(182), suggesting that tetraspanins and TEMs are important in clustering and transporting 
pMHC complexes to the plasma membrane. Indeed some studies show that newly loaded 
pMHC-II molecules arriving from MIIC segregate into TEMs on the plasma membrane 
(145, 153, 343). Since the FN1 mAb was shown to specifically recognize oligomerized 
pMHC-II in tetraspanin-enriched clusters that contain a select set of peptides (213, 369), 
we hypothesized that the DRB1*04 epitopes may also associate with TEMs.  However, 
our efforts to prove this hypothesis were problematic as treatment with saponin, which 
has been reported to disrupt tetraspanin-tetraspanin interactions in a cholesterol dependent 
manner but without disturbing lipid rafts or affecting total surface DR expression (153, 
210), had a negative impact on TEM- and non-TEM-associated markers. For example, 
not only did saponin treatment decrease the tetraspanin CD82, it also significantly 
decreased lipid raft-associated CD59, non-TEM-associated proteins CD45 and CD71, as 
well as MHC-I, peptide/DR, and MHC-II/CLIP complexes (Figure 4.9).  
Intriguingly, DRB1*04 molecules, determined by the peptide-independent and 
DM-resistant pan-DRB1*04-specific NFLD.D1 mAb, were the only molecules that were 
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increased by saponin treatment (Figure 4.9). Thus, significantly decreased amounts of 
D11-0401, D13-0401, and D13-0404 in saponin treated cells cannot be easily discounted 
given that the D13-0401 and D13-0404 epitopes were not altered by lipid raft disruption. 
It is possible that the global effect of saponin-mediated changes in TEM and non-TEM 
expression may result from a disruption of several types of microdomains, especially 
since the distinction between TEMs, lipid rafts, and other specializations of the plasma 
membrane may not be clearly defined as once thought (370). The incorporation of 
cholesterol in both TEMs and lipid rafts is a defining feature for both microdomains in 
terms of their formation and biological function (210, 371-373). Thus, it is probable that 
the cholesterol-dependent action of saponin for disruption of TEMs was also responsible 
for the alteration of additional membrane microdomains including lipid rafts.  
The exosomal expression and raft-association of the DRB1*04 epitopes in this 
study may give some insight into the presentation of unique pMHC-II epitopes. The D11-
0401 epitope is reminiscent of the previously described Ia.2 epitope, which is recognized 
by the 11-5.2 mAb and defines a subset of cell surface I-A
k
 molecules predominantly 
found within membrane lipid rafts (186). Thus, D11-0401 may represent an ideal epitope 
to study the model of lipid raft-mediated coordination of MHC-II peptide loading and 
transport to the plasma membrane proposed by Roche and colleagues (152). In addition, 
the findings in this study support further investigation into the functional or therapeutic 
role of D11-0401+ exosomes, especially given the strong linkage of DRB1*04:01 to 
autoimmune diseases such as RA. Conversely, the discordant expression of D13-0401 
between the plasma membrane and exosomes suggests that this epitope might be actively 
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excluded from presentation, which may provide a basis for further studies into antigen 
presentation mechanisms to limit the presentation of DM-sensitive self-epitopes. 
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Summary and Future Directions 
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5.1 Overview 
The focus of the thesis was to further characterize the factors which influence the 
formation and expression of DRB1*04 epitopes defined by the mAbs NFLD.D11 and 
NFLD.D13.  These antibodies, along with other anti-DRB1*04 mAbs, were originally 
developed and characterized by Dr. S. Drover and Dr. W.H. Marshall (78, 276-280, 283, 
310). The study of both NFLD.D11 and NFLD.D13 mAbs was initially undertaken given 
that they recognize epitopes on DRB1*04 molecules that contain the “shared epitope” 
(SE), a five amino acid sequence motif in residues 70-74 of the DRB chain (QKRAA / 
QRRAA), which is strongly associated with the development of severe rheumatoid 
arthritis (284, 285, 332). The mechanisms which account for the association of the SE 
with rheumatoid arthritis are unclear and inconclusive, with some attributing it to the 
selection of the T cell repertoire (374) or the presentation of arthritis-related autoantigens 
(375). Previous studies in our laboratory suggested that a specific set of peptides 
contribute to formation of the D11-0401, D13-0401, and D13-0404 epitopes (278-280, 
283). Furthermore, the presentation of these epitopes depends on a delicate balance of 
factors including DM expression, peptide availability, and other unknown cellular 
elements (78, 280, 283). In order to identify these unknown factors, one of the major 
goals of this work was to ascertain under what conditions these DM-modulated epitopes 
are optimally expressed, with a particular focus on the effect of HLA-DO, association 
with membrane microdomains, and exosomal expression. Given the relationship between 
DM-sensitivity of MHC-II epitopes and autoreactive T cell development in autoimmune 
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disease, further study into these contributing elements may provide insight into a 
mechanism for the development of SE-associated autoimmunity. 
 
5.2 Summary and potential implications of major findings 
The research presented in this thesis examined the mechanisms involved in the 
presentation of antibody-defined DRB1*04 epitopes making use of B-LCL and antigen 
presentation defective cell lines which naturally express these epitopes. The D11-0401, 
D13-0401, and D13-0404 epitopes have been previously studied in some detail (78, 280, 
283). Nevertheless, there remains an incomplete understanding of the conditions under 
which these epitopes are optimally expressed. 
Previous studies have categorized peptide antigens or epitopes based on the effect 
of DM on their presentation or expression (102-104). DM-resistant peptides or epitopes 
are unaffected by DM expression and can be expressed on any MHC-II-expressing cells 
irrespective of DM or DO co-expression. Conversely, DM-sensitive peptides or epitopes 
are abolished by the presence of DM, but can be restored by the expression of DO which 
is typically restricted to pAPC (102). Finally, DM-dependent peptides or epitopes require 
the expression of DM for presentation (103), suggesting that these epitopes would be 
abrogated by DO. The findings presented in this thesis, particularly Chapter 3, help 
classify the D11-0401, D13-0401, and D13-0404 epitopes into the above defined 
categories. 
The most important observations from previous experiments focused on D11-
0401 were that (a) D11-0401 requires DM for expression in B-LCL, and (b) a subset of 
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endolysosomal and/or cytoplasmic cysteine proteases are required for epitope expression 
(78, 283), thus suggesting that the peptide(s) forming this epitope is DM-dependent. 
However, analysis of D11-0401 expression in this study on several DM+ cell lines such 
as BL cell lines Daudi, BJAB, and Ramos, and in DM-restored 5.2.4 0401 cells indicated 
that additional factors, possibly DO are required. Transfection of DO into BJAB did not 
induce D11-0401 formation, indicating that DO is not the missing factor for generating 
this epitope in BL cell lines. Without knowing the exact peptide(s) that contribute to this 
epitope, it is difficult to definitively rule out DO as a contributing factor, since a possible 
explanation for D11-0401 deficient expression on these DM-positive cell lines is they 
simply do not contain the proper antigens for proteases to generate the peptide(s) required 
for epitope expression. It can only be concluded from these experiments that DO may still 
be required along with DM, but other factors such as an appropriate antigenic peptide 
source may be missing in BL cell lines and other DM+ D11-0401- cells. 
In contrast to D11-0401, the D13-0401 epitope was previously found to be only 
expressed in the absence of DM expression, indicating that the peptide(s) forming this 
epitope is DM-sensitive (78, 280). Additional expression analysis of D13-0401 on DM- 
and DM+ cell lines in Chapter 3.2.3 confirmed that expression of this epitope is confined 
to DM- cells, but also suggested that other cellular factors such as a specific antigen or 
peptide are required for epitope formation. Whereas the role of DO in D11-0401 
expression was intriguing to examine given its DM-dependence, the contribution of DO 
to D13-0401 formation in the absence of DM is more difficult to envision given that DO 
performs its function by directly binding DM. For this reason, the involvement of DO in 
D13-0401 formation was not investigated in detail in this study. However, it is possible 
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that under circumstances of abnormally high DO expression, where the majority of DM 
remains bound to DO, this inhibition of DM may lead to the expression of D13-0401, as 
previously described for DM-sensitive epitopes (102, 104).  
Regarding the DM-sensitivity and dependency of D13-0401 on specific proteases, 
it is reminiscent of another previously described epitope consisting of a peptide from type 
II collagen (aa261-273) bound to HLA-DRB1*04 (376). Type II collagen is a candidate 
autoantigen for rheumatoid arthritis and the peptide aa261-273 forms an 
immunodominant pathogenic epitope with HLA-DRB1*04 which can activate CD4+ T 
cells. Interestingly, this epitope is expressed by APC lacking DM and its presentation is 
inhibited by DM in the recycling pathway, resulting in decreased presentation and T cell 
activation (376).  
Concerning the D13-0404 epitope, prior experiments demonstrated that DM 
expression and specific proteases were not necessary for expression (283). This is further 
demonstrated in Chapter 3.2.5 where the DM- 5.2.4 0404 cell line was found to 
abundantly express D13-0404. Furthermore, transfection of DM into 5.2.4 0404 only 
minimally affected D13-0404 expression and only in cells exhibiting the greatest 
expression. Therefore, this epitope is similar to that described above for DM-resistant 
epitopes (103).  
Consistent with previous findings by Spurrell, D.R. (283), endolysosomal and 
cytoplasmic cysteine proteases were necessary for optimal expression of DM-dependent 
D11-0401 and DM-sensitive D13-0401, while being dispensable for DM- resistant D13-
0404. Contribution of calpains to D11-0401 and D13-0401formation, suggests 
cytoplasmically-derived proteins could be a source of the putative peptide(s) involved in 
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epitope formation. This would not be surprising since as about 30% of the peptides bound 
to MHC-II are derived from nuclear and cytoplasmic proteins (136), which may access 
the endosomal pathway by autophagy (137). Autophagy in APCs can result in the 
generation of citrullinated peptides which are presented in the context of MHC-II (142), 
and the presence of anti-citrullinated protein/peptide antibodies is a defining characteristic 
of rheumatoid arthritis (377). The presentation of citrullinated peptides by MHC-II have 
been linked to the development of rheumatoid arthritis, and interestingly, the production 
of these autoantibodies is associated with the HLA-DRB1 shared epitope (143, 377, 378). 
Since both D11-0401 and D13-0401 may consist of cytoplasmic-derived peptide(s) bound 
to DRB1*04:01 and because D11-0401 was detected on PBMC from rheumatoid arthritis 
patients (310), it is speculative that these epitopes consist of citrullinated peptides 
processed in the cytoplasm of APCs and transported to the endosomal pathway via 
autophagy. Although briefly mentioned in Chapter 3.3 and Spurrell, D.R. (283), the role 
of autophagy in D11-040, D13-0401, and D13-0404 formation was investigated using the 
inhibitor wortmannin, with inconclusive results. For this reason, we believe that the role 
of autophagy requires further study, and that the use of more specific synthetic protease 
and autophagy inhibitors available today will provide a more precise definition 
concerning the peptide species bound to DRB1*04 that forms these epitopes.  
A significant question that remains from this study concerns the structural basis of 
the D13-0401 epitope. The results presented in Chapter 3.2.4 indicate that specific 
proteolytic processing events affect D13-0401 expression, suggesting that this epitope 
defines a particular peptide or subset of peptides in combination with DRB1*04:01. 
Alternatively, since inhibition of the same proteases caused a strikingly similar decrease 
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of D13-0401 in 9.5.3 0401 as with D11-0401 in SAVC and 8.1.6 0401, one could argue 
that these epitopes define conformational isomers of DRB1*04:01 independent of the 
bound peptide like that reported for type A and type B pMHC-II complexes, described by 
Unanue (258). Although the exact structural differences between types A and B pMHC-II 
are unknown, it is well established that type A molecules require DM, whereas type B 
complexes are destroyed by interaction with DM. Further support of the idea that D13-
0401 corresponds to type B complexes is that this epitope is expressed intracellularly in 
SAVC cells, but only minimally and sometimes undetectable at the cell surface. If this 
epitope is directly destroyed by DM binding in SAVC independent of bound peptide, then 
DRB1*04:01 molecules on route to MIIC which have not yet encountered DM would 
contain the D13-0401 epitope and only after arrival in the DM-rich MIIC environment 
would this epitope be destroyed. Further support for this hypothesis is the observation that 
exosomes released by SAVC cells do not express D13-0401 as demonstrated in Chapter 
4.2.1. Since exosomes originate from MIIC and contain very little MHC-II-CLIP, 
exosomal pMHC-II have likely come into contact with DM, thus inducing a 
conformational change which destroys D13-0401. Moreover, the absence of D13-0401 on 
9.5.3 0401 exosomes may indicate that this epitope is not present in MIIC, which is also 
comparable to type B complexes (379).  
Recent studies suggest that for successful stimulation of T cells, pMHC-II 
complexes require concentration in distinct microdomains including lipid rafts and TEMs 
within the plasma membrane (150-154). The relevance and mechanisms of pMHC-II 
association with lipid rafts TEMs is not fully understood; however, it has been previously 
hypothesized that membrane microdomains contain MHC-II that bind and display 
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specific sets of peptides (153, 163). Since prior experiments in the lab indicated possible 
association of the DRB1*04 epitopes with membrane microdomains (283), we questioned 
whether the DM-sensitivity of these epitopes affected their ability to segregate in different 
microdomains. By examining surface expression on B-LCL using flow cytometry prior 
and subsequent to chemical disruption of lipid rafts and TEMs, we found that a fraction of 
DM-dependent D11-0401 is associated with rafts in the plasma membrane, while 
presentation of both DM-sensitive D13-0401 and DM-resistant D13-0404 was not 
affected (Chapter 4.2.3). In support of this later observation, D13-0404+ DRB1*04:04 
molecules were not observed in DRM fractions isolated from MT14B cells. Previous 
experiments by Spurrell, D.R. indicated that the D11-0401 and D13-0404 epitopes were 
not affected by MBCD-disruption of lipid rafts (283); however, these previous 
experiments involved MBCD treatment on PFA-fixed cells whereas the current procedure 
used live cells. This discrepancy between findings is likely due to the difference in 
methodologies; however the current method appears to be appropriate given the specific 
disruption of raft-associated membrane proteins but not non-raft proteins. 
A previously described MHC-II epitope on I-A
k
 molecules termed the Ia.2 
epitope, which is recognized by the 11-5.2 mAb and defines a subset of cell surface I-A
k
 
predominantly found within lipid rafts (186). This study also demonstrated that the Ia.2-
positive MHC-II molecules are critically necessary for a successful interaction between B 
and T lymphocytes, especially under circumstances of limited antigen. This is consistent 
with previous reports detailing the importance of raft-resident pMHC-II in antigen 
presentation (154, 186). Unlike the Ia.2 epitope, it is not clear from our studies whether 
D11-0401 defines a unique subset of pMHC-II that are sequestered in lipid raft domains. 
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Since complete abrogation of D11-0401 was not observed after lipid raft disruption in 
SAVC, Boleth, and PF97387 cells, and no disruption of epitope expression occurred on 
8.1.6 0401 cells, it is unlikely that this epitope is created from a pMHC-II association 
with lipid rafts, but that D11-0401 instead defines a subset of pMHC-II that dynamically 
passage in and out of rafts at the cell surface. This is supported by our previous findings 
that the main determining factors governing D11-0401 expression are DM and peptide 
availability, and that D11-0401-positive pMHC-II are present both in the presence and 
absence of the lipid raft marker CD59.  
Preliminary experiments performed by Spurrell, D.R. (283) found that cell surface 
D11-0401 expression was disrupted by low concentrations of the detergent saponin, 
suggesting that this epitope is concentrated in TEMs similar to that described for the 
CDw78 epitope (153, 210). We performed the same protocol in this study and also 
observed a significant decrease in the DRB1*04 epitopes as shown in Chapter 4.2.3; 
however, saponin treatment also caused a general decrease in all surface molecules 
investigated, including proteins not known to localize within TEMs. These non-specific 
results, combined with a criticism of this method by Poloso et al. (212) who questioned 
the use saponin treatment on cells that have been previously fixed with PFA to disrupt 
membrane protein interactions, makes it difficult to arrive at a conclusion concerning the 
association of D11-0401, D13-0401, or D13-0404 with TEMs. An attempt was made in 
this study to visualize D11-0401 and D13-0404 with TEMs simultaneously using 
immunofluorescent staining confocal microscopy, but this proved to be technically 
difficult. The concept that TEMs contain unique MHC-II epitopes such as CDw78 was 
contested by Poloso et al. (212), who found that CDw78 does not uniquely identify 
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tetraspanin-associated MHC-II, thus calling into question the use of this epitope as an 
indicator of MHC-II-tetraspanin complexes, and suggests that this epitope defines a 
subset of pMHC-II associated with tetraspanins that reside in lipid rafts. 
An additional aim of this study was to characterize the expression of the D11-
0401, D13-0401, and D13-0404 epitopes on B-LCL-derived exosomes. Purified 
exosomes expressed typical exosomal proteins reported in the literature, including DR. 
However, the expression of the DRB1*04 epitopes was cell specific and independent of 
the epitope expression at the cell surface. While both DM-dependent D11-0401 and DM-
resistant D13-0404 epitopes were abundantly expressed on exosomes from DM-
expressing B-LCL, exosomes from DM-deficient cells were devoid of DM-resistant D13-
0401 expression. Taken together, these results suggest a role for DM in the recruitment of 
specific pMHC-II to exosomes during their biogenesis. 
The finding that the D11-0401 and D13-0404 epitopes are contained on exosomes 
has several important implications. It reaffirms that these epitopes are formed on nascent 
DR molecules trafficking through the classical MHC-II antigen processing pathway to 
peptide-loading late endocytic vesicles, since exosomes originate from ILVs within MIIC. 
It also supports the assertion that D11-0401+ and D13-0404+ pMHC-II consist of mature 
molecules containing bound peptide because MHC-II-CLIP complexes are sorted onto 
ILVs during the process of DM-mediated peptide loading (13). Finally, exosomal 
expression also supports the observation that D11-0401 associates with lipid rafts, since 
ILVs are known to contain several raft-associated molecules (195-197) and the majority 
of exosomal pMHC-II can reside within lipid rafts (195). However, these assertions are 
complicated by the observations that D13-0404 does not appear to be associated with 
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lipid rafts. Nonetheless, the D11-0401 epitope may represent an ideal epitope to study the 
hypothetical model of lipid raft-mediated coordination of MHC-II peptide loading and 
transport to the plasma membrane proposed by Roche and colleagues (152). However, 
additional research is required to clarify the relevance of the exosomal expression of these 
epitopes to the factors governing their expression. 
The lack of D13-0401 despite abundant pMHC-II complexes on exosomes from 
9.5.3 0401 is intriguing for several reasons. First, it provides additional support that the 
D13-0401 epitope is not comprised of MHC-II-CLIP molecules, since substantial MHC-
II-CLIP was observed on the same exosomes. Secondly, assuming that this epitope is 
found within MIIC given its DM-sensitive classification, the lack of D13-0401 on 
exosomes from SAVC, 8.1.6 0401, and 9.5.3 0401 suggests that pMHC-II bearing this 
epitope are actively prohibited from trafficking onto exosomes. Although it cannot be 
determined from this study what mechanisms are responsible for this exclusion, a 
potential explanation may involve the resistance of this epitope to MBCD-induced lipid 
raft disruption. Previous studies have proposed a lipid raft-mediated mechanism 
involvement in the recruitment of pMHC-II to exosomes (194, 359). Alternatively, the 
lack of GPI-anchored proteins or MHC-II accessory molecules such as DM in 9.5.3 0401 
may point to a direct role for these molecules in loading pMHC-II onto exosomes. 
Regardless, the idea that there is an active mechanism in pAPC to ensure that only DM-
edited pMHC-II complexes are presented on exosomes to prevent exosomal presentation 
of low-affinity potentially autoantigenic epitopes leading to undesired autoimmune 
activation is an attractive hypothesis to consider. In line with this thinking, the idea that 
non-APCs which upregulate MHC-II but not DM or DO can present DM-unedited or 
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DM-sensitive low affinity pMHC-II epitopes on exosomes activation of auto-reactive T 
cells is also intriguing. Finally, the idea that APC have the ability to regulate which 
particular pMHC-II epitopes are released to the external environment via exosomes raises 
many questions concerning their significance in immune activation and regulation. 
Whether particular antigens or peptides are preferentially presented on exosomal MHC-II 
and under what circumstances can dysregulation of this process lead to the presentation of 
autoantigenic MHC-II epitopes and subsequent activation of autoimmune responses 
would be an avenue worth exploring. The D13-0401 epitope may represent a unique tool, 
and in combination with D11-0401 and their associated cell lines, a potential model to 
investigate mechanisms of MHC-II incorporation onto exosomes.  
 
5.3 Study limitations and future directions 
The work described in this thesis has furthered our understanding of the factors 
influencing expression of unique antibody-defined DRB1*04 epitopes. However, there 
are several limitations to consider and unanswered questions for future studies, as well as 
new research avenues that have the potential for investigation. 
 
1) Many of the same proteases required for antigen processing and MHC-II 
presentation also degrade the Ii chain, an integral step preceding peptide loading. Thus, 
inhibition of these same proteases can have several adversely affect the MHC-II 
presentation pathway, including blocking transport of MHC-II to antigen loading 
compartments and the cell surface (117, 380, 381). A limitation of this study is that 
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incomplete invariant chain degradation was detected in protease inhibitor-treated B-LCL 
as shown in Chapter 3.2.7, suggesting that a general impairment of peptide loading and 
MHC-II transport instead of a decrease in a specific peptide species may be responsible 
for the observed reduction in D11-0401, D13-0401, and D13-0404 in these experiments. 
This does not fully discount the conclusion that these epitopes represent a specific peptide 
or group of peptides bound to DRB1*04, but instead suggests that at some point during 
their synthesis, these epitopes transit through the classical pathway of MHC-II 
presentation. 
 
2) Since undertaking this study, the precise function and effect of DO on the 
repertoire of peptides presented by MHC-II has been further clarified in the literature (81, 
382). Because DO is a MHC-II substrate mimic for DM resulting in reduced DM-
function, the overall pMHC-II expression at the cell surface is ultimately controlled by 
the ratio of active DM to inactive DM-DO complexes (383). Therefore, perhaps a more 
relevant set of experiments to determine the contribution of DO to expression of both 
D11-0401 and D13-0401 would be to quantify the ratio of DO to DM by using western 
blot or flow cytometry analysis of expression in cell lines constitutively expressing each 
epitope. Given this new understanding of DO function, it is likely that optimal D11-0401 
expression requires high DO levels since the epitope likely consists of low stability self-
peptide(s) bound to DRB1*04:01 molecules. Thus, optimal D11-0401 expression is 
conceivably dependent on (1) the presence of the appropriate protein(s) or peptide(s) and 
(2) the ratio of functional DM to inactive DO-bound DM. Alternatively, a more direct 
approach to measure the effect of DO on D11-0401 or D13-0401 would be to knock 
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down DO expression in D11-0401+ or D13-0401+ cells, respectively, utilizing RNA 
interference knockdown or CRISPR/Cas9 gene editing technology. However, interpreting 
the results of these experiments would be complicated by the fact that knockdown of DO 
would also affect the level of functional DM. Regardless, a more complete understanding 
of how DM and DO simultaneously shape the presentation of specific epitopes could 
provide insight to mechanisms of immune tolerance and initiation of autoimmunity. 
 
3) The current study is limited in its conclusions regarding the specificity of the 
cellular proteases contributing to D11-0401, D13-0401, and D13-0404 formation and 
future experiments should make use of more specific protease and cellular pathway 
inhibitors to clarify the nature of the antigen or peptides which form these epitopes. 
Cysteine cathepsins, which constitute a major portion of the endolysosomal proteolytic 
activity, are responsible for the generation of several MHC-II epitopes (61, 384, 385). In 
addition, both GILT and AEP have been shown to contribute to the generation of MHC-II 
epitopes (125, 126, 128, 386). Therefore, particular attention should be devoted to 
specific lysosomal cysteine proteases such as cathepsins L and S, GILT, and AEP. 
Furthermore, additional focus should be made to the contribution of autophagy to the 
formation of these epitopes, especially since cytoplasmic-derived citrullinated peptides 
presented by DRB1*04:01 may represent these epitopes as previously discussed. An 
alternative method to determine whether citrullinated proteins or peptides contribute to 
epitope formation would be to (1) test whether anti-citrullinated protein abs block 
NFLD.D11 and NFLD.D13 binding, or (2) stain D11-0401+, D13-0401+, and D13-0404+ 
cells with anti-citrullinated proteins/peptide antibodies and visualize by confocal 
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microscopy for cellular localization. The identity of the specific peptide or peptides that 
are bound by DRB1*04 molecules forming these epitopes would be valuable given the 
potential biologically relevance of this epitope to DRB1*04:01and *04:04 associated 
autoimmunity.  
 
4) The role of one or more tetraspanin proteins in expression of D11-0401, D13-
0401, and D13-0404 remains unanswered. A more appropriate approach to examine the 
importance of D11-0401-tetraspanin interactions in the expression of this epitope might 
be to make use of RNA interference or CRISPR/Cas9 gene editing techniques to 
knockdown individual tetraspanin expression. However, the question of whether D11-
0401 associates with larger tetraspanin-enriched microclusters distinct from lipid rafts 
might be difficult to ascertain, especially given that both microdomains may be more 
closely related than what was initially postulated (152). 
 
5) Due to the aforementioned difficulty of using the NFLD.D11 and NFLD.D13 
antibodies in several assays, a complete analysis of the association of these epitopes with 
DRMs could not be determined, as well as immunofluorescence colocalization 
experiments were inconclusive, both of which would have provided additional insight 
into epitope raft association. As an alternative to the sucrose density gradient 
ultracentrifugation technique, a unique flow cytometric assay of differential detergent 
resistance (FCDR) was employed, which is based on the resistance of lipid rafts and 
associated proteins to be solubilized in nonionic detergents such as Triton X-100 (387-
389). Contrary to the previous experiments utilizing MBCD to disrupt lipid raft integrity, 
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the FCDR results indicated that D11-0401 was detergent soluble in SAVC and 8.1.6 0401 
cells, suggesting limited association of this epitope with cell surface lipid rafts (Appendix 
G). However, the FCDR results are less reliable since detergent resistance or solubility 
can be affected by several other factors independent of raft-association (390). We propose 
additional experiments are performed which involve the biotinylation of the NFLD.D11 
and NFLD.D13 mAbs prior to incubation with D11-0401-positive cells, followed by 
streptavidin-HRP labelling and lipid raft isolation by sucrose density gradient 
ultracentrifugation. This would allow examination of the distribution of the HRP-tagged 
mAbs in raft and non-raft fractions, thus allowing calculation of the proportion of surface 
pMHC-II bearing these epitopes that is raft-associated.  
 
6) Given the similarity of the D13-0401 epitope to another DRB1*04-restricted 
epitope consisting of a peptide from type II collagen as described above (376), it might be 
worthwhile to examine the functional relevance of D13-0401, with a particular focus on 
the in vivo expression profile in the context of DRB1*04-associated autoimmune disease 
such as RA or the ability of this mAb to block autoreactive T cell activation. For example, 
expression of D13-0401, as well as D11-0401 and D13-0404, could be investigated in 
arthritic tissue sections or primary cells from inflamed synovium by 
immunohistochemistry and immunocytochemistry, respectively. Alternatively, epitope 
expression could be evaluated on B cells isolated from inflamed synovium or synovial 
fluid from RA patients. To determine the potential therapeutic use of these mAbs, their 
ability to block autoreactive T cell activation could be measured using ELISPOT or flow 
cytometry-based T cell activation/proliferation assays by stimulating peripheral T cells 
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from RA patients in vitro using overlapping peptide pools of known RA-causing 
autoantigenic proteins in the presence of blocking NFLD.D11 and NFLD.D13 mAbs. If 
these epitopes are indeed responsible for the activation or expansion of autoreactive T 
cells in RA or other autoimmune disorders, then a potential therapeutic use of these 
antibodies would be invaluable. 
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Preamble 
 The results presented in the Appendices include mostly preliminary data that 
requires further follow with additional experiments. The author did not feel that these 
results warranted inclusion in Chapter 3 or 4, as the data would likely be excluded from a 
future manuscript prepared from these chapters. Appendices D, E and F show results 
from several independent experiments and are meant to compliment the data presented in 
Figures 4.6A, 4.6B, and 4.9, respectively, which display mean values compiled from the 
independent experiments. 
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Appendix A. The effect of additional protease inhibitors on surface DR epitope 
expression. 
 
Figure A.1. SAVC cells were treated with several protease inhibitors or with the 
appropriate diluent control and surface expression of HLA-DR (L243), DRB1*04 
(NFLD.D1), D11-0401 (NFLD.D11), CLIP (cerCLIP), and Ii (LN2) was measured by 
CELISA. Brefeldin A prevents transport of proteins from the ER to the Golgi apparatus. 
Chloroquine prevents acidification of late endosomes and thus lysosomal degradation of 
proteins. Leupeptin is an inhibitor of cysteine, serine, and threonine peptidases. E64d is 
an inhibitor of a wide range of cysteine peptidades including papain, cathepsin B, 
cathepsin L, and calpain. Pepstatin inhibits aspartyl proteases. Calpeptin is a calpain 
inhibitor. Bafilomycin is an endosomal acidification and late autophagy inhibitor. 
Lactacystin is an inhibitor of the proteasome. Results are displayed as a ratio of protease 
inhibitor-treated expression values to untreated controls. Results are from at least two 
independent experiments (n ≥ 2). Error bars indicate standard error. DRB1*04, D11-
0401, and CLIP expression was compared to DR using a paired t-test and asterisks 
indicate significant differences (* = p < 0.05; ** = p < 0.01).  
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Figure A.2. MT14B cells were treated with several protease inhibitors or with the 
appropriate diluent control and surface expression of HLA-DR (L243), DRB1*04 
(NFLD.D1), D13-0404 (NFLD.D13), CLIP (cerCLIP), and Ii (LN2) was measured by 
CELISA. Brefeldin A prevents transport of proteins from the ER to the Golgi apparatus. 
Chloroquine prevents acidification of late endosomes and thus lysosomal degradation of 
proteins. Leupeptin is an inhibitor of cysteine, serine, and threonine peptidases. E64d is 
an inhibitor of a wide range of cysteine peptidades including papain, cathepsin B, 
cathepsin L, and calpain. Pepstatin inhibits aspartyl proteases. Calpeptin is a calpain 
inhibitor. Bafilomycin is an endosomal acidification and late autophagy inhibitor. 
Lactacystin is an inhibitor of the proteasome. Results are displayed as a ratio of protease 
inhibitor-treated expression values to untreated controls. Results are from at least two 
independent experiments (n ≥ 2). Error bars indicate standard error. DRB1*04, D13-
0404, and CLIP expression was compared to DR using a paired t-test and asterisks 
indicate significant differences (* = p < 0.05; ** = p < 0.01).  
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Appendix B. Surface and intracellular expression of membrane proteins assessed on 
exosomes.  
 
Figure B.1. 8.1.6 0401 cells were analyzed for surface and intracellular expression of 
antigen presentation molecules, DRB1*04 epitopes, and exosomal markers using flow 
cytometry. Isotype control staining was performed in parallel and had an MFI ≤ 10.  
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Figure B.2. 9.5.3 0401 cells were analyzed for surface and intracellular expression of 
antigen presentation molecules, DRB1*04 epitopes, and exosomal markers using flow 
cytometry. Isotype control staining was performed in parallel and had an MFI ≤ 10. 
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Appendix C. The effect of lipid raft disruption on the surface expression of raft 
markers and DRB1*04 epitopes in additional DRB1*04 B cell lines. 
 
Figure C.1. Lipid rafts were disrupted by membrane cholesterol depletion using MBCD 
to treat (A) Boleth, (B) PF97387, and (C) BM92 and expression of CD59 (MEM-43), 
CD71 (M-A712), CD82 (TS82b), total DR (L243), DRB1*04 (NFLD.D1), D11-0401, 
and D13-0404 was compared to untreated control cells. Results from one flow cytometry 
are shown. D. The fold change in expression was calculated in by dividing the MFI 
values of MBCD-treated cells by the MFI values of untreated controls. The broken line in 
the graph represents no change in expression caused by MBCD. 
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Appendix D. The effect of lipid raft disruption on the surface expression of 
transmembrane proteins. 
 
Figure D.1. The effect of lipid raft disruption on the surface expression of (A) CD59 
(MEM-43), (B) CD45 (HI30), (C) CD71 (M-A712), (D) CD82 (TS82b), and (E) MHC-I 
(W6/32) on SAVC, MT14B, 8.1.6 0401, and 9.5.3 0401 was determined  as displayed in 
Figure 4.6A. The fold change in expression caused by MBCD treatment (Fold change in 
MFI) for each individual experiment is shown and was calculated by dividing the MFI 
expression value of MBCD-treated cells by the MFI of untreated controls. Each dot 
denotes an individual experiment and the solid lines indicate the mean fold change in 
MFI. The broken line in each graph represents no effect of MBCD-treatment on 
expression. A paired t-test was performed to compare expression between MBCD-treated 
and untreated control cells for a given cell line. Significant differences are indicated by an 
asterisk (p < 0.05). 
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Appendix E. The effect of lipid raft disruption on the surface expression of DRB1*04 
epitopes. 
 
Figure E.1. The effect of lipid raft disruption on the surface expression of  (A) total DR 
(L243), (B) DRB1*04 (NFLD.D1), (C) class-II-CLIP (cerCLIP), (D) D11-0401, and (E) 
D13-0401/D13-0404 on SAVC, MT14B, 8.1.6 0401, and 9.5.3 0401 was determined as 
displayed in Figure 4.6B. The fold change in expression caused by MBCD treatment 
(Fold change in MFI) for each individual experiment is shown and was calculated by 
dividing the MFI expression value of MBCD-treated cells by the MFI of untreated 
controls. Each dot denotes an individual experiment and the solid lines indicate the mean 
fold change in MFI. The broken line in each graph represents no effect of MBCD 
treatment on expression. A paired t-test was performed to compare expression between 
MBCD-treated and untreated control cells for a given cell line. Significant differences are 
indicated by an asterisk (p < 0.05). ND, not determined. 
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Appendix F. The effect of TEM disruption on the surface expression of 
transmembrane proteins and DRB1*04 epitopes. 
 
Figure F.1. The effect of saponin treatment on the surface expression of (A) 
transmembrane proteins and (B) DRB1*04 epitopes on SAVC, MT14B, 8.1.6 0401, and 
9.5.3 0401 was determined as displayed in Figure 4.9. The fold change in expression 
caused by saponin treatment (Fold change in MFI) for each individual experiment is 
shown and was calculated by dividing the MFI expression value of saponin-treated cells 
by the MFI of untreated controls. Each dot denotes an individual experiment and the solid 
lines indicate the mean fold change in MFI. The broken line in each graph represents no 
effect of saponin-treatment on expression. A paired t-test was performed to compare 
expression between saponin-treated and untreated control cells for a given cell line. 
Significant differences are indicated by an asterisk (p < 0.05). ND, not determined. 
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Appendix G. Flow cytometric assay of detergent resistance. 
 
G.1 Flow cytometric assay of differential detergent resistance 
As an alternative to sucrose density gradient ultracentrifugation, a unique flow 
cytometric assay of differential detergent resistance (FCDR) was used to analyze whether 
DRB1*04 epitopes associate with detergent resistant membranes. Similar to sucrose 
density gradient ultracentrifugation, the FCDR assay is based on the principle that lipid 
rafts and associated proteins are resistant to solubilisation in nonionic detergent such as 
Triton X-100 (1-2). Association of DRB1*04 epitopes with rafts was measured by their 
differential sensitivity to Triton X-100 before and after cholesterol depletion using 
MBCD. Since this method involves intact cells instead of cell lysates, the chance that 
proteins become associated with rafts after cell lysis are not of concern. 
The FCDR protocol has been previously described in detail (1). Freshly harvested 
cells (5 x 10
5
/test) were washed with RPMI media and incubated in media for 15 minutes 
at 37
o
C. The cells were then washed with media followed by a wash with FACS buffer 
(PBS containing 0.2% FCS and 0.02% sodium azide). Cells were then labeled with the 
appropriate primary and secondary antibody as previously described for flow cytometry 
and analyzed using a BD FACSCalibur flow cytometer. After a baseline level of 
expression was acquired, cells were treated with 0.1% ice-cold Triton X-100 in PBS for 5 
minutes on ice, followed by a second analysis of surface expression by flow cytometry. 
Analysis of flow cytometric data was performed using FlowJo 7.6 software. 
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Detergent resistance was quantified using the mean fluorescence intensity (MFI) 
values of the following fluorescence histograms as previously described (1): MFI of 
labeled untreated cells (MFIUT), MFI of labeled cells treated with 0.1% Triton X-100 for 
5 minutes (MFITX), MFI of isotype control untreated cells (MFIUTiso), MFI of isotype 
control cells treated with 0.1% Triton X-100 for 5 minutes (MFITXiso). The extent of 
detergent resistance was calculated using the below equation: 
 
FCDR value = (MFITX – MFITxiso) / (MFIUT – MFIUTiso) 
 
Therefore, the FCDR value is approximately less than 0.5 if a membrane protein 
is solubilized by Triton X-100 treatment and is approximately equal to 1 in the case of a 
typical detergent resistant protein. For a detergent resistant protein, pretreatment of the 
cells with 10mM MBCD in media for 15 minutes at 37
o
C can provide insight into the 
cause of the detergent resistance. For example, a significant decrease in the FCDR value 
after cholesterol depletion with MBCD indicates that the observed detergent resistance is 
likely caused by the association of the membrane protein with lipid rafts. When a 
detergent resistant FCDR value does not significantly change after MBCD treatment, it 
indicates that factors other than lipid raft association are responsible for the observed 
detergent resistance. The possible outcomes of the FCDR assay and the interpretations are 
summarized in Figure G.1. 
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Figure G.1. Summary of potential outcomes and interpretation of the FCDR assay. 
Immunostaining of cells for a particular protein is first performed followed by analysis of 
surface expression by flow cytometry before and after treatment with Triton X-100. If 
surface expression substantially decreases after Triton X-100 treatment (upper left 
histogram), the protein is considered detergent soluble and likely not associated with 
membrane rafts.  If expression is unaffected by Triton X-100 (upper right histogram), the 
protein is considered detergent resistant. The change in expression due to Triton X-100 
treatment is quantified using the FCDR value, where a value markedly less than 1 
indicates detergent-solubility and a value approximately equal to 1 indicates detergent-
resistance. Once a protein is considered detergent resistant by this method, pretreatment 
of the cells in culture with MBCD to reduce membrane cholesterol before performing the 
FCDR assay can determine whether the observed detergent resistance is caused by 
association with membrane rafts. If cholesterol depletion with MBCD results in a 
decrease of the FCDR (bottom left histogram), this indicates that the observed detergent 
resistance is likely due to lipid raft association. If MBCD treatment has no effect on the 
FCDR (bottom right histogram), addition cellular factors other than raft association (i.e. 
cytoskeletal attachment) are most likely responsible for the observed detergent resistance. 
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G.2 Determination of detergent solubility of DRB1*04 epitopes using the FCDR 
assay 
The association of DRB1*04 epitopes with lipid rafts was measured by their 
differential sensitivity to the nonionic detergent Triton X-100 using the FCDR assay as 
described above. The detergent resistance of CD59, CD71, and CD82 was first analyzed. 
As expected, CD71 on SAVC and MT14B cells displayed a high sensitivity to treatment 
with detergent, resulting in FCDR values of 0.27 and 0.25 for SAVC and MT14B 
respectively, indicating that CD71 was almost completely solubilized from the membrane 
with 0.1% Triton X-100 (Figure G.2). Similar results were observed in 8.1.6 0401 and 
9.5.3 0401 cells (Table G.1). The tetraspanin CD82 also exhibited a high sensitivity to 
detergent treatment with FCDR values of 0.15 and 0.22 in SAVC and MT14B 
respectively, suggesting that this protein is not associated with membrane rafts in these 
cells (Figure G.2). In contrast, the raft marker CD59 was mostly detergent resistant in 
both SAVC and MT14B, with FCDR values of 0.73 and 0.88 respectively (Figure G.2). 
In addition, CD59 displayed detergent resistance in 8.1.6 0401 cells with a FCDR value 
of 0.76 (Table G.1). The detergent resistance of CD59 in 9.5.3 0401 was not performed as 
these cells were previously shown not to express this protein (Figure 4.4). 
Since the detergent solubility of CD59 and CD71 corresponded to their known 
raft-association properties, the FCDR assay was used to analyze the detergent resistance 
of total DR and DRB1*04 epitopes. Total DRαβ dimers (L243), MHC-II/CLIP, and total 
DRB1*04 (NFLD.D1) were largely detergent soluble in SAVC, MT14B, 8.1.6 0401, and 
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Figure G.2. Total DR and D11-0401 are detergent soluble while D13-0404 is detergent 
resistant measured using the FCDR assay. 
The association of membrane proteins with lipid rafts in SAVC and MT14B cells was 
analyzed by measuring detergent resistance using the FCDR assay. Surface expression of 
CD59, CD71, CD82, DRαβ (L243), class-II-CLIP, DRB1*04, and D11-0401 or D13-
0404 on live SAVC and MT14B cells was measured before (thick histogram) and after 
(broken histogram) treatment with 0.1% Triton X-100 to determine the detergent 
resistance of this proteins. Isotype controls (thin histogram) were adjusted to a MFI equal 
to 10. The calculated FCDR value is shown to the right of each histogram.  
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Table G.1. Summary of FCDR values for various molecules and DRB1*04 epitopes. 
The association of membrane proteins with lipid rafts in 8.1.6 0401 and 9.5.3 0401 cells 
was analyzed by measuring detergent resistance using the FCDR assay. Surface 
expression of CD59, CD71, CD82, DRab (L243), class-II-CLIP, DRB1*04, D11-0401 
and D13-0401 on live 8.1.6 0401 and 9.5.3 0401 cells was measured before and after 
treatment with 0.1% Triton X-100 to determine the detergent resistance of this proteins. 
The calculated FCDR values are displayed, along with those from SAVC and MT14B for 
comparison. NT, not tested. 
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9.5.3 0401 cells, with FCDR values ranging from 0.01 to 0.16 (Figure G.2, Table G.1). 
Similarly, D11-0401 was found to be detergent soluble in SAVC and 8.1.6 0401 cells 
with FCDR values of 0.32 and 0.13 respectively (Figure G.2, Table G.1). D13-0401 in 
9.5.3 0401 was also detergent soluble with an FCDR value of 0.43 (Table G.1). In 
contrast to the other DRB1*04 epitopes, D13-0404 exhibited partial detergent resistance 
in MT14B cells with an FCDR value of 0.63 (Figure G.2), suggesting that this molecule 
partially resides in lipid rafts.  
In total, these FCDR results suggest that the majority of total DR, D11-0401, and 
D13-0401 are not associated with lipid rafts, while a portion of D13-0404 molecules may 
be raft-associated. These findings are not in agreement with the MBCD disruption and 
sucrose density gradient ultracentrifugation experiments, but instead suggest the exact 
opposite concerning the raft-association of these epitopes. Furthermore, it is well 
documented in the literature that a substantial fraction of total surface pMHC-II resides in 
lipid rafts (3). Given these discrepancies, it is apparent that further validation of this assay 
is required before its results can be correctly interpreted. 
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